Company Stories K-L

Stories that earlier appeared in Nelson's News 
Note 1: Carl Nelson Consulting, Inc is not an investment adviser and may hold a financial interest or client relationship in companies discussed.
(Note 2: Carl Nelson Consulting does not endorse these companies or organizations or their activities.) 
Looking for other older stories? Visit the archives


K2M .... K2 Therapeutics .... KAER Biotherapeutics .... Kala Pharmaceuticals ... Kaleido Biosciences .... Kalion .... Kallyope .... KaloBios Pharmaceuticals .... Kalocyte ..... Kalon Biotherapeutics ..... KalVista Pharmaceuticals ..... Karius .... Karuna Therapeutics .... Karyopharm Therapeutics ... Kateeva ..... Kayo TechnologyKaZaK ... KC BioMediX ... KCI .... KDH Defense Systems ... Kebotix ..... Kelyniam ... Keithley Instruments ... Kenall Manufacturing ..... Kensey-Nash ... Kentucky BioProcessing ... KeyW .... Kezar Life Sciences .... Kilawatt Technologies ... Kent Displays ... KeraNetics .....Keros Therapeutics ..... Kezar Life Sciences .... KeyW ..... Kinaset Therapeutics .... Kindara ..... KinDex ... KindHeart ..... KineMed .... Kinestral Technologies ..... Kineta ... Kinetic Concepts ... Kinex Pharmaceuticals .... Kingbright ... Kinnate Biopharma .... Kior ... Kips Bay Medical ... Kiromac Biopharma ..... Kite Pharma ..... Kitware ... Kiva Systems ... KLD Energy Technologies... Klotho Therapeutics ..... KMel Robotics .... Knightscope .... Knome ... Knopp Neurosciences ... KNOW Bio ..... Know Labs ..... KnuEdge ..... Koam Engineering Systems .... Kodiak Sciences ..... Kolltan Pharmaceuticals ...Komoku ... Kona Medical .... Konarka ... Koning ... Kopin .... Kord Technologies ..... KOR Electronics ... Koronis Pharmaceuticals ... Korro Bio .... Kosan Biosciences ... Kosmetikos .... Kovio ... KPI Therapeutics (from Kineta) .... Kraig Biocraft ..... Kratos Defense & Security Solutions ... Kriya Therapeutics ..... Kronos Advanced Technologies ... Krystal Biotech ..... KSE ... KSQ Therapeutics ...... Kultevat ..... Kumu Networks .... Kura Oncology .... KVH ... Kylin Therapeutics ... Kyma Technologies ... Kymera Therapeutics ..... Kymeta ... Kyn Therapeutics ..... Kyocera Solar ... Kypha .... Kyras Therapeutics .... Kyron Clinical Imaging ... Kytopen ..... LAAMScience ... LaBelle Associates ..... LabNow ... Laborie Medical Technologies ... Labrys Biologics .... Lacerta Therapeutics ..... Lactic Solutions .... Laguna Pharmaceuticals (formerly ChanRx) ..... La Jolla Pharmaceutical ... Lake Shore Cryotronics .... Landec ... Landos Biopharma ..... Lantern Pharma .... Lantheus .... Lantos Technologies ... Lariat Biosciences .... Laser Design .... Lasergen ..... LaserMax ..... LaserMotive ... Laser Tissue Welding .... Lassen Therapeutics ... Lattice Biologics ..... Lattice Biotech ..... LaunchPad Medical .... Lawrie Technology ... Lazarus Effect .... LDR Holding ... Leading Edge Crystal Technologies .... Lead Therapeutics ... LeafBio ... Learning Ovations ... LeCroy ... LED Lighting Fixtures ... Lehigh Technologies ..... Leica Microsystems .... Leto Solutions .... Leuko .... LexaGene ... Lexeo Therapeutics<./a> .... a href="#Lexicon">Lexicon Genetics ... Lexicon Pharmaceuticals ... Lexington Medical .... Leyden Energy .... ... Libra BioSciences .... LifeCell ... LifeGen Technologies .... Life Image ... LifeMine Therapeutics .... LifeSprout.... Life Technologies ...Ligand Pharmaceuticals ... Lightpointe ... Light Sciences Oncology ... LightWorks Optics ... Ligon Discovery ... Lillac Solutions .... Lilliputian Systems ... Lily Robotics ..... Linares Management Associates ... Lingotek ... Linnaeus Therapeutics ..... LinQuest .... Lionano .... Lion Biotechnologies ..... Lipocine ..... LipoScience ... Liquid Biotech ..... Liquidia Technologies ... Liquid Light .... Liquid Metal Battery ... LiquidPiston ... Liquid Robotics ... Liquid X Printed Metals ... LiQuifix ... Lithium Technology ... LiveData ... LiveLeaf Bioscience ..... Living Carbon .... LKC Technologies .... Locana .... Locus Biosciences ..... Lodo Therapeutics .... LogicBio Therapeutics ..... Logisys Technical Services .... Logos Tech .... Lohocla Research ..... Lombard Medical .... Longeveron ..... Longeviti .... Lookingglass .... Loon Medical .... LonoCloud ... Lotus Tissue Repair ... Loxo Oncology ... LPath Thera .... Lq3 Pharmaceuticals ... LS9 ... Luca Technologies ..... Lucerno Dynamics ..... Lucigen ... LumaSense Technologies ... Lumena Pharmaceuticals .... Lumencor ... Lumense .... Lumera . ... Lumicell Diagnostics ... Luminar Technologies ..... Luminary Micro ... Luminex ... Luminus Devices ... Lumisyn ..... Lumitex ... LumiThera .... Lumos Pharma .... Luna Innovations ... Luna Technologies ... Lung Therapeutics .... Lutonix .... Luxtera ... Lycera ... LyGenesis ..... Lyncean .... Lyndra Therapeutic .... Lynntech .. Lynx Biosciences ..... Lyra Therapeutics .... Lysosomal Therapeutics ... Lytro

K2M (Leesburg, VA)

K2M  (Leesburg, VA; no SBIR, founded 2004) that makes implants, instruments and other products to repair spinal injuries, said it hopes to raise about $136 million in [IPO]  ... to reduce debt and expand the company’s global distribution network. [Dan Beyers, Washington Post, Apr 24, 14]

K2 Therapeutics (Boston, MA)

Former Trius Therapeutics (no SBIR) CEO Jeff Stein has taken the helm at a new San Diego biotech that has raised more than $30 million of a planned $42.7 million round of equity funding. ... developing new drugs for treating life-threatening invasive fungal infections. ... K2 Therapeutics  (Boston, MA; no SBIR, founded 2012) is undergoing a name change [TBD]. [Alex Lash,, Jun 26, 14]

KAER Biotherapeutics

KAER Biotherapeutics (no SBIR), a company spawned from Larta Alumni company BioTechPlex  (San Marcos, IL; $6.2M SBIR), develops a variety of services and devices for the treatment of lung diseases including new methods of delivering biologic pharmaceuticals in aerosol form. When considering other aerosol drug delivery systems available in the market today, KAER’s patented SUPRAER technology has been deemed superior due to its ability to provide deeper lung treatment.   [Gaby Huizar, May 13 ]

Kala Pharmaceuticals (Waltham, MA)

Kala Pharmaceuticals (Watertowwn, MA; $400K SBIR) down 19%[Oct 27, 20] announced that the [FDA] approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. [company press release, Oct 27, 20]

Kala Pharmaceuticals (Watertown, MA; no SBIR) up 26% {Mar 9, 20], a biopharmaceutical focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced positive topline results from STRIDE 3, a Phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. [company ress release, Mar 8, 20]

Kala Pharma (Waltham, MA; $400K SBIR) down 16% [Oct 3, 18] announced a public offering to raise $62M [company press release, Oct 3, 18]

Kala Pharmaceuticals (Waltham, MA; $500K SBIR) won FDA approval for lotoprednol etabonate, an eye drop that uses the , company’s nanoparticle technology to more efficiently deliver a pain and inflammation therapy to the eye. [Ben Fidler,, Aug 24, 18]

Kala Pharmaceuticals (Waltham, MA; $400K SBIR, founded 2009) raised a $68 million Series C round ... is trying to use nanoparticle technology to treat a group of eye diseases. The company’s “mucosal penetrating product” platform attaches nanoparticles to engineered polymers so small they can supposedly slip through the barriers of mucous that guard the eyes from dust and viruses.  ... has now raised more than $100 million in equity backing since its inception  [Ben Fidler,, Apr 13, 16]

Kala Pharmaceuticals (Waltham, MA; no SBIR) said it has secured $11.5 million in Series A equity financing.  ...  developing products that are capable of penetrating mucosal barriers for the treatment of major diseases that affect the eyes, lungs, gastrointestinal tract, and female reproductive system... [Chris Reidy, Boston Globe, Feb 28, 13] Government help? Alongside the equity financing, the National Heart, Lung, and Blood Institute is funding the development of an improved inhaled treatment for cystic fibrosis related infection,and the National Eye Institute is supporting the advancement of better formulations for ocular drug administration. [company website Mar 2012]

Kala Pharmaceuticals (Waltham, MA; no SBIR) developer of treatments for such diseases as cystic fibrosis, announced that it raised $6.2 million in additional equity financing.    .... added that it has also been awarded two grants from separate divisions of the National Institutes of Health that will advance its cystic fibrosis and ocular disease programs.  [Boston Globe, Mar 14, 12]

Kala Pharmaceuticals (Waltham, MA; no SBIR), a stealthy biotech startup with MIT chemical engineering professor Robert Langer on its board of directors, has taken in $3 million in new funding  [Mass High Tech, Nov 11, 10]

Kaleido Biosciences (Bedford, MA)

Kaleido Biosciences (Bedford, MA; no SBIR, founded 2017), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, announced the pricing of its [IPO]... expected to be $75 million. [company press release, Feb 27, 19]

Kalion (Milton, MA)

Kalion (Milton, MA; $450K prior SBIR) was awarded a $747K NSF SBIR [for] improving the bio-based production of glucaric acid. Glucaric acid and its related compounds enhance sustainability as well as improve the chemical properties of products ranging from water treatment, polymers & textiles, coatings, detergents and pharmaceuticals. [company press release, Jul 30, 20]


Columbia University spinout Kallyope (New York, NY; no SBIR, launched 2015 with $44M) focused on identifying therapeutic opportunities involving the gut-brain axis, announced a $66 million Series B financing and significant progress in building an industry-leading research program. [company press release, Feb 20, 18]

Maniatis has co-founded a new company, Kallyope, backed by three Nobel laureates and has secured one of the largest Series A funding rounds for a New York-based biotech in recent memory. ...  the $44 million Kallyope raised is nowhere near the biggest seen in the sector. This year alone, San Francisco Bay Area startups Denali Therapeutics and Gritstone Oncology have raised Series A dollars in the nine figures. In Boston, Third Rock Ventures frequently starts up companies, such as Neon Therapeutics and Decibel Therapeutics, with commitments of around $50 million. [Ben Fidler,, Dec 10, 15]

Kallyope wasn’t the only Columbia spinout to launch this past week. Through its Highline Therapeutics incubator, Versant Ventures put $5 million into a new company called Kyras Therapeutics  (no SBIR). The company is based on the work of Columbia’s Brent Stockwell, who is using computational methods to develop drugs that directly bind to one of cancer’s hard targets, a family of genes called RAS. Versant also formed a second company, Inception IBD, which Celgene  has nabbed an option to acquire.

KaloBios Pharmaceuticals (South San Francisco, CA)

KaloBios Pharmaceuticals stock plunged more than 90 percent early on its first day of over-the-counter trading, after it was delisted by Nasdaq.  [Cromwell Schubarth, Silicon Valley Business Journal, Jan 13, 16]

KaloBios Pharmaceuticals up 43% [Nov 25, 15]

KaloBios Pharmaceuticals down 53% [Nov 24, 15]

KaloBios Pharmaceuticals up 116% [Nov 23, 15]

KaloBios Pharmaceuticals up 75% [Nov 20, 15]

KaloBios Pharmaceuticals (South San Francisco CA; no SBIR) up 400% [Nov 19, 15], which last week announced plans to wind down operations, said an investor group that included Martin Shkreli had acquired more than 50% of the company's stock. ,,, Mr. Shkreli is the founder and chief executive of Turing Pharmaceuticals, a privately held biopharmaceutical company that gained notoriety recently when it raised the price of an anti-parasite drug more than 50-fold after buying the U.S. rights in August. [company website]

 KaloBios Pharmaceuticals (South San Francisco, CA; no SBIR) said it would let go its chief medical officer and more than 20 percent of its staff after the Phase 2 failure of its antibody to treat bacterial infections in cystic fibrosis patients.  [Alex Lash,, Feb 6, 15]

Eight months after a $70 million [IPO], KaloBios Pharmaceuticals (South San Francisco, CA; no SBIR) said it would net more than $27.8 million by selling another 7.5 million shares.  The target is half of the South San Francisco-based antibody drug developer's IPO price.  .... would use the cash to develop and advance its drugs through clinical trials. [Ron Leuty, San Francisco Business Times, Sep 26, 13] 

Kalocyte (St Louis, MO)

Kalocyte (St Louis, MO; $2M SBIR, founded 2016) raised $800K seed round. ... supported by a $2M Fast Track Phase I/II STTR from the National Heart Blood and Lung Institute and a $3M grant through the Congressionally-Directed Medical Research Program (CDMRP) from [DOD]. [, Jun 12, 18] developing ErythroMer novel blood substitute composed of a patented nanobialys nanoparticle. [Washington University website]

Kalon Biotherapeutics (College Station, TX)

Kalon Biotherapeutics (College Station, TX; no SBIR) biotech manufacturer that specializes in vaccines, has been acquired by the U.S. arm of Japan-based FujiFilm Diosynth Biotechnologies. ... received funding from the state's Emerging Technology Fund, was launched in 2011 out of the Texas A&M University system. ... will now be named FujiFilm Diosynth Biotechnology Texas LLC, has specialized in manufacturing vaccines for biotechnology companies, most notably GlaxoSmithKline, [CEO Andrew] Strong said.   [Joe Martin,  Houston Business Journal, Dec 18, 14]

KalVista Pharmaceuticals)

KalVista Pharmaceuticals (no SBIR)  up 39% [Oct 10, 17],  on news that Merck has acquired a 9.9% ownership stake in the company for $9.1 million.  Merck will also pay KalVista $37 million upfront for the option to acquire KalVista's diabetic macular edema drug candidate, which the companies will collaborate to develop, and a similar option for other future oral diabetic macular edema compounds. KalVista is also eligible for additional payments that could total up to $715 million  [Emma Court, MarketWatch, Oct 10, 17]

Karius (Redwood City, CA)

Karius (Redwood City, CA; no SBIR), the world leader in liquid biopsy for infectious diseases, secured $165 million in a new funding round [to] help more patients faster, fuel the next wave of clinical studies, and accelerate technology innovation,” said Karius CEO, Mickey Kertesz. [company press release, Feb 24, 20]

Karius (Redwood City, CA: no SBIR) raised $50 million to boost clinical trials and commercialization of its blood-based test that detects more than 1,250 pathogens.  [Amirah Al Idrus, Fierce Biotech, Aug 7, 17]

Karuna Therapeutics (Boston, MA)

Karuna Thera down 19% [Jan 22, 20]

Karuna Therapeutics down 27% [Nov 21, 19]

Karuna Therapeutics (Boston, MA; no SBIR) up 29% [Nov 19, 19]

Karuna Therapeutics (Boston, MA; no SBIR) up 442% [Nov 18, 19] developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, announced results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. In the clinical trial, KarXT demonstrated a statistically significant and clinically meaningful 11.6 point mean reduction in total Positive and Negative Syndrome Scale (PANSS) score compared to placebo (p<0.0001) and also demonstrated good overall tolerability. ... also announced that it has commenced an underwritten public offering of 2,600,000 shares of its common stock. [company press release, Nov 18, 19]

Karuna Therapeutics (Boston, MA; no SBIR), up 25% [Jun 28, 19] a clinical-stage biopharmaceutical primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, announced the pricing of its upsized [IPO] to raise $89M. [company press release, Jun 28, 19]

Karuna Therapeutics (formerly Karuna Pharmaceuticals, Boston, MA; no SBIR), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders including psychosis in schizophrenia, psychosis in Alzheimer’s disease, and pain, announced the completion of a $68 million Series B [company press release, Mar 18, 19]

Karyopharm Therapeutics (Newton, MA)

Karyopharm Therapeutics down 28% [Feb 22, 22]

Karyopharm Therapeutics (Newton, MA; $2.2M SBIR) up 20% [Feb 18, 22]

Karyopharm Therapeutics ($2.2M SBIR) up 37% [Nov 3, 21] reported a strong third quarter, which saw a significant increase in net product revenues versus the second quarter of 2021. XPOVIO continues to move into earlier lines of therapy in multiple myeloma as a new and effective modality that can become the standard of care in second line plus where utilizing new mechanisms is critical to improve patient outcomes," said [CEO] Richard Paulson [company pres release, Nov 3, 21]

Karyopharm Therapeutics announced that [FDA] has approved oral XPOVIO® (selinexor), the Company’s first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. [copany press release, Jun 22, 20]

Karyopharm Thera up 70% [Mar 2, 20] announced positive top-line results from the randomized Phase 3 BOSTON study evaluating once-weekly XPOVIO(R) (selinexor) in combination with once-weekly Velcade(R) (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. [company press release, Mar 2, 20]

Cancer drug maker Karyopharm Therapeutics reported revenues of $12.8 million for its third quarter, driven by the commercial launch of its recently approved cancer drug, Xpovio, exceeding analyst expectations. [Yahoo Finance, Nov 4, 19]

Karyopharm Therapeutics announced a royalty agreement with HealthCare Royalty Partners for up to $150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), the Company’s first-in-class, oral SINE compound, which is currently marketed in the U.S. for the treatment of patients with heavily pretreated multiple myeloma. [company press release, Sep 16, 19]

Karyopharm Thera (Newton, MA; $1.2M SBIR) up 36% [Jul 3, 19] announced that the [FDA] approved oral XPOVIO(TM) (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. [company press release, Jul 2, 19]

Karyopharm Thera down 43% [Feb 22, 19] FDA staff raised questions about the therapy’s efficacy and safety. [, Feb 22, 19]

Karyopharm Thera down 20% [Oct 10, 18]

Karyopharm Therapeutics  up 11% [May 1, 18] reported that its cancer drug selinexor has passed a big test in treating some of the most desperate multiple myeloma patients—those who have failed at least five other therapies. ....  will ask U.S. and European drug regulators to consider selinexor for approval. [Ben Fidler,, Apr 30, 18]

Karyopharm Thera down 14%  [Apr 30, 18]

Karyopharm Thera up 10% [Apr 12, 18]

Karyopharm Thera up 12% [Feb 6,18]

Karyopharm Therapeutics (Newton, MA; no SBIR) announced the pricing of a registered underwritten public offering [with] gross proceeds expected to be $40M.  [company press release, Apr 28, 17]

A compound that Karyopharm Therapeutics (Newton, MA; no SBIR) tested as a potential treatment for cancer and viruses was licensed to  which plans to bring the drug to market to treat dogs diagnosed with lymphoma. [Ben Fidler,, May 5, 17]

Karyopharm down 10% [Mar 10, 17]

Karyopharm Thera down 16% [Mar 3, 17]

Karyopharm Thera up 25% [Mar 2, 17] announced the results of a planned interim analysis of the Phase 2 SOPRA study evaluating single agent selinexor in relapsed/refractory acute myeloid leukemia (AML). The Company determined in concert with the study's independent Data Safety Monitoring Board (DSMB) that SOPRA will not reach statistical significance for overall survival (OS), the study's primary endpoint. However, since selinexor-treated patients that achieved a complete response (CR) showed a substantial OS benefit as compared with the physician's choice (PC) arm, Karyopharm and the DSMB agreed that patients would be permitted to continue on the selinexor arm or the PC arm, as applicable, following discussion between the patient and their treating physician. [company press release, Mar 2, 17]

Karyopharm Thera up 10% [Feb 27,17]

Karyopharm Thera up 20% [Nov 9, 16]

Karyopharm Thera up 17% [Nov 8, 16]

Karyopharm Thera down 16% [Sep 6, 16] reported positive top-line results from its Phase 2b STORM study evaluating the activity of selinexor (KPT-330) in multiple myeloma (MM)  [company press release, Sep 6, 16]

Karyopharm Thera up 12% [Sep 1, 16]

Karyopharm Thera   up 37% [Aug 30, 16] intends to expand its Phase 2b STORM study evaluating the activity of selinexor in multiple myeloma (MM) to include approximately 120 additional patients with penta-refractory MM.  [company press release, Aug 30, 16]

Karyopharm  up 11% [Aug 18, 16]

Karyopharm up 10% [Apr 21, 16]

Karyopharm Thera down 10% [Mar 23,16]

Karyopharm Thera down 14% [Mar 15,16]

Karyopharm Thera up 12% [Mar 14,16]

Karyopharm Thera down 15% [Jan 13, 16]

Karyopharm down 14% [Jan 11, 16]

Karyopharm Thera up 11% [Oct 15,15]

Sangamo Bio up 11% [Oct 15,15]

Karyopharm Therapeutics up 20% [Aug 17, 15]

Karyopharm Thera down 39% [Aug 10, 15]

Karyopharm Thera up 12% [Mar 16, 15]

Karyopharm Thera up 11% [Dec 18, 14]

Karyopharm Thera down 11% [Dec 11, 14] 

Karyopharm Thera  down 10% [Dec 9, 14]

Karyopharm Thera up 11% [Nov 6, 14]

Karyopharm Pharma up 11% [Sep 26, 14]

Karyopharm down 14% [Jul 8,14]

Karyopharm Therapeutics down 10% [Jun 16, 14]    

Karyopharm Therapeutics up 94% [Jun 13, 14] 

A day after getting its first orphan drug designation, Karyopharm (Natick, MA; no SBIR) announced its second. The designation is for the same experimental drug, called Selinexor, but for a different type of blood cancer.  [Don Seiffert, Boston Business Journal, May 20, 14]

Karyopharm Thera up 10% [Apr 9, 14]

Karyopharm up 15% [Apr 8, 14]

Karyopharm down 14%[Mar 24, 14]

 Karyopharm Thera up 14%  [Mar 6, 14]

Karyopharm Therapeutics  up 12% [Dec 16, 13] 

Karyopharm Therapeutics (Natick, MA; no SBIR) up 10% [Dec 13, 13] day after IPO

clinical-stage pharmaceutical company Karyopharm Therapeutics (Natick, MA; no SBIR) announced yesterday that its initial public offering, pegged at $80 million early last month, raised $125.1 million   ..... within the next six months or so  start a couple of randomized studies [Jim Schakenbach, Mass High Tech, Dec 12, 13]

Karyopharm Therapeutics (Natick, MA; no SBIR) pricing an upsized IPO at the top end of its projected range.  ....  raised close to $109 million. [Ben Fidler,, Nov 8, 13]

Karyopharm Therapeutics (Newton, MA; no SBIR), a biotech startup, has bumped up its Series A round with an A2 tranche worth $10 million ... to expand its planned Phase 1 trial program of its oral selective inhibitors of nuclear export (SINE) platform for potential use against various cancers.  [Rodney Brown, Mass High Tech, Nov 2, 11]

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals (Cambridge, MA; no SBIR) Epizyme (Cambridge, MA; no SBIR) and Karyopharm Therapeutics (Natick, MA; no SBIR) Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.  [press release, Jan 6, 11]

Stealthy pharmaceutical startup Karyopharm Therapeutics (Newton, MA; no SBIR) born out of the ashes of Epix Pharmaceuticals, has raised a $20 million Series A financing round  [Rodney Brown, Mass High Tech, Nov 3, 10]

Kateeva (Newark, CA)

Kateeva (Newark, CA; no SBIR) announced that it has closed its Series E funding round with $88 million in new financing. The Silicon Valley technology leader disrupted the flat panel display industry when it launched a breakthrough equipment solution to mass-produce flexible Organic Light Emitting Diodes (OLEDs).  ...   has raised $200 million since it was founded in 2008 [company press release, May 19, 16]  In SBIR-supported OLED, Universal Display (Ewing, NJ) had about $12M to lead funding total of about $30M.

Kayo Technology Madison, WI)

Kayo Technology(Madison, WI; no SBIR, founded 2011)  invented a device, which attaches to resistance bands, helps physical therapists precisely measure and chart the amount of pressure from a patient's exercise. Then, it transfers the data to computers, smartphones and medical records ....raised $1.3 million in just six weeks at the end of 2012 following a presentation at the Wisconsin Early Stage Symposium   [Kathleen Gallagher, Milwaukee Journal Sentinel, Feb 6, 13]

KaZaK (Woburn, MA)

Plasan  (Bennington, VT; no SBIR) ) that manufactures products for the auto and defense industries has bought a Massachusetts design company.....  announced a deal to buy KaZaK (Woburn, MA; $40+M SBIR over 15 years). Plasan describes KaZaK as a leader in composite structures and low-cost, automated composite manufacturing. The Bennington Banner reports that Plasan CEO Dan Ziv says KaZaK will help Plasan boost its manufacturing capability. Plasan North America in Bennington produces armor for military vehicles. Plasan Carbon Composites makes auto parts. [AP, Jul 1, 11]

KC BioMediX (DeSoto, KS)

The Kansas Bioscience Authority announced four grants totaling $4.85 million to help companies in the state. KC BioMediX of De Soto, VasoGenix Pharmaceuticals of Lenexa , Ventria Bioscience of Junction City ($500K SBIR), MGP Ingredients (public) of Atchison. [Kansas City Business Journal, Jul 15, 08]

KDH Defense Systems (Johnstown PA)

 KDH Defense Systems (Johnstown PA; no SBIR) makes Navy body armor and Army elbow pads in a converted bra factory, and Mr. Murtha asked for a $2 million earmark to help the company improve its bulletproof vests. Another earmark would provide $3 million for KDH to develop a “waterways threat detection system.”  The company’s lobbying firm is KSA Consulting, which employed Mr. Murtha’s younger brother, Kit, until 2006. The firm has contributed $4,000 to Mr. Murtha’s campaign since 2005.  [Marilyn Thompson and Ron Nixon, New York Times, Nov 4]

KCI (San Antonio, TX)

KCI  (San Antonio, TX; no SBIR), LifeCell (Somerville, NJ;  $3.8M SBIR), and Systagenix  (UK) now form one company, a global leader in medical technology with more than $2 billion in revenue, poised for future success as a geographically diversified company with world-class wound care and biologics franchises. [KCI press release, Oct 28, 13]

Kebotix (Cambridge, MA)

Kebotix (Cambridge, MA; $200K SBIR) a technology platform company for new chemicals and materials, has been selected as the industry partner of a new $15-million interdisciplinary research institute led by Colorado School of Mines and funded by the National Science Foundation. [company press release, Sept. 28, 2021]

Kebotix (Harvard spinout, Cambridge, MA; no SBIR, founded 2017) came out of stealth mode with a $5M seed round ... Developing the world’s first [AI] self-driving lab for materials discovery powered by AI and robotics, Kebotix is committed to accelerating the exploration, discovery, applications and production of new molecules and, a technology company ushering in the future of new materials discovery, today came out of stealth mode with a $5 million seed round [company press release, Nov 7, 18]

Kebotix (Cambridge, MA; still in stealth) materials discovery company, raised over $5 million of seed finance [in August 2018] [Srividya Kalyanaraman, Boston Inno, September 5, 2018]

Keithley Instruments

Keithley Instruments fell 16%. The Cleveland maker of measurement technology for electronics manufacturers warned of a fiscal second-quarter sales shortfall, citing a reluctance among customers to spend on capital equipment. [Wall Street Journal, Apr 14]

Kelyniam (Canton, CT)

Kelyniam (Canton, CT; no SBIR, 12 employees), a custom skull implant designer and manufacturer ...  had its second visit from a congressman in the hopes that these politicians can help the company's sales people get a foot in the door with [DOD]. People severely wounded in Iraq and Afghanistan often get skull and facial reconstructions ...  but Kelyniam has not been able to sell any of its implants there.  It has sold nearly 200 custom implants nationwide since it began producing them last year. ....  Synthes (no SBIR), the company with the biggest share of custom skull implants, has been around for decades, has more than $1 billion a year in medical device sales and just was acquired by Johnson & Johnson.  [Mara Lee, Hartford Courant, Aug 14, 12]

Kenall Manufacturing (Kenosha, WI)

Kenall Manufacturing (Kenosha, WI; no SBIR) is poised to begin marketing bacteria-killing light fixtures that could open a new front in the war on hospital-acquired infections.  ...  the Indigo-Clean, a light fixture that uses a narrow spectrum of indigo-colored light to kill bacteria in hospitals. ...   the technology comes from the University of Strathclyde in Glasgow, Scotland ... Last November, the company moved from Gurnee, Ill., to a $25 million headquarters and factory it built in Kenosha ... Kenall was offered up to $11.5 million in public assistance. The aid includes up to $6.25 million in state tax credits keyed to the number of jobs the company adds. Also part of the package are a $1.25 million forgivable loan from Kenosha County, and a $4 million grant from the City of Kenosha      [Rick Romell, Milwaukee Journal Sentinel, Jun 25, 15]


Kensey Nash up 32% [May 3, 12] said  it will be acquired for about $360 million by Royal DSM, a Dutch manufacturer with operations in the pharmaceutical, food and automotive sectors  [AP].....   but a law firm is investigating the Board of Directors of Kensey Nash Corporation for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the company to royal dsm  [Business Wire]

Kensey Nash   up 23% [Mar 19, 12]

Kensey Nash  down 22% [Dec 16, 11]

Kensey Nash  down 15% [Feb 5, 10]

Kensey-Nash down 10% [Mar 5, 09]

Kent Displays (Kent, OH)

NIST TIP winners  $22 million in funding for nine research projects targeting innovative manufacturing technologies in fields ranging from biopharmaceuticals and electronics to renewable energy sources and energy storage:  Isogenis (Aurora, CO; $4.8M SBIR);  ActaCell,  (Austin, TX; no SBIR);  Engineered BioPharmaceuticals (Manchester, CT; no SBIR); Arsenal Medical  (Watertown, MA; no SBIR); Kent Displays (Kent, OH; $2.6M SBIR); Precision BioSciences (Research Triangle Park, NC; $340K SBIR); Ginkgo BioWorks (Boston, MA; one SBIR); Sinmat (Gainesville, FL; $4.4M SBIR); Polyera (Skokie, IL; no SBIR).

Kentucky BioProcessing (Owensboro, KY)

The DARPA effort, called Blue Angel, has been working since May 2009 to develop a surge capacity for flu viruses ....      Four companies are working to transform protein-producing tobacco plants from a proof of concept to a demonstration of the capability. The next step will be to develop full industrial processes for producing the proteins. The companies are Fraunhofer USA Center for Molecular Biotechnology in Delaware, Kentucky BioProcessing (Owensboro, KY; no SBIR, bought by Reynolds Tobacco Jan 2014), a consortium called Project GreenVax, whose partners are the Texas A&M University system and a Texas company called G-Con, and Medicago USA in North Carolina. [Cheryl Pellerin, American Forces Press Service]   In 2009  DARPA, launched Blue Angel, a program that challenged three tobacco pharming facilities—among them,  and Caliber Biotherapeutics (Bryan, TX; no SBIR) —to produce 10 million doses of flu vaccine in one month. The reward? Tens of millions in funding. [Erika Fry, Fortune, Sep 22, 2014]

KeraNetics (Winston-Salem, NC)

Regenerative medicine firm KeraNetics  (Winston-Salem, NC; at least $2.3M SBIR) which was spun out of research from the Wake Forest Institute for Regenerative Medicine, is seeking $1.25 million financing in a private offering, according to [SEC] documents.   [Katie Arcieri, Triad Business Journal, Dec 21, 16]

Keros Therapeutics (Lexington, MA)

Keros Thera up 19% [Apr 14, 20] announced the closing of its [IPO] for total gross proceeds of $110.4 million, [company press release, Apr 13, 20]

Keros Thera up 26% [Apr 8, 20]

Keros Therapeutics (Lexington, MA; no SBIR) managed to raise more money [$86M] in its public market debut than it had initially planned [to] o advance the development of its investigational drugs for patients with blood and musculoskeletal disorders. The drugs that Keros is developing target a family of proteins called TGF-beta, signaling pathways that regulate red blood cell and platelet production, and growth, repair, and maintenance of muscle and bone. [Sarah de Crescenzo,, Apr 8, 20]

Keros Therapeutics (Lexington, MA; no SBIR), a biotech which raised more than $50 million this month in venture capital, is now looking to tap the public markets for additional cash amid a time of historic tumult. ..... a clinical-stage biotech that aims to develop new treatments for patients with blood and musculoskeletal disorders by developing drugs that inhibit a family of proteins called TGF-beta. [Sarah de Crescenzo,, Mar 23, 20]

Keros Therapeutics (Lexington, MA; no SBIR) biotech developing treatments for hematological and musculoskeletal disorders, filed for an $86M IPO. [BostInno, Mar 17, 20]

Keros Therapeutics (Lexington, MA; no SBIR) raised $23 million in Series B financing, which will help the startup move two drugs for rare neuromuscular diseases through to mid-stage clinical testing. [Frank Vinluan,, Jan 7, 19] prior funding $11M []

Kezar Life Sciences (S San Francisco, CA)

Kezar Life Sciences (South San Francisco, CA; no SBIR, 47 employees) up 35% [Nov 16, 21] reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis (LN). "The MISSION Phase 2 interim results present a strong signal that KZR-616 is active and could be a meaningful therapy for patients with lupus nephritis, a long term and difficult to treat disease," said Noreen R. Henig, M.D., Kezar's Chief Medical Officer. [company press release, Nov 15, 21]

Kezar Life Sciences (South San Francisco, CA; no SBIR) up 35% [Feb 10, 20] announced the closing of an underwritten public offering that raised $56.8M [company release, Feb 10, 20]

Kezar Life Sciences (S San Francisco, CA; no SBIR, founded 2015) down 41% [May 28, 19] a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced that data from the first two cohorts of an open-label dose escalation trial of KZR-616 in patients with systemic lupus erythematosus (SLE) will be featured in a poster presentation at the European League Against Rheumatism (EULAR) 2019 annual meeting [company press release, May 28, 19] total funding $78M plus IPO 2018 []

KeyW (Hanover, MD)

KeyW (Hanover, MD; $200K  SBIR)  and MacAulay-Brown (Beavercreek, OH; $5M SBIR)  were awarded spots on a potential 10-year, $500 million contract to eight companies and one nonprofit organization to support missions of DIA’s science and technology directorate.  [Peter Grahm, GovConWire, Sep 17, 18]

Kezar Life Sciences (SOUTH SAN FRANCISCO, CA)

Kezar Life Sciences (South San Francisco, CA; no SBIR) up 73% [Jun 4, 20] announced updated results from the Phase 1b (Ph1b) portion of MISSION, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without nephritis. [company press release, Jun 3, 20]

Kezar Life Sciences (SOUTH SAN FRANCISCO, CA; no SBIR), discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced [that its IPO raised] $86.3 million. [company press release, Jun 25, 18]

KeyW (Hanover, MD)

The Navy awarded KeyW (Hanover, MD; one SBIR) a potential five-year, $43.7 million contract to help the Naval Research Laboratory develop sea acoustic techniques. [Joanna Crews, GovConWire, Jun 14, 18]

Kilawatt Technologies (Shelburne, VT)

TheVermont Center for Emerging Technologies has added $1.8 million in new federal stimulus funds, boosting to $5 million the fund the quasi-public technology incubator has at its disposal ...  Returns from investments will be paid back into the 10-year fund and reinvested, [fund manager David Bradbury] said. ... has already made a handful of investments out of miscellaneous funds, including Hearforward, (Colchester, VT; no SBIR) social media analytics software company; Kilawatt Technologies (Shelburne, VT; no SBIR) energy efficiency analytics company; and SemiProbe (Colchester, VT; no SBIR) semiconductor equipment company. [Mass High Tech, Apr 21, 10]

Kinaset Therapeutics (Medfield, MA)

Kinaset Therapeutics (Medfield, MA; no SBIR) raised $1.5M in equity in a $40M funding round, according to an SEC filing. [Rowan Walrath, BostInno, Aug 18, 20]

Kindara (Boulder, CO)

Kindara (Boulder, CO; no SBIR) focusing on women's health, said it's completed a $5.3 million [seed] round  ... to finalize the manufacturing of its first connected device, Wink, an advanced Bluetooth basal thermometer that connects wirelessly with the Kindara app to give women a seamless experience when aiming to achieve or avoid pregnancy naturally," the company said in a statement. [Ben Miller, Denver Busines Jourrnal, Aug 20, 15]

KinDex (Seattle, WA)

KinDex (Seattle, WA; no SBIR) is announcing today that it’s raised a $5 million Series A round.  ...will help the startup kick off a Phase 2 trial testing its lead drug, KDT501, in people with Type 2 diabetes. The drug is a derivative of an extract of hops that KinDex serendipitously found to play a role not only in quelling an immune response related to fatty diets and diabetes, but potentially in weight loss as well.  [Ben Fiddler,, Mar 25, 14]

KindHeart(Chapel Hill, NC )

KindHeart (Chapel Hill, NC;  no SBIR) startup with UNC roots has closed out an angel investment round and will go after institutional investors this year.....   develops and sells tissue surgery simulation systems for robotic surgery.  ...   [CEO] So far, KindHeart has stayed in “stealth mode,” says [CEO] Grubbs ....  But the company is beginning to emerge in 2016, after it began booking revenue in the fourth quarter last year. [Jason deBruyn, Triangle Business Journal, Feb 18, 16]

KineMed (Emeryville,CA)

KineMed (Emeryville, CA; $6.8M SBIR incl one at $4.5M, founded 2001), filed for Chapter 11 bankruptcy last week ...  accumulated more than 600 investors, according to filings. The firm tried to go public in early 2014 as the biotech bull run was gaining steam but withdrew the attempt six months later without giving a reason. At that time the firm had accumulated about $56 million in losses since inception.  [Alex Lash,, May 13, 16]

KineMed (Emeryville, CA; $7M SBIR), which develops biomarkers used by pharmaceutical companies in drug development, cut its IPO target to $41 million, according to a regulatory filing. ... has raised $34 million  [Cromwell Schubarth,  Silicon Valley Business Journal, Jun 10, 14]

KineMed (Emeryville, CA; $6.7M SBIR, 48 employees, founded 2001) registered for an [IPO] up to $51 million.  .... makes biomarker tests used by pharmaceutical companies in drug development. [Steven E.F. Brown, San Francisco Business Times, Jan 8, 14]

Amgen  will use technology from KineMed (Emeryville, CA; $6.9M SBIR) as the biotech giant zeroes in on diseases like Alzheimer's, Parkinson's and Huntington's diseases. .... will use KineMed's mass spectrometric "Dynamic Proteomics" technology to track how misfolded proteins, which accumulate in the brains of many people with neurodegenerative diseases, are created and cleared out of the brain.  [Ron Leuty, San Francisco Business Times, Oct 15, 13] One SBIR was $4.4M from NIH]

Kinestral Technologies (South San Francisco, CA)

Kinestral Technologies (South San Francisco, CA; no SBIR) announced it has raised $65 million [Series C round led by one of its partners, Japanese glass manufacturer AGC] to help bring its new glass-tinting technology to market.  [Luke Stangel, Silicon Valley Business Journal, Jan 31, 17]

Kineta (Seattle, WA)

Kineta (Seattle,WA; $5.7M SBIR) announced that it has entered into a strategic research collaboration with Pfizer to develop RIG-I agonist immunotherapies for the treatment of cancer. The agreement grants to Pfizer the exclusive rights to KIO’s RIG-I screening platform and related compounds and technologies. ... KIO will receive a $15 million upfront  and will be eligible to receive up to $505 million in potential research, development and sales milestone payments. Additionally, KIO is eligible to receive tiered royalties on net sales. Pfizer will fund RIG-I target-related research conducted by Kineta for an initial period of three years, after which Pfizer will be responsible for further development and commercialization of product candidates. [company press release,Dec 17, 18]

Kineta (Seattle, WA; $5.7M SBIR, founded 2007) announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, to develop Kineta’s α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain. .... will receive an undisclosed upfront payment and is eligible to receive development and commercialization milestone payments up to $359 million based on achievement of certain predetermined milestones. [company press release, Apr 16, 18] total funding $28M []

Recently biotech Kineta (Seattle, WA; $1.2M SBIR) received an undisclosed amount of [NIH] funding to expand testing for a drug that could potentially treat the virus, which is spreading throughout the world and can cause babies to be born with unusually small heads— a condition known as microcephaly. ....  In May, Kineta received $7.2 million to further its development of a drug to treat a type of severe viral illness endemic to West Africa known as Lessa fever. ...  The World Health Organization declared the virus a public health emergency.     [Coral Garnick, Puget Sound Business Journal, Aug 5, 16]  Despite all its bureaucracy for normal public funding, the federal government can move immediately and massively in an emergency.

Seattle’s Kineta Therapeutics will tap up to $7.2 million in funding from the Wellcome Trust to develop a treatment for Lassa fever. The cash should take the program through Phase 1 trials, according to Kineta. [Bruce Bigelow,, May 6, 16] Henry Wellcome invented the pill, and his Trust has a very interesting [free] museum in London with regular fascinating special exhibitions.

Kineta (Seattle, WA; $1.2M SBIR, nearly 50 employees) announced the award  of  a $1.1million contract from  the  US  Army  for further  development  of  lead candidate CSP4, a novel peripherally acting treatment targeting chronic pain management  [company press release, Sep 28, 15]  ....  has raised more than $40 million since it began operating in 2008  ... is also part of a new Seattle-based consortium known as KPI Therapeutics that is supporting Kineta’s efforts to take a pipeline of promising new drugs through clinical trials and bring them to market more efficiently.  [Taylor Soper,, Jul 29, 15]

Kineta (Seattle, WA; $1.2M SBIR, founded 2008, 50 employees) just landed a [NIH] contract for about $4 million to develop an immunotherapy treatment which would treat a variety of infectious diseases, such as the flu, dengue fever, Ebola and others. ....  develops drugs for chronic pain, autoimmune and infectious diseases. The funding will be used to bring a specific drug candidate to the pre-clinical stage, with the goal of eventually advancing it through clinical trials. [Annie Zak,  Puget Sound Business Journal, Jul 29, 15] ...   has raised more than $40 million .... also part of a new Seattle-based consortium known as KPI Therapeutics that is supporting Kineta’s efforts to take a pipeline of promising new drugs through clinical trials and bring them to market more efficiently.  [Taylor Soper,, July 29, 2015]

 Kineta (Seattle, WA; $1.2M SBIR) has entered into a partnership with UW Medicine and the University of Washington's commercialization center CoMotion to bring more drug therapeutics to market.  The new arrangement, called the Alliance for Innovation in Therapeutics, will identify, fund and develop promising new therapeutics emerging from UW, with the goal of commercializing more drug therapies.  [Annie Zak, Puget Sound Business Journal, Apr 21, 15]

biotech Kineta (Seattle, WA; $1.2M SBIR) just finished a $1.3 million funding round to advance clinical development of three of its main drug programs [that] develop treatments for psoriasis, pain, antiviral drugs for influenza, dengue fever and other viruses, and autoimmune diseases like multiple sclerosis and arthritis. ...  One of the company's lead products, called ShK-186, is already in a clinical trial for psoriasis.   [Annie Zak, Puget Sound Business Journal, Jan 15, 15]

An international partnership that includes biotech Kineta (Seattle, WA; $1.2M SBIR) has created a new company with a unique approach to accelerating the development of new drug candidates.  The new company, KPI Therapeutics, will act as both an investment group and a strategic hub to unify research and development efforts.  KPI doesn’t own any of the companies involved, but will allow them to unite their overlapping areas of research and develop an umbrella strategy for drug development.  [Valerie Bauman, Puget Sound Business Journal, Jun 5, 14]

The University of Washington and biotech Kineta (Seattle, WA;  $1.2M SBIR) have won a $6.8 million [NIH] contract to develop vaccine ingredients that help boost the body’s immune response.  .... studying the activity of adjuvants — added ingredients — in experimental vaccines that protect against influenza A virus, West Nile virus and other emerging pathogens, including dengue virus and Japanese encephalitis virus.  [Valeria Bauman, Puget Sound Business Journal, Nov 4, 13]

Kineta (Seattle, WA; $1.2M SBIR) has found some more support for its drug development work from ... a group of [13] oil traders. ....  has secured a total of $46 million in R&D support through government grants, contracts, and investment capital since its inception in December 2007   [Luke Timmerman, xconomy,com, May 21, 13]

Smaller return sooner.  A new biotech business model aimed at earning faster returns for investors will be facing its first test in the next 12 months.  biotech Kineta (Seattle, WA; $1.2M SBIR) is taking a nontraditional approach, essentially hoping to make a profit more quickly by licensing its drug discoveries without investing heavily in production.  [Valerie Bauman, Puget Sound Business Journal, Apr 30, 13]

Kineta (Seattle, WA; $1.2M SBIR) got a venture infusion of undisclosed amount. Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs. We believe our unique approach will yield a new class of drugs to respond to diseases caused by viruses such as, Influenza, Hepatitis C and West Nile virus: diseases that afflict millions of people. [, Feb 8, 13]

Kineta (Seattle, WA; $1.2M SBIR), the developer of drugs for immune disorders, said it received a $2.8 million [NIH] grant. .. will support Kineta’s work on a new class of antiviral drugs that trigger the innate immune system to fight various viruses like hepatitis C, influenza, and West Nile. The company said it expects to pick a lead drug candidate in 2012. [Luke Timmerman,, Aug 16, 11]

Biotechnology company Kineta (Seattle, WA,founded in 2007 ; $1.2M SBIR). said it received a $2.8 million [NIH] grant to develop new antiviral drugs aimed at hepatitis, flu and the common cold. ... , said the grant will help researchers improve drugs that target deadly RNA viruses. Hepatitis C, influenza, West Nile virus, respiratory syncytial virus (RSV) and the common cold are among the RNA viruses that the company plans to treat.[Mwiza Kalisa, Puget Sound Business Journal, Aug 11,11]

Kineta (Seattle, WA; no SBIR) is trying a new approach. ... plans to fund its research step by step, relying on revenue-generating deals to undertake the next step in research. ... started the company last December but unveiled it publicly only this month.  Their new venture quickly came after the $9 million sale of their previous company, Illumigen Biosciences ($2M SBIR)... If Illumigen's research and commercial potential fully pans out, its shareholders could get up to $330 million in additional payments from Cubist. ... Kineta has so far partnered with Cubist for early-stage work on a hepatitis C drug, and has received funding from the National Institutes of Health. But it is also pitching itself to investors.  [Angel Gonzalez, Seattle Times, Dec 23, 08]

Kinetic Concepts (San Antonio, TX)

Acelity LP (San Antonio, TX; no SBIR) is again expanding its product portfolio. The advanced wound care and regenerative medicine company is rolling out its BIOSORB Gelling Fiber Dressing in the U.S. [W. Scott Bailey, San Antonio Business Journal, Jul 28, 16]  a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, LifeCell. and Systagenix Wound Management, Limited. [company website]

Kinetic Concepts (San Antonio, TX)say [subsidiary] LifeCell ($4M SBIR) has acquired an advanced adipose Tissue Injector, or aTI, from TauTona Group, a medical device incubator based in Menlo Park, Calif. [W. Scott Bailey,  San Antonio Business Journal, Jan 31, 14]

Kinex Pharmaceuticals (Buffalo, NY)

Kinex Pharmaceuticals (Buffalo, NY; $1.1M SBIR) has raised a substantial new sum of money to fund its drug development and commercialization efforts.  The Buffalo Niagara Medical Campus company, focused specifically on cancer therapies, is considered one of the most promising pharmaceutical endeavors in Buffalo and has raised tens of millions from investors in Buffalo and Asia.  .... said it was the largest private placement equity raise in its history and led by Huateng Ma, a billionaire technology entrepreneur from China.  [Dan Miner, Buffalo Business First, May 18, 15]

Kinex Pharmaceuticals  (Buffalo, NY; $1.1M SBIR) is suing a longtime executive in a case that involves trade secrets and billionaire entrepreneurs from California.  The financial implication of the situation is symbolized by Kinex’s demand for compensation from the defendants: nearly $3 billion. .... [former co-founder Dyster]  is now defending herself along with the companies for which she worked as a consultantFulgent Therapeutics (Temple City, CA; no SBIR) and ANP Technologies (Newark, DE; $3.5M SBIR).   [Dan Miner, Buffalo Business First, May 5, 15]

Kinex Pharmaceuticals (Buffalo, NY; $1.1M SBIR, founded 2003) and its Korean partner Hanmi Pharmaceutica l executed an agreement whereby Kinex is leading the development of its Orascovery program [allows intravenous cancer drugs to be taken orally] in India. .... Last year,  Kinex bought Newstead-based pharmaceutical manufacturer QuaDPharma (Cherry Hill, NJ; $300K SBIR) ...  Kinex now has offices in Hong Kong, Taipei, New Jersey and Buffalo  [David Bertola,  Buffalo Business First, Apr 21, 15]

A top executive at Kinex Pharmaceuticals (Buffalo, NY; $1,.1M SBIR, 30 employees) said company officials have been eager to add a manufacturing segment in recent years.  And Kinex followed through with the announcement it has acquired QuaDPharma LLC (Clarence, NY; no SBIR, 13 employees, founded 2011), a pharmaceutical manufacturer.  ...  Earlier this year, Kinex expanded its Asian research efforts when it entered into a new licensing agreement with Taiwan-based PharmaEssentia Corp. The agreement grants PharmaEssentia exclusive development and commercial rights in Taiwan and Singapore to Kinex drugs Oraxol and Oratecan.    [David Bertola, Buffalo Business First Reporter, Sep 9, 14]   To meet growing manufacturing demand for clinical testing products with an FDA seal of approval, Empire Genomics LLC (Buffalo, NY; no SBIR) has partnered with commercial contract manufacturer QuaDPharma.    The companies recently completed a first batch of products for Empire Genomics customers that meet an FDA standard called “Current Good Manufacturing Practice.” [David Bertola, Buffalo Business First Reporter, Aug 29, 14]

[FDA] authorized Kinex Pharmaceuticals (Buffalo, NY; $1.1M SBIR)  to begin U.S.-based clinical trials for cancer drug Oraxol [which]  allows for oral delivery of paclitaxel when combined with an absorption enhancer from Korea-based Hanmi Pharmaceutical Co. Ltd.. [David Bertola, Buffalo Business First, Jul 25, 13]

Kingbright (City of Industry, CA)

Cree said it has filed patent infringement lawsuits against [LED makers] Harvatek (Taiwan) and Kingbright (City of Industry, CA; no SBIR) in U.S. District Court for the Western District of Wisconsin. [Milwaukee Journal Sentinel, Sep 16, 14]

Kinnate Biopharma (San Diego, CA)

Kinnate Biopharma (San Diego, CA; no SBIR, founded 2018) focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, announced that it has raised $98 million in a Series C financing [company press release, Aug 26, 20] total funding $172M []

Kior (Pasadena, TX)

Biofuel dream turns to ashes. KiOR filed for bankruptcy, leaving behind 2,067 creditors, including the state of Mississippi, which had given KiOR a $75 million, 20-year, no-interest loan after the company assured officials that it would invest $500 million in the plant and create 1,000 jobs by December 2015. During its short life, KiOR lost money on every gallon it produced; costs ran $5 to $10 a gallon even without counting the cost of building the plant, according to biofuel industry analysts.  ... Even injections of money from Khosla ($85 million) and Bill Gates ($15 million) in October 2013 could not stave off bankruptcy. ....  [Vinod] Khosla is one of the gods of high-tech venture capital  ....  Khosla also backed Range Fuels, which closed its Georgia wood-chip-to-ethanol plant in late 2011, after getting $46.3 million of a $76 million Energy Department grant and half of an $80 million loan from the Agriculture Department, according to a Bloomberg News report.    [Steven Mufson, Washington Post, Nov 30, 14]   Lesson learned with new tech - start a small experiment, and include the economics.

Kior (Pasadena, TX; no SBIR) filed for bankruptcy.  accepted a bid for its assets from affiliates of billionaire venture capitalist Vinod Khosla that have been providing and will continue to provide financing for Kior ...  The state of Mississippi loaned Kior $75 million in 2010 for a plant that would convert wood waste and nonfood crops into gasoline and diesel. The plant stopped production in January  [Olivia Pulsinelli,  Houston Business Journal, Nov 10, 14]

Kior (Pasadena, TX; no SBIR) biofuels producer might sell itself after missing a $1.88 million loan payment ...  the state of Mississippi loaned Kior $75 million in 2010 for a plant in Columbus that would convert wood waste and non-food crops into gasoline and diesel. The plant stopped production in January.  ....In March, Kior was struggling to stay afloat, flirting with bankruptcy before billionaire venture capitalist Vinod Khosla agreed to invest up to $25 million to keep the company running.  [Josh Cain, Houston Business Journal, Jul 11, 14] Hope oozes eternal in biofuel.

Big job, big bucks, big question. Kior, a company that turns wood chips into gasoline and diesel fuel, announced that it had raised $100 million, which should be enough to keep it in business for another year or so and help it build a new biorefinery.  ....  Although dozens of companies have trotted out lab-scale technologies for breaking down recalcitrant biomass and turning it into fuel, they’ve struggled to commercialize these systems, in part because it’s been difficult to raise funds to build large refineries and in part because the methods often fail to perform as well at a large scale as they do in the lab.  [Kevin Bullis, MIT tech review, Oct 23]

Kips Bay Medical (Plymouth, MN)

Kips Bay Medical (Minneapolis, MN; no SBIR, founded 2007) announced the first implant in the United States as part of its eMESH I clinical feasibility trial. The eMESH trial will collect patient data on the performance of Kips Bay’s eSVS Mesh, which is designed to strengthen veins used in coronary bypass graft surgery and keep the grafted vessel from closing.  [James Walsh, Minneapolis Star Tribune, Feb 5, 13]

Med-tech startup Kips Bay Medical (Plymouth, MN; no SBIR) raised $6.5 million through a public stock offering, the company announced .... to fund clinical trials of its sSVS Mesh device, which is used during coronary artery bypass grafting surgery. [Katherine Grayson, Minneapolis St Paul Business Journal, Dec 28, 12]

Kiromac Biopharma (Houston, TX)

Kiromic Biopharma down 28% [Jun 30, 21]

Kiromac Biopharma (Houston, TX; $1.3M SBIR) down 17%, [Jun 29, 21]

Kiromac Biopharma (Houston, TX; $1.3M SBIR) down 20%, [Jun 28, 21] announced We intend to use our AI target, Mesothelin isoform 2, in the upcoming first-in-human dosing for solid tumors in 3Q-2021. [company press release, Jun 28, 21]

Kite Pharma

Young immunotherapy biotech company Alpine Immune Sciences (Seattle, WA; founded Jan 2015) landed its first collaboration deal [as it] announced that it is teaming up with California-based immunotherapy biotech Kite Pharma (Santa Monica, CA; no SBIR) to discover and develop immunotherapy treatments for cancer. ...  raised about $2.6 million earlier this year.  [Annie Zak,  Puget Sound Business Journal, Oct 27, 15]

A baby girl who was close to dying from cancer [acute lymphoblastic leukemia] has been rescued by a cell therapy [developed by Cellectis (France)] envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday. ... Other companies pursuing this approach, often called CAR-T, including Juno Therapeutics and Kite Pharma, have achieved large stock market valuations.  [ANDREW POLLACK, New York Times, NOV 5, 2015]

Hopes that fledgling companies will repeat and extend upon those advances [by Bristol-Myers-Squibb] are behind the recent share-price gains in Juno Therapeutics, Kite Pharma and bluebird bio. Their treatments, which take a different approach than Bristol-Myers’s, haven’t yet reached the market.  ....   Shares of Juno, which is developing therapies for leukemias and lymphomas, ended Friday’s trading at $45.52, following a December initial public offering at $24. Kite Pharma has soared to $62.80 from $28 since the beginning of October. Bluebird bio, driven more by advances by gene-therapy drugs than in immunotherapy, has climbed to $93.32 from $39 since early December.   [Gregory Zuckerman and Ron Winslow, Wall Street Journal, Feb 22, 15]

Kitware (Clifton Park, NY)

Kitware (Clifton Park, NY; $11M SBIR)  that builds open source platforms and develops advanced research software, has received a $13.8 million [DARPA] contract  .... will develop software that will be used to detect potential threats and perform forensic analysis. [The Business Review (Albany), Jul 19, 10]

Kiva Systems (Woburn MA)

Amazon expects to add 10,000 robot workers to its warehouses by the end of the year, according to CNN. While robots are not new to Amazon -- it already uses 1,000 robots in its fulfillment centers -- it would mark a ten-fold jump in non-organic employees. The robots are manufactured by Kiva Systems (no SBIR), which Amazon purchased two years ago for $775 million.  .... Although it's easy to see how these robots, along with the delivery drones it introduced last year, could displace a large portion of Amazon's 88,400 employees worldwide, the company has stated that these robot workers wouldn't impact the size of its human workforce.   [Leo Sun,, May 29, 14]

Martin Buehler, iRobot’s former director of research -  “Robot Guy” - touted the disruption that robotics companies in New England have made, such as Rethink Robotics (no SBIR),  iRobot  ($8M SBIR), Harvest Automation  (no SBIR), Kiva Systems (no SBIR; acquired by, Symbotic (no SBIR) and, of course, his company, Vecna Technologies (Greenbelt, MD; $8.5M SBIR). Buehler showed how iRobot’s devices are used in defenseapplications as well as cleaning floors, pools and gutters. He also showed how Harvest’s robots are used in labor-intensive agriculture applications. The audience was amazed by Kiva’s robots driving efficiency, and how the robots have replaced the “runners” who fill product orders.  [Patircia Resende, Boston Business Journal, Mar 7, 13]

Walgreen's installed Kiva Systems (Woburn MA; no SBIR) robots in its warehouse.  Kiva got $10M VC in 2005. [Mass High Tech, Nov 7, 07]

KLD Energy Technologies (Austin, TX)

KLD Energy (Austin, TX; no SBIR, founded 2007, 50 employees) electric engines powering two-wheeled bikes through the streets of cities in China, Malaysia and other Asian countries....  The use of electric motorcycles and electric scooters in the Asia-Pacific market is expected to increase dramatically in the next five years, potentially reaching 22 million by 2017, according to a report by industry research company Pike Research. The affordability of these vehicles — combined with a ban on combustion engine two-wheeled vehicles in 90 cities across China — have made them a promising market for KLD, company officials say. ....  complete system design of a battery, controller and motor. That allows the engineers at KLD to better optimize the performance of the vehicles,  [Austin Kurth, Austin American Statesman, Dec 11, 11]

Less than a week after winning [a $2.8 million grant from the Texas Emerging Technology Fund], KLD Energy Technologies (Austin, TX; no SBIR) said it has expanded its Austin operations to accommodate a growing work force.  The company, which is developing an electric drive system for electric vehicles, said its work force has grown from 5 to 55 employees this year, including more than 20 engineers and research and development experts.  ...  It also has expanded its Morgan Hill, Calif., propulsion research facility and opened sales and service offices in China, Malaysia and Vietnam.  [Austin American Statesman, Jan 4, 11]

$2.8 million to KLD Energy Technologies (Austin, TX; no SBIR) to commercialize its motor system for electric vehicles. The company is working with UT's Department of Electrical and Computer Engineering.  [Austin American Statesman, Dec 30, 10]

Klotho Therapeutics (San Diego, CA)

Klotho Therapeutics (San Diego, CA; no SBIR) focused on commercializing its patent pending version of the protein/hormone Klotho, announced the first closing of a $10 million Series A Preferred round of financing to advance Klotho development for the highest priority indication: kidney disease. [company press release, Nov 2, 17]


KMel Robotics (Philadelphia, PA)

a new heavyweight competitor now has its sights set on the [image processing system-on-chips (SoCs)] sector. Qualcomm, the largest mobile chipmaker in the world, recently started selling SoCs for action cameras and drones as well. Could that move throttle Ambarella (Santa Clara, CA; no SBIR)'s growth in both markets? ...  As for drones, Qualcomm has several advantages over Ambarella. In February, it acquired KMel Robotics (Philadelphia, PA; no SBIR), a startup which develops multi-rotor drones which can coordinate with one another in "swarms". Neither Ambarella nor Intel (which has drone ambitions of its own) owns this type of technology   [The Motley Fool, Sep 26, 15]

KMel Robotics (Philadelphia, PA; no SBIR) has been acquired by Qualcomm Technologies. KMel's founders, two University of Pennsylvania graduates, announced the news on their company's website. ... Last month, local tech blogger reported that the DARPA was looking for a "tiny, speedy drone," and that it had its eyes on KMel.  [Lauren Hertzler, Philadelphia Business Journal, Feb 3, 15]  

Knightscope (Mountain View, CA)

Knightscope (Mountain View, CA; no SBIR), a startup has been busy designing, building, and testing the robot, known as the K5, since 2013. Seven have been built so far, and the company plans to deploy four before the end of the year at an as-yet-unnamed technology company in the area. The robots are designed to detect anomalous behavior, such as someone walking through a building at night, and report back to a remote security center.   [Rachel Metz ,, Nov 13, 14]

Knome (Cambridge, MA)

Knome (Cambridge, MA; no SBIR, founded 2007) received a $5 million equity stake and a strategic partnership from French diagnostics firm bioMerieux. The agreement will see bioMerieux using Cambridge-based Knome’s genome analysis platform under an exclusive license deal to develop next-generation, sequence-based in vitro diagnostics.  [Mass High Tech, Apr 21, 10]

Knopp Biosciences (parent of Knopp Neurosciences)

Drug discovery and development company Knopp Biosciences (Pittsburgh, PA; no SBIR) is raising an additional $30 million to help accelerate testing for further development of novel compounds designed, this time, to treat other neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease.  [Malia Spencer, Pittsburgh Business Times, Jul 13, 12]

October 14, 2010--Knopp Neurosciences Inc. announced today that it has formed a new parent entity called Knopp Biosciences LLC

Innovation Works, Hazelwood (PA) VC fund, in 2007 invested $6.1 M in technology companies, including its 100th investment.  The  specializes in giving a leg up to young technology companies cites three [no SBIR] success stories: Knopp Neurosciences, which is working on a drug therapy to slow the advance ALS ("Lou Gehrig's disease"). ... granted "orphan drug" status by the FDA ; Printed electronics manufacturer Plextronics, which attracted more than $20 M in new investment last year and set an efficiency record with its solar cells;  Thorley Industries signed a $215 M deal with Hasbro for that company to manufacture and sell a new line of Thorley products  [Elwin Greene, Pittsburgh Post-Gazette, May 2].

KNOW Bio (Morrisville, NC )

KNOW Bio, LLC, (Morrisville, NC, no SBIR) created in late 2015 from the separation of all non- dermatological assets from Novan [company press release, Jan 26, 17] had a venture funding of  $2.61M  on May 16, 2017 [, May 16, 17]

Know Labs (Seattle, WA)

Know Labs (formerly Visualant, Seattle, WA; no SBIR, founded 1998), developing non-invasive technology to detect and measure glucose, alcohol, and other substances in the blood, raised nearly $4 million in March. [Jeff Buchanan,, Apr 2, 19]

KnuEdge (San Diego, CA)

Deep learning demands new chips. The Semiconductor Industry Association and its research affiliate have enlisted 22 tech companies to launch a broad study of technologies that might bring computing advances. Alternatives range from stacking circuitry in space-saving layers to making chips from biological materials such as proteins.  Development is particularly intense in deep learning --- training systems by exposing them to immense quantities of data rather than programming them with explicit instructions. ... IBM is targeting deep learning with TrueNorth, a chip unveiled in 2014 and composed of one million structures patterned after the brain’s neurons. Mr. Modha said it has shown startling acceleration of deep-learning applications and is on track to create a “business at scale” by 2019.  Venture capitalists have taken notice. ... Cerebras Systems,(Los Altos, CA; no SBIR,25 employees) plans to design processors targeting deep learning, found it surprisingly easy to raise venture-capital funds, said founder Andrew Feldman. ... Other startups designing chips for deep learning include KnuEdge (San Diego, CA; no SBIR), Graphcore Ltd  (UK), Cornami (Santa Clara, CA; no SBIR) and Wave Computing (Campbell, CA; no SBIR).     [Don Clark, Wall Street Journal, Jan 11, 17]  Why no SBIR? Such companies are reaching too far too fast needing too much capital for federal mission agencies to keep up with plodding SBIR.

Dan Goldin spent nine years [1992-2001]as chief of [NASA] ... Now another challenging launch: a startup that has been working in secret for 10 years on a form of brain-like computing.  ... KnuEdge (San Diego, CA: no SBIR) developed an unusual processor chip and related hardware and software, aiming to bring dramatic speed improvements to tough chores like finding patterns in images, sounds and financial data. KnuEdge is disclosing its plans for the first time, along with a parallel effort in software to help recognize speech in noisy environments. [Don Clark, Wall Street Journal, Jun 6, 16]  NASA HQ talked about commercialization of SBIR but let the Centers, which have no interest in commercialization, decide the SBIR winners.  An recent NAP report panned NASA's SBIR.

Koam Engineering Systems (San Diego, CA)

Three small businesses have been awarded spots on a potential five-year contract to support analysis and test engineering work on the U.S. Navy’s command, control, communications, computers, cyber, intelligence, surveillance and reconnaissance systems: Highbury Defense Group (San Diego, CA), Koam Engineering Systems (San Diego, CA), Tactical Engineering and Analysis (San Diego, CA). [Peter Graham, GovConWire, Oct 1, 18] None had SBIR. The whole best national talent for the job live around the flagpole in San Diego?

Kodiak Sciences (Palo Alto, CA)

Kodiak Sciences (Palo Alto, CA; no SBIR, founded 2009) announced it has filed [for preliminary $100 million target IPO] ... developing experimental drug [for age-relted macular degenration] that may require less frequent injections [Frank Vinluan,, Sep 10, 18] total funding $69M []

Kodiak Sciences (Palo Alto, CA; no SBIR) biopharmaceutical developing new drugs for eye disease, said it has closed on a $34 million Series B financing round ... With the latest round, Kodiak has raised more than $60 million altogether.  [Bruce Bigelow,, Jan 18, 16]

Kolltan Pharmaceuticals (New Haven, CT)

Xetrios Therapeutics (San Diego, CA; no SBIR) was purchased by Kolltan Pharmaceuticals (New Haven, CT; no SBIR)  [Xetrios] owns intellectual property from [founder Greg] Lemke’s research into the Axl and Mer receptors, along with another receptor called Tyro3.  On Sep 12 Kolltan filed for a potential [IPO]. ...  Lemke found that two cellular receptors or switches, once believed to work in similar ways, actually play different roles. Knowing which receptor does what is essential for treating disorders caused when one or the other malfunctions, Lemke said.   [Bradley Fikes, utsandiego. com, Sep 15, 14]

Connecticut’s largest quarterly tally for venture capital deals in years, $189 million. Kolltan Pharmaceuticals,  (New Haven, CT; no SBIR) a cancer-drug developer received $60 million last month from a variety of investors. Kolltan, with technology developed at Yale, is in Phase 1 trials for a revolutionary therapy.   ....   Melinta Therapeutics (New Haven, CT; no SBIR)  now in Phase 3 trials for a drug to treat gonorrhea and other infections with a single pill, received $70 million in February from a group led by Vatera Healthcare Partners, its major current equity owner.  [Dan Haar, Hartford Courent, Apr 21, 14]

Kolltan Pharmaceuticals (New Haven, CT; no SBIR) raised $2.5 million in new funding, according to federal documents. The company is focused on developing therapies to fight tumor growth based on a particular enzyme mechanism in cells.  [Rodney Brown, Mass High Tech, Jan 5, 10]

Kolltan Pharmaceuticals (New Haven, CT; no SBIR) oncology therapeutics company, has announced the closing of a $40 million Series A funding round  [Mass High Tech, Aug 18, 09]

Kolltan Pharmaceuticals (New Haven, CT; no SBIR) oncology therapeutics company, has raised more than $35 million in Series A round of preferred stock funding. [Mass High Tech, Jan 9, 09]

Komoku   (College Park, MD)

A startup funded by [DARPA] is ready to emerge from stealth mode with hardware- and software-based technologies to fight therapid spread of malicious rootkits.  Komoku, of College Park, Md., plans to ship a beta of Gamma, a new rootkit detection tool that builds on a prototype used by several sensitive U.S. government departments to find operating system abnormalities that may be linked to malicious rootkit activity. [Ryan Naraine, eWeek, Apr 24, 06]

Kona Medical (Menlo Park, CA and Bellevue, WA)

Kona Medical (Menlo Park, CA and Bellevue, WA; no SBIR)  raised $10 million in Series D financing, ... develops non-invasive hypertension treatments  ....  funding will be used to build Kona's footprint in [China]. ....  In December, completed a $40 million round of financing.  [Vincent Lara-Cinisomo, Web contributor, Silicon Valley Business Journal, Oct 21, 13]

Konarka Technologies  (Lowell, MA)

Konarka Technologies (Lowell, MA; $1.6M SBIR and $150M private capital) filed for Chapter 7 bankruptcy protection, the company announced  [Mass High Tech, Jun 4, 12]  founded [2001] by Mr. [Howard] Berke and by Dr. Alan Heeger, the winner of the Nobel Prize for his work in conductive polymers. Among the Company’s assets are over hundreds of owned and licensed patents and patent applications in the field of solar energy and a state-of-the-art manufacturing plant in New Bedford, Massachusetts. [company website]  Heeger was also a founder of Uniax  (Santa Barbara, CA; $5M SBIR), now a wholly-owned subsidiary of DuPont.

Low efficiency,lower price. In early April, Mitsubishi Chemical reportedly set a new efficiency record, producing organic solar cells with a 9.2% conversion efficiency, according to The Nikkei, a Japanese business daily. Meanwhile, three other companies—Konarka Technologies in Lowell, Massachusetts; Solarmer Energy (El Monte, CA no SBIR) and Heliatek in Dresden (now beautifully restored), Germany—are now reporting cells with efficiencies greater than 8%. Many researchers in the field are confident that the figure could soon top 10% and possibly reach 15%. [Robert Service, Science, Apr 15]

Konarka Technologies has taken in a $20 million investment from Japanese giant Konica Minolta Holdings Inc. in a deal that will have the two companies collaborate on organic thin-film photovoltaics. [Mass High Tech, Mar 2, 10]

Konarka Technologies raised $23.8 million in a Series G round of funding as well as a warrant sale, according to regulatory filings.  [Mass High Tech, Jan 8, 10]

“You may be able to go out of state and get a workforce at 20 to 30 percent less, but you’re not going to get the same quality,’’ said David Theriault, president of Elite Envelope, ... After spending years developing plastic solar energy cells, Konarka Technologies was ready to begin full-scale production of flexible films that could be incorporated into purses and backpacks to create solar chargers for electronic devices. ... chose New Bedford, MA, where it found a former Polaroid plant with equipment suited to rolling out its thin films. But more important, said Konarka chief executive Rick Hess, the company was able to hire former Polaroid workers who had the skills to do it.  [Robert Gavin, Boston Globe, Nov 21, 09]  Our porking politicians should note that investing public money in "innovation" won't produce big returns unless the resulting product can be produced in volume. Cheap labor in isolated areas just cannot do the job.

Photovoltaic cells made from organic polymers, rather than crystalline silicon, could make solar power much cheaper. Last year Konarka opened a factory for such solar panels, which are flexible and produced in a process akin to printing (see "Mass Production of Plastic Solar Cells"). The first application of Konarka's potentially transformative technology? Umbrellas. SkyShades, based in Orlando, FL, is incorporating the panels into umbrellas designed for outdoor seating areas in places like restaurants and bars. Patrons can recharge mobile devices such as laptops and cell phones from outlets built into the stem of the umbrella. The four-meter-wide Powerbrella can generate up to 128 watts of electricity, which charges a bank of batteries located in its base. [MIT Tech Review, Sep/Oct09]

Konarka Technologies landed $5 million in new state funding from the Emerging Technology Fund of Massachusetts Development Finance Agency and the Massachusetts Renewable Energy Trust’s Business Expansion Initiative. [Mass High Tech, Feb 18, 09]

Plastic Power.  CEO Rick Hess unfurls a roll of brown plastic film attached to a small electric meter. "Three volts," he says, smiling. "And that's just from the light in this room. Imagine what this reads when we're outside."  Hess, who runs solar upstart Konarka (Lowell, MA; $1M SBIR) , is showing off Power Plastic, a new lightweight, flexible, and cheap material that converts indoor and outdoor light into electricity. Think of it as a solar panel that rolls up like camera film. "Soon you may not even need batteries," Hess says, holding a prototype of a portable device that will recharge your cellphone in an hour. "We can put this stuff anywhere."  ... impressed investors,  have put $145 million into the closely held venture, including a recent $45 million in funding from French oil giant Total. [Barney Gimbel, Fortune, Feb 2, 09] technology is based on the work of the late Dr. Sukant Tripathy, an internationally known materials scientist and professor at UMASS Lowell, and Dr. Alan Heeger, a 2000 Nobel Laureate in Chemistry. By 2006 it had partners in at least four Euro countries and first shipments to Army and AF. [company website] If the Navy's 2003 Phase 2 SBIR provided the previously lacking technical credibility for Hess's idea, SBIR did its intended job in launching an infant technology. 

<Konarka Technologies launched a new $45 million R&D deal with Total Gas & Power Ltd., a UK-based oil and gas company.  With the deal, Total will become the leading stakeholder in Konarka, with a slightly less than 20 percent share. ... Konarka’s thin-film technology allows for the colored printing and application of a polymer material that can convert light into energy. The technology, originally developed by the late Sukant Tripathy, a materials scientist and professor at the University of Massachusetts Lowell, and Alan Heeger, a 2000 Nobel Laureate in Chemistry, has attracted a lot of attention since the company was founded in 2001, as well as more than $100 million in private funding from a number of investors. [Mass High Tech, Dec 15]  Heeger did the chemistry of conductive plastics that became the bedrock of UNIAX that Heeger co-founded and got SBIR from BMDO in 1992.

Konarka Technologies opened its first commercial scale, roll-to-roll solar manufacturing facility at the former home of the advanced printing technology division of Polaroid Corp. in New Bedford.  [Mass High Tech, Oct 7, 08]

Konarka claims the first-ever demonstration of inkjet printing manufacturing of solar cells of Power Plastic®, a material that converts light to energy. [press release, Mar 4, 08]

Konarka Technologies (Lowell MA) got a $4.7M ATP award with Air Products and Chemicals ($21B market cap with $150M R&D) for R&D on transparent, flexible solar modules for windows and other building-related applications. Earlier this month, the company closed a $45M round of funding, bringing its total capital investment to more than $105M .[Mass High Tech, Oct 9] Where is the line between technology nurturing and corporate welfare? When is too much government?  But we let our politicians use the same tired lines to get our votes when we and they know they have no hope of actually doing what they promise. The Arizona senator promised to rein in runaway federal spending, simplify the tax code, help U.S. industries become more competitive and control spiraling health care costs.... "I will not let the Democrats roll back the Bush tax cuts,"  while he offers no way to pay for the war he applauds. Another candidate Robin Hood offered: Every citizen could get a 401(k) retirement account and up to $1,000 in annual matching funds from the government.  At least that candidate had a plan to pay for it - taxing rich estates.  Have we learned anything in the last six years about free lunches and government getting out of control?

Konarka entered into a development agreement with Tokyo-based Toppan Forms Co. Ltd., a maker of printable electronics and digital information technologies.  [Mass High Tech, Sep 11]

Konarka Technologies which has developed an organic plastic film that converts light into low levels of energy and can be used to power electronic devices, plans to raise another $40 million to add to the $80 million of venture capital it already has. The Lowell, Mass., firm is putting the finishing touches on commercial prototypes and expects to be in broader production by 2008. [J Schieber and Y Chernova, Wall Street Journal, Aug 27]

Konarka and its flexible plastic solar cell strips are expecting a visit from Energy Secretary Bodman who will announce a grand award from Bush's Solar America Initiative. The six-year-old private company has attracted nearly $60M in venture capital funding. and nearly $10M in grant money from U.S. and European governments. [Mark Jewell, AP, Mar 8]

Michael Grätzel, [Swiss] chemistry professor is most famous for inventing a new type of solar cell that could cost much less than conventional photovoltaics. Now, 15 years after the first prototypes, (the Grätzel cell) is in limited production by Konarka, a company based in Lowell, MA, and will soon be more widely available. [Kevin Bullis, MIT Tech Review, Sep 12]  Still private Konarka had one Navy SBIR Phase II but apparently missed the Energy Dept train last year for  a second.

Konarka Technologies (Lowell, MA), a developer of Power Plastic photovoltaic products, got another $20M of VC which pushes total VC over $60M since 2001.  [Mass High Tech]  

Konarka got a $1.6M Army contract light-activated power plastic. [Apr 05]

The cheap nanomaterial photovoltaic by Konarka Technologies (Lowell, MA) raised $18M and expects to introduce its first products by New Year's before it even finishes its Navy Phase 2 SBIR. The Navy liked enough to invite the company for a show-and-tell at a recent big Navy conference “Naval Research in the 21st Century: Dilemmas and Solutions.” Konarka which has subsidiaries in Austria and Switzerland has as its technical leader Alan Heeger, Nobel laureate who was connected to SBIR at his earlier California company - UNIAX.

Koning (Rochester, NY)

Koning (West Henrietta, NY; $6.5M single SBIR) a 2008 Larta NIH-CAP participant, is a leading developer of advanced medical imaging systems which enable the early detection and diagnosis of breast cancer, one of the most common forms of cancer in North America, Europe and China.  The company recently announced that they have obtained the CE mark of approval for their Koning Breast CT (KBCT) system, which signals compliance with European Union medical device regulations, allowing it to be marketed and sold throughout the EU and other countries recognizing the CE Mark. [LARTAVox,  Mar 21, 12]

NIH Commercialization Assistance Program participant Koning's (Rochester, NY; $2.7M SBIR) technology platform, Cone Beam Computed Tomography (CBCT) affords accurate 3-D imaging of breast tissue with an innovative cone beam X-ray source, a detector that captures high resolution data as it circles the breast, and patented software that generates 3-D images of the tissue. The potential of the technology has been recognized by the scientific and business communities. Currently, funding for the development of CBCT has reached nearly $11 million dollars, including a $2.5 million SBIR grant from NIH awarded in 2005. [LARTA Vox Oct 16]

Kopin Corp (Taunton, MA)

After 37 years, micro-display firm Kopin (Taunton, MA; 48 SBIRs 1987-2010) replaces founding CEO [John Fan] [Boston Business Journal [Sep 8, 2022]

Kopin (Taunton, MA; $9M SBIR) down 19% [Aug 3, 21]

Kopin up 17% [Mar 31, 21]

Kopin (Taunton, MA; $6.4M SBIR going back SBIR start) up 25% [Feb 16, 21]

Kopin up 17% [Aug 8, 17]

Kopin down 10% [May 9, 17]

Kopin up 11% [Mar 13, 17]

Kopin (Taunton, MA; $10M SBIR) up 20% [Jan 3, 17] a leading developer of innovative wearable computing technologies and solutions, today announced it had entered into a strategic relationship with Goertek Inc. ("Goertek"), a leading innovative global technology company headquartered in Weifang China that provides vertically integrated total solutions and services to globally-renowned companies such as Samsung, Sony, Microsoft, Huawei and Xiaomi to name a few. .. Goertek will pay $24M for 10% of Kopin's stock.   [company press release, Jan 3, 17]

Kopin up 14% [Dec 18, 15]

Kopin up 11% [May 6,15]

Kopin up 11% [Jan 7, 15]

Kopin  ($10M SBIR, founded 1984, 180 employees), maker of head-mounted wearables similar to [Google] Glass, is getting ready for a boom in that industry.  ... opened a wearable tech center and acoustics lab in California last year and refocused itself as a display maker to a wearables-focused technology company.  ..... [in] February [2014], Kopin officially launched a new pair of "smart glasses" at an event in Santa Clara, Calif. .... The product, called Pupil, is still in beta and is set to be manufactured sometime this summer. ....  as a total of ten customers, including Verizon, which released a Kopin-developed headset meant for public safety officials  [David Harris, Boston Business Journal, Jul 3, 14]

Kopin up 11% [Dec 17, 13]

Kopin  down 10%  [Oct 31, 13]

Kopin is expanding to the West Coast.  [by] opening its first Wearable Tech Center in Silicon Valley.< [Patricia Resende, Boston Business Journal, May 15, 13]

Kopin plans to buy back up to $30 million of its own stock - about 13 percent - using available cash over the next 12 months.  ... “With approximately $140 million in cash and equivalents, and no long-term debt, [says CEO-founder John Fan]. ...  in January said it would sell its assets in high-performance vertical transistors, used in smartphones and other mobile communication devices, to U.K.-based, semiconductor wafer developer, IQE plc for $75 million.   [Don Seiffert, Boston Business Journal, Mar 20, 13]

Just weeks after getting the green light for a $15 million company common stock buyback from its board of directors, Kopin ($9M SBIR 1987-2010) announced it will sell its III-V HBTs (high-performance vertical transistors or heterojunction bipolar transistors) assets to U.K.-based, semiconductor wafer developer, IQE plc, in a $75 million cash deal. ....   to focus on expanding commercial growth of its Golden-i product, a proprietary voice-activated, cloud computing, wireless, hands-free technology used in headset computers. Kopin reported $44 million in revenues for the first nine months of 2012.   [Maureen McCarthy, Mass High Tech, Jan 10, 12]  Should retunring capital to investors in buy-backs or dividends disqualify a firm nursery programs like SBIR? Or is Congress only interested in slaking the thirst of constituents for a handout? And if so, is that simply a natural consequence of representative democracy where every component sends representatives to mine the other components for handouts, where the assembled representatives make the rules?

Kopin down 10% [Nov 9, 11]

Kopin up 22% [Oct 4, 11]

Kopin down 10% [Oct 3, 11]

Kopin said that it has been awarded $23.2 million in follow-on production orders for display systems in support of US Army’s Thermal Weapon Sight Bridge program  [Boston Globe, Jun 16, 11]

Kopin, maker of heterojunction bipolar transistor (HBT) wafers used in mobile devices, has been given approval from its board of directors for a buyback of $15 million in company common stock.  [Mass High Tech, Dec 10, 10]   Its latest SBA-listed SBIR was in 2009 which seems out of order for an infant technology program.  If a company has enough spare capital to pay dividends or buy back stock, it doesn't need a government handout of capital infusion for its R&D. I wonder if any federal agencies even look at such information when assessing a company's need for subsidy.   DOD, in particular, only asks whether the company can perform the R&D for the product wanted by the service and whether it is eligible for SBIR.

Kopin  down 13% [Aug 3, 10]

Kopin said it has received a $16 million follow-on production order of display modules for the U.S. Army's Thermal Weapon Sight program.[Boston Globe, Jun 9, 10]

With a price-to-earnings ratio of 22.3 and shares at around $4.30, Kopin looks unproven, but the two analysts who cover it have price targets above $5. The company, with a market capitalization of $287.5 million, expects sales of $90 million to $110 million this year—a slight drop from 2008, but analysts forecast a rebound in 2010. .. Kopin's technology offers an investment opportunity in smart-phone growth, and analysts say its military business is strong, even if the company's high reliance on customers keeps it risky.  [David Benoit, Wall Street Journal, Dec 16, 09]

Kopin up 11% [Aug 19,09] after Wedbush Morgan initiated coverage on the Taunton, Mass., semiconductor company with an "outperform" rating [Wall Street Journal, Aug 20]

Kopin has renewed a nearly 62,000-square-foot lease for its corporate headquarters in Taunton  [Boston Globe, Jul 15, 09]

Kopin up 12% [Dec 16, 08]

Kopin up 12% [Dec 12, 08]

Kopin won a $600,000 NASA contract for nanostructured solar cells made of indium gallium phosphide (InGaP) materials. [Mass High Tech, Dec 10] ....  the second NASA contract awarded to Kopin in 2008 for the development of nanostructured solar cell technology, the company noted; in May, Kopin received a two-year, $600,000 award for the development of indium nitride-based solar cells. [Boston Globe, Dec 10]  Let NASA and the SBIR advocates explain why a company with $92M cash, which just announced plans to buy $15 M worth of the company’s common stock, should get a government subsidy from a seed program for R&D with commercial prospects. Because the government disdains the seed mission of SBIR, and uses it only for the R&D it would have bought anyway if SBIR never existed. And if it had real commercial prospects, the company would not be handing over the patent rights to the government for a mere $600K when it has $92M available cash for investment.  And also the SBIR advocates only want a piece of the government spending pie for their member companies. If the SBTC and the other pleaders had any care about SBIR's mission, it would be advocating some way to steer the handouts to companies and ideas that have technically risky high-potential ideas and no other way to raise the capital to start their development. Note that stock buybacks are purely financial engineering with no potential for any economic growth. As in all government handout programs, there's no interest like a vested interest. Kopin  has initiated a stock repurchase program, aimed at retrieving $15 million worth of the company’s common stock. ... boasts $92 million in cash and equivalents on hand. [Mass High Tech, Dec 9, 08]

Kopin reports it has landed $3.1 million from the U.S. military for displays used in weapon sights.... In 2007, Kopin reported a $6.6 million net loss on $98 million in revenue.  [Mass High Tech, Dec 3]

Kopin up 17% [Sep 18, 08]

Kopin down 10% [Sep 17, 08]

Kopin up 10% [Sep 16, 08]

Kopin down 10% [Jul 14, 08]

Kopin got a $600K NASA contract to participate in a solar-cell development program for future space exploration missions. [Boston Globe, May 2, 08]  If you can't make a big profit in the real marketplace, you can make a small profit and cover some overhead with government R&D contracts.

Still SBIRing.  Public for nearly two decades with a large cumulative net loss, Kopin won a NASA STTR Phase 2 InN-Based Quantum Dot Solar Cellswith VaTech. Hey, it's riskless and free revenue, even though it comes from an investor with no concern for the company's fortunes.

Kopin up 24% [Mar 28, 08]

Kopin up 18% [Mar 18, 08]

Kopin said that Fujifilm will put Kopin's electronic viewfinder in a new ultra high-zoom digital camera [Nov 07]

Kopin reports it will supply [maybe 150,000 of] its CyberDisplay liquid crystal display to the U.S. Army's new thermal weapon sight program, the TWS Bridge. [Mass High Tech, Nov 6, 07]

Kopin got  a delisting warning from NASDAQ. [Aug 3, 07]

More, More, the Army Wants More of Kopin's display system hardware, the war-time demand for which contributed nicely to Kopin's $12M profit for 2005.  

Kopin got hit 14% when it reported a little less revenue and a huge percent dip in profit, although big profit never has been a Kopin hallmark. [May06]

Kopin got a production sub-contract from ITT Industries Night Vision (ITT) which wants Kopin's micro-displays for its potential $560M contract to supply the Army’s Enhanced Night Vision Goggles. [Mass High Tech, Nov 29, 05]

Kopin cut two deals at the ElectronicAsia Show in Hong Kong: a HK semiconductor company will sell  Kopin’s plug-and-play Binocular Display Module for mobile video eyewear in China , and a Taiwan company is putting Kopin’s BDM into a Theatre system it has just started shipping worldwide. [Mass High Tech, Oct 13] 

Kopin rose 12% for reporting a profit, any profit. [Aug 05]

Kopin got a $3.2M contract to develop ultra-high resolution color postage-stamp size head mounted microdisplays for the  Army's Future Force Warrior.  It will be an enhanced full-color version of Kopin's monochrome CyberDisplay 1280 AMLCD. [Mass High Tech, Mar 3, 04]  Now if Kopin could also make a profit. In its decade of being public, it has lost a big pile. Still CEO John Fan keeps smiling in public, We begin the new year well-positioned with compelling technologies, differentiable products, tier-one customers and solid financial resources.

Bright ideas.    [Scott Kirsner, Boston Globe, 8/25/03]  Kopin (among many) wants to replace all these crazy light bulbs with LEDs. .Kopin has been poaching engineers from other local chip companies, and investing heavily in a new production line in Taunton to produce LEDs. The company shipped 20 million LEDs in the second quarter, most of which will be used to illuminate the displays and keypads of cellphones.  John Fan, Kopin founder-CEO, has had such dreams in the past about GaAs and teeny TVs but has never been able to turn any idea into a cash and profit cow. 

Kopin now is talking  about being an LED company, having already been a GaAs company and then a mini-display company. What it has never been is a consistent money-making company as reflected in its stock price being about 8% of its Y2K bubble price. Kopin "spokesman" Tim Monroe told the Wall Street Journal (Dec 19) about how much energy would be saved for the nation. Companies should stop talking such nonsense since consumer behavior in the face of a lower cost per unit of energy may actually use more energy. SBIR companies know nothing about the complex markets where consumers operate. But then talking up your product is part of capitalism. SBIR proposers probably needn't worry about talking nonsense since all the evidence points to the government's wanting to hear the nonsense so they can repeat it in self-serving tech transfer stories.  [Jan 03]

Although the quarterly profit was as flat as the Kopin's flat panel mini-displays, the traders pounded the stock price down 29% Friday when the company issued a gloomy forecast of a 25% cut in revenue (which is typically optimistic). For a decade now Koipn has been a consumer of capital without any return of profit From a peak of $50 a share back to its 1992 IPO price. Kopin of course is not alone as all the semiconductor companies suffer the present down-cycle in their boom-bust industry. (Oct 28, 02)

Announce an advance; lose 10%. Kopin lost 10% on a day that it announced milestone performance results for GaAs-based GaInAsN (GAIN) heterojunction bipolar transistors (HBT). With an operating voltage more than 150 mV lower than conventional GaAs-based HBTs. Could it be that the market wants to see profits more than it wants more technical advances?

Kopin reported soggy earnings. Quarterly revenue down 25% and a net loss of $6.8M, compared with $2.3M profit last year's quarter.Kopin's market cap slipped below $500M (which ain't terrible for an SBIR stock) from its highs a year ago in the $3B range.

Kopin fell 26% when it reported a fourth-quarter loss because of restructuring costs and said it would post a loss in the first quarter, too, due to a softer consumer electronics market and other issues. The company press release highlighted the 81% growth in revenue. The market didn't think that the verbiage about re-structuring sufficiently explained the failure to be a high profit growth company after a decade of capital consumption as dream company.Kopin's stock price is down 80% from its high a year ago. Benchmarking Not Much Help. Even though Kopin was named to the S&P Small Cap 600 Index, it has fallen 80% from its spring high after another 7% cut yesterday. Kopin claims to be the leading provider of gallium arsenide (GaAs) heterojunction bipolar transistors (HBT) for advanced telecommunications, and miniature flat panel displays for digital imaging applications.

Kopin, the leading U.S. manufacturer of miniature flat-panel displays for the consumer electronics market, has shipped its one-millionth CyberDisplay(TM) 320. CyberDisplay is an integrated system that uses Kopin's proprietary single-crystal silicon on glass display technology to offer superior image quality and low-power consumption in an ultra-compact size. Kopin sold its one-millionth display slightly more than one year after launching the product. The first CyberDisplay was introduced in Victor Company of Japan (JVC) camcorders in July 1999. Matsushita Electric Industrial Co., Inc. (Panasonic) and Samsung Electronics followed JVC with the introduction of CyberDisplay-enabled camcorders earlier this year.

Kopin got a $2.3M engineering contract from the Army to develop the production model of its CyberDsiplay1280. Normally, such a contract precedes a good size production run (if the Army can get the big money from the fractious Congress.) Still Kopin's stock is down by half from its spring high but 500 times its negligible earnings.

Kopin starts shipping (Jan 27) Kopin (Taunton. MA) says it began volume shipment of its CyberDisplay to Matsushita, the world's largest consumer electronics company. The displays are incorporated into Panasonic camcorders that Matsushita is launching in Europe this week.The NASDAQ traders liked that development and bid Kopin up 25% in the early going to a $2.4B market cap. Pretty good for a company that has been public since the early 90s without making a profit. What's the innovation? Kopin says, CyberDisplay is a 0.24-inch diagonal transmissive active matrix liquid crystal display (AMLCD) that displays information at a pixel resolution of 320 x 240. At 1,700 lines per inch, it is the world's densest AMLCD. Along with displaying standard text and graphics, the CyberDisplay operates at video speeds and consumes less than 20mW of power, including the backlight.

Kopin caps a killer quarter with wonderful wafer deal. A lot can happen in three months. For Kopin Corp quite a lot did. The Taunton company announced the multi-million dollar sale of its transistor wafers to Mitsubishi Electric Corp; demand for its products outstripped the rate at which Kopin could manufacture its technology. And Kopin’s share price on NASDAQ rose about 162 percent, settling around $78 a share last week and spiking the company’s market valuation to $1.2B. This all occurred despite Kopin reporting a net loss of $354K in the third quarter. For a company created by visionaries from MIT’s Lincoln Lab, which has been long on technology and short on commercial application and sales, things are looking up. Analysts who thought the company was on the brink of an upturn several times during the past few years say that this time, it’s for real. Sales in 1998 increased 64% to $27M. The consensus of brokers surveyed by Zacks Investors rate Kopin a strong buy, driving up its share price. [Kate Munro Mass High Tech, 27 Dec 99]

Kopin RisingQuiet Kopin's technology set to make noise at last, say Steven Syre and Charles Stein in the Boston Globe Nov 16]. Kopin is a small technology company with no profits and a stock that has tripled in price since June. An Internet company, right? Wrong. Internet companies are born hot. Kopin, which is based in Taunton, has been plugging away for 15 years, mostly in obscurity. It has taken that long for the company's scientists to find real-world applications for their Buck Rogers technology. ''I think our technology was ahead of the market,'' says John Fan, Kopin's patient founder and chief executive. Fan and a handful of others left MIT's Lincoln Laboratories in 1984 to start Kopin. Their goal was to make semiconductors using a technique with parallels to genetic engineering. Like their counterparts in biotechnology, they found the task more difficult than they imagined. The company went public in 1992 and didn't come out with its first product until 1995; its second product debuted in 1997. Kopin has never had a profitable year. But that may be about to change. The small group of analysts who follow Kopin's fortunes predict the firm will mark the millennium with its first-ever profit.

Kopin Wins in Japan Kopin Wins in Japan (Jul 19) The viewfinder in Victor's new JVC video camera will come from Kopin (Taunton, MA), a company helped in its early days of gallium arsenide by SBIR. The display technology was almost exclusively an massive private sector venture although apparently $20M came from the government which, of course, could not invest that sum fast enough in SBIR. SBIR wasn't designed to take those size gambles. Competition? About 30 companies working on mini-displays for the tons of tourists walking around talking into their cameras. Profits? After a decade of losses (capital consumption) Kopin reported a quarterly profit which helps explain the recent stock rise. [facts from Wall Street Journal, July 19]

Kopin Expands Again
(Apr 15) Kopin (Taunton, MA) announced its third major expansion of manufacturing capacity for its GaAs heterojunction bipolar transistor (HBT) device wafers, following the doubling of capacity just announced in January 1999. Kopin's investment in increased capacity is driven by growing customer demand for its four inch and six inch HBT device wafers. Kopin builds a high performance transistor device in their wafers, which are then used to produce power amplifier circuits for digital GSM, TDMA and CDMA cellular phone handsets. The market liked it, pushing Kopin stock up 20% yesterday.

Profit or Loss for Kopin?
(Feb 22) Kopin (Taunton, MA) says it either made or lost money for 1998 depending on how you see a non-recurring charge of $3.5M associated with the write-down of inventory, equipment and intangible assets resulting from the refinement of certain processes in the production of CyberDisplay products that will allow Kopin to improve manufacturing flexibility and meet customer requirements. The good news of a 70% revenue increase comes from the technology Kopin started with - gallium arsenide. CyberDisplay, the dream of most of the investment is mired in consumer acceptance problems as would be expected from any consumer product. Even though Kopin is proud being incorporated in British Telecom's fountain pen sized computer "SmartQuill" and IBM's prototype clip-on computer, those are gizmos that win more beauty contests than profit streams. (OK, SBIR advocates love gizmo beauty contests that furnish a convenient diversion from the central problem of SBIR companies - making a profit on a commercial item. Someday, all that investment in Kopin over the past decade will demand a either a return or a new management. So far, John Fan, an MIT spinout with an optimistic $10M, has been able to keep the reins. Kopin wnet public in 1992, about the first SBIR user to do so. (Nichols Research (Huntsville, AL), a 90% government contract house IPO'd in 1987 but can hardly be used as an SBIR example since it never had any intent to be anything but a government captive.)

Sound Vision today announced an agreement to develop production-ready digital camera designs that incorporate Kopin's color CyberDisplay. The first design resulting from this partnership, the 1301 Reference Design, is for digital imaging manufacturers that desire to build a low power VGA camera at the most competitive cost possible. CyberDisplay will function as the camera's viewfinder and as the display used to review previously stored photographs. The CyberDisplay will also allow OEMs to build very small, lightweight cameras and other imaging devices for entirely new markets. The 1301 Reference Design, now being made available to camera OEMs, combinesSound Vision's new Clarity 2.0 digital imaging technology with the color CyberDisplay. [Business Wire, Dec 17]

Kopin Sliding If you bought the secondary issue of Kopin at 19 a few weeks ago, you would be minus 25% while the Dow-Jones is making new highs. The problem probably runs deeper than the Chinese reference to peace in Kopin's name. Kopin has bled capital since its beginning in the 80s, but always with optimistic investors ever to be found anew.

Kopin-POC combine technologies. Kopin's world's smallest active-matrix LCD was helped by Physical Optics Corp (Torrance, CA), says December Photonics Spectra. POC contributed a holographic light shaping diffuser. Making a going concern of the product, though, depends on consumer acceptance - a chancy proposition especially for small companies. For when the acceptance is purely economic, both sides can estimate the chances of success. But when consumer psychology enters, anything could happen. What, for example, is the economic value of the ability to view your e-mail in your cellular phone? If you are proposing such technology to SBIR, you will have a problem convincing any government skeptic of the market value of something that does not exist today. If Kopin is lucky, the market will accept the product before the capital finally runs out. Eventually, all that capital poured into Kopin will end and Kopin may be forced back to SBIR on a much smaller scale that its past five years of burning capital. Meanwhile, Kopin plans to sell another $2M shares to the public half of which goes to Kopin and the other half to cash-out of earlier investors.

Quarter-Inch Screen Quarter-Inch Screen
(Sep 5) Kopin Corp (Taunton, MA) cut a multi-million deal to supply quarter-inch TV screens for cellular phones. The CyberDisplay is a 0.24-inch diagonal transmissive active matrix liquid crystal display imaging device which displays information at 320 by 240 pixel resolution. [Dow Jones Newswire] Kopin's stock price jumped 17%.

Kopin Rolls Out Wafer Kopin Rolls Out Wafer (Aug 26) Kopin Corp (Taunton, MA) rolled out a higher grade telco wafer while Sharp Corp and Nortel smiled. Its indium gallium phosphide wafer, which upgrades its AlGaAs wafer for cellular phone circuits, withstood testing by Sharp. The press release did not mention either the price nor the ton of money that Kopin has lost (invested) since its founding in the 80s. Some of Kopin's earlier development of its wafer technology got SBIR support.

Kopin-Siemens Deal Kopin Corp (Taunton, MA) saw its stock jump up when it announced a licensing deal with Siemens.

The tiny camera of Kopin Corp (Apr 8 story) made Business Week, Apr 21.

Tiny Video Display Buy for $60 a CyberDisplay, a monochrome 20-inch computer display from Kopin (Taunton, MA). Color version to be priced later. It's Kopin's newest product with which it hopes to reverse the annual losses, $21.6M last year, that are eating the capital and the capitalists' convictions. Still, the stock price reflects a lot more confidence than does the price of SI Diamond Technology, a competitor for future displays.

Up Capacity for GaAs Kopin Corp (Taunton, MA) will triple its capacity for GaAs wafers to meet skyrocketing demand for semiconductors for wireless and fiber optics. Kopin claims to supply 90% of the market for heterojunction bipolar transistor GaAs wafers. The capital was obviously available for the purchase despite Kopin's losing money in big hunks in its quest for the flat panel display market. Kopin used SBIR for some of its early R&D in GaAs but survived on private capital for flat panel displays.

Kopin Takes a Bath Kopin Corp (Taunton, MA) got soaked in a $6.2M quarterly loss leading to a $21.6M loss for the year. $8.9M was a write-down which in principle happens only once. Revenues were down for the quarter but up for the year. The flat panel display industry has a lot of wounded soldiers.

Kopin's Results: Growth 23%
Headline readers see growth; fine print readers see more losses. Kopin Corp (Taunton, MA) lost another $3.9M in the 2d quarter on a 23% growth in revenues. (The investors must be asking how much growth they can afford.) Kopin had several SBIR awards from SDIO in its early years during which it shifted its emphasis to the display market where SBIR could not provide anywhere near enough quick capital for market-pace competitive R&D. CEO and entrepreneur John Fan opted for the big gamble in which he must turn growth to profit before the capital runs out. The market doesn't seem too worried as the market cap hovers around $100M.

Kord Technologies (Huntsville, AL)

The US Army selected four companies for positions on a potential $93.4 million contract for [RDT&E] services focused on aerial target systems over a five-year period. Griffon Aerospace (Madison, AL; no SBIR), Kord Technologies (Huntsville, AL; $2.2M SBIR), Kratos Defense and Security Solutions (San Diego, CA; no SBIR) and Trideum (Huntsville, AL; $200K SBIR) may bid for orders under the cost-plus-fixed-fee contract. [GovConWire, May 22, 18]

KOR Electronics (Cypress, CA)

Mercury Computer Systems  (Chelmsford, MA; no SBIR, market cap $400M) will pay $70 million to acquire a pair of companies that make electronic warfare and intelligence-gathering systems. Mercury is buying style="font-weight: bold;">KOR Electronics (Cypress, CA; $6.8M SBIR mostly USAF) which makes digital radio and radar test gear, as well as Paragon Dynamics (Aurora, CO; no SBIR), which provides intelligence analysis and exploitation services.  [Hiawatha Bray, Boston Globe, Dec 23, 11]

Koronis Pharmaceuticals (Redmond, WA)

Koronis Pharmaceuticals (Redmond, WA, one SBIR) got $20M VC. [Seattle Times, Jun 29] No apparent connection to SBIR winner Koronis Biomedical in Minnesota. 

Korro Bio (Cambridge, MA)

Korro Bio (Cambridge, MA; no SBIR) biotech, raised more than $90M to advance its technology to repair genetic mutations that cause a variety of diseases.

Kosan Biosciences

Kosan Biosciences more than tripled in Nasdaq trading after Bristol-Myers Squibb Co. agreed to buy the company for $235 M.  Bristol-Myers, bracing for the loss of $3 billion when its top-selling blood thinner Plavix faces generic competition in four years, is slashing costs and searching for new products. The purchase gives it Kosan's anti-cancer compounds, now in human testing.   [San Jose Mercury News, May 29, 08]

Kosan Biosciences down 10% [Feb 14, 08]

Kosan Biosciences up 13% [Feb 13, 08]

Kosan Biosciences up 11% [Feb 11, 08]

Kosan Biosciences up 12% [Jan 24, 08]

Kosan Biosciences up 15% [Jan 23, 08]

Kosan Biosciences  down 11% [Jan 17, 08]

Kosan Biosciences up 12% [Dec 19, 07]

Kosan Biosciences down 43% [Dec 10, 07] on bad news from its blood-cancer patients.

Kosan Biosciences up 11% [Nov 13, 07]

Kosan Biosciences up 10% [Sep 18, 07]

Kosan Biosciences up 14% [Aug 16,07]

Kosan Biosciences up 11% after broker's upgrade.  [Feb 07]

Kosmetikos (Marshfield, WI)

Five bioscience companies winners of [Wisconsin] BIOforward’s 2014 Emerging Company Showcase. ... chosen because they have transitioned successfully out of research and development, with good proof of concept for their products.  BioTechnique  (Madison, WI; no SBIR) will make cancer-fighting drugs and other types of drugs for other companies; Cellara (Madison, WI; no SBIR) working on a small-platform modular robotic system for use in stem cell production;
Gel Combs (Madison, WI; no SBIR) designs and makes improved combs for gel electrophoresis applications as well as custom plastic parts for the microscopy and microbiology industries; Kosmetikos (Marshfield, WI; no SBIR) a skin care company start-up; and Organic Research (Milwaukee, WI; no SBIR) develops digital pathology software tools to provide critical decision support to pathologists by automatically identifying disease markers.   The winning companies receive high-visibility exhibit space at the Oct. 8 Bioscience Vision Summit, recognition at one of the summit’s large plenary sessions, a free year of membership in BIOforward, and specialized one-on-one technical assistance ranging from business planning and investor introductions to collaborative partnerships.  ...   BioForward was founded in 1987, as the Wisconsin Biotechnology Association, a partnership among leaders in Wisconsin’s emerging biotechnology industry.   [Bob Van Enkenvoort, Wisconsin State Journal, Sep 26, 14]


Printing Chips on the Cheap.  Silicon Valley startup Kovio (Sunnyvale, CA; no SBIR) says it has refined a process that uses regular printing-press technology to create low-power chips [which] could represent a step forward in developing cheap, mass-produced radio-frequency identification (RFID) tags. ... will use a process that could drop the price of the tiny radio chips, which help companies keep track of products they ship, from 15 cents per tag to 5 cents by late 2008. ... uses long-established graphics printing techniques, but instead of color inks it sprays what it calls "silicon ink"--consisting of silicon electronics and thin-film transistors--onto stainless steel foil that is paired with a tiny radio antenna. Silicon ink devices can be made using cheaper equipment than that used to make regular chips. [Cliff Edwards , Business Week, Dec 10]

Kovio, a Sunnyvale developer of semiconductor products using thin-film technologies, or "printed electronics," has raised $19.5 million in the first part of a fourth (series D) round; Sunnyvale-based [Matt Marshall, Venture Beat, Sep 5]

KPI Therapeutics (Seattle, WA)

KPI Therapeutics (Seattle, WA; no SBIR) is looking to raise more than $25 million to bring its autoimmune drugs to clinical trials. [Puget Sound Business Journal, Feb 23, 16]  ... KPI’s operating model allows each drug candidate family to be separately developed and commercialized by our development and commercialization partners [company website]

An international partnership that includes biotech Kineta (Seattle, WA; $1.2M SBIR) has created a new company with a unique approach to accelerating the development of new drug candidates.  The new company, KPI Therapeutics, will act as both an investment group and a strategic hub to unify research and development efforts.  KPI doesn’t own any of the companies involved, but will allow them to unite their overlapping areas of research and develop an umbrella strategy for drug development.  [Valerie Bauman, Puget Sound Business Journal, Jun 5, 14]

Kraig Biocraft (Ann Arbor, MI)

Kraig Biocraft Laboratories, (Ann Arbor, MI; no SBIR) the leading developer of spider silk based fibers,  announced that the U.S. Army awarded the optional phase of its contract with the Company valued at more than $900,000.  Under this exercised option, the Company will work to design, produce, and deliver additional recombinant spider silk materials tailored for the protective needs of our Soldiers. [company press release, Aug 2, 17]  announced that it has identified and selected the location for its operational headquarters in Vietnam.  Located in the heart of Quang Nam province, this area provides a vast supply of skilled workers, close proximity to mulberry fields, and easy access to international air and sea ports. [company press release, Jul 24, 17]

Spider silk is one of nature’s toughest substances, similar in strength to the Kevlar plastic found in bulletproof vests but much more flexible. Kraig Biocraft  (Ann Arbor, MI; no SBIR), genetically altered silkworms to produce a fiber that’s similar to pure spider silk. Today, they announced an Army contract [up to $1.0 million] to test this so-called Dragon Silk for possible use in body armor. [Defense One, Jul 12, 16]   has made considerable progress in establishing a subsidiary for setting up commercial production and research in Vietnam. [company website, Jan 2016]

Kratos Defense & Security Solutions (San Diego, CA)

The US Army selected four companies for positions on a potential $93.4 million contract for [RDT&E] services focused on aerial target systems over a five-year period. Griffon Aerospace (Madison, AL; no SBIR), Kord Technologies (Huntsville, AL; $2.2M SBIR), Kratos Defense and Security Solutions (San Diego, CA; no SBIR) and Trideum (Huntsville, AL; $200K SBIR) may bid for orders under the cost-plus-fixed-fee contract. [GovConWire, May 22, 18]

DARPA's "Gremlin" swarm drone attack and recovery program is picking up speed with a late-April "21-month, $38.6 million contract to Dynetics (Huntsville, AL; $6M SBIR)" the Washington Post reported this weekend. Dynetics will be working with " Kratos (San Diego, CA; no SBIR), a venture-funded tech company that specializes in cheap drones used for target practice." [DefOne, May 7, 18]

Kratos Defense & Security Solutions (San Diego, CA; no SBIR) will Digital Fusion (Huntsville, AL; $600K SBIR) in an all-stock $38M deal. [San Diego Union Tribune, Nov 25]

Kriya Therapeutics (Palo Alto, CA and Research Triangle Park, NC)

Kriya Therapeutics (Palo Alto, CA and Research Triangle Park, NC; no SBIR, founded 2019) announced that it has raised $80.5 million in a Series A financing to fund the development of transformative gene therapies for highly prevalent serious diseases. ... focused on developing gene therapies for diseases affecting millions of patients, expanding the field of gene therapy beyond rare monogenic disorders. Kriya is targeting diseases where the underlying biology is well-understood, with the goal of rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. [company press release, May 12, 20]

Kronos Advanced Technologies  (Belmont, MA)

Kronos Advanced Technologies (Belmont, MA; no SBIR), a maker of air movement and purification technologies, has “curtailed operations and reduced its workforce to the fullest extent,” in response to the receipt of a notice of default by investor AirWorks Funding LLLP. .... The company was initially founded in 2000 and funded by the U.S. military to develop electrostatic air movers. Eventually the company moved into the consumer air purification business. [Mass High Tech, Oct 10]

Krystal Biotech (Pittsburgh, PA)

Krystal Biotech (Pittsburgh, PA; no SBIR) up 41% [Jun 24, 19] announced that it has priced the previously announced underwritten public offering [to raise $100M] [company press release, Jun 24, 19]

Krystal Biotech (Pittburgh, PA; no SBIR) ), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that construction of Ancoris, a new state-of-the-art Good Manufacturing Practice (GMP) facility, is complete. The new facility is located near the Company’s headquarters in Pittsburgh and will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). The facility will be officially open in 1Q 2019 following completion of the first engineering run. [company press release, Jan 15, 19] total funding $7M plus IPO $45M []

Jan 16, 2019

Krystal Biotech down 13% [Oct 17, 18]

Krystal Biotech up 24% [Oct 15, 18]

Krystal Biotech down 15% [Sep 12, 18]

Krystal Biotech up 13%  [Jun 6, 18]

Krystal Biotech down 11% [Apr 23, 18]

Krystal Biotech (Pittsburgh, PA; no SBIR) announces that KB103, a gene therapy candidate for dystrophic epidermolysis bullosa (“DEB”), was granted Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA) [company press release, Apr 18, 18].

Krystal Biotech up 16% [Jan 3, 18]

Krystal Biotech down 10% [Jan 2, 18]

Krystal Biotech up 11% [Dec 28, 17]

Krystal Biotech up 15% [Oct 18, 17]

Krystal Biotech is a gene therapy company that develops novel treatments for dermatological conditions. The company plans IPO this week to  raise $30 million at an implied market cap of around $87 million. [, Sep 18, 17]

Krystal Biotech (Pittsburgh, PA; no SBIR) plans to raise up to $35 million ]IPO], according to [SEC]. The gene therapy company is a developer of treatments for dermatological diseases. With no revenue, [Wallace Witkowski,, Aug 21, 17]

KSE (Amherst, MA)

KSE (Amherst, MA; $10M SBIR) received $3 million for a project to reduce the reliance on distillation for water removal from biomass-derived ethanol ... part of a nationwide award of $57 million aimed at accelerating the commercialization of clean technologies, and comes from the the DOE’s Small Business Phase 3 “Xlerator” program [Kyle Alspach, Mass High Tech, Sep 16, 10]

KSQ Therapeutics (Cambridge, MA)

CRISPR-Cas9 makes headlines as a gene editing tool for potential therapies, but pharma and biotech are also using it to as a tool to discover new drugs. A high-powered startup, KSQ Therapeutics  (Cambridge, MA; no SBIR, founded 2015, 40 employees), is the latest firm to join their ranks. ...  closed a $76 million financing  [Ben Fidler,, Oct 2, 17]

Kultevat (Creve Coeur, MO)

biotech Kultevat (Creve Coeur, MO; no SBIR) is looking to raise $880,551, according to [SEC] filing ...   combines advanced genetic techniques — namely, increasing plants’ yield traits — with the ability to mass-produce natural rubber and fermentable sugar syrups that can be sold into the biofuels market. ...  operates out of the Helix Center Biotech Incubator   [Brian Feldt, St. Louis Business Journal, Sep 22, 16]

biotech Kultevat (St Louis, MO; no SBIR, founded 2010)  has entered a research and development agreement with Japan-based Sumitomo Rubber Industries to expedite the development of an alternative source of natural rubber from Russian dandelions.  ...  because the dandelions can be grown in many more regions around the world, including North America   ...  Kultevat is the brainchild of [CEO Dan] Swiger, who in 1995 founded Yulex (Phoenix, AZ; no SBIR), a company that makes rubber latex from guayule plant extracts. ... Kultevat was recruited to St. Louis in 2013 by Roger Beachy, founding president of the Donald Danforth Plant Science Center. [Ryan Collins, St. Louis Business Journal, Aug 11, 15]

Kumu Networks (Santa Clara, CA)

A startup spun out of Stanford says it has solved an age-old problem in radio communications with a new circuit and algorithm that allow data to be sent and received on the same radio frequency—thus doubling wireless capacity, at least in theory. Kumu Networks (Santa Clara, CA; no SBIR) has demonstrated the feat in a prototype and says it has agreed to run trials of the technology with unspecified major wireless carriers early next year. [David Talbot,, Oct 29, 13]

Kura Oncology (La Jolla, CA)

Kura Oncology (San iego, CA; no SBIR, founded 2014), a clinical-stage biopharmaceutical focused on the development of precision medicines for oncology, announced the pricing of stock shares to rise $100M [company press release, Jun 18, 19] prior funding $60M; claims the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit.  []

Kura Oncology (San Diego, CA; no SBIR)  announced positive topline results from a Phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC). The Phase 2 trial achieved its primary endpoint prior to the completion of enrollment.  [company press release, Sep 7, 17]  Two years ago  announced it has entered into an agreement with Janssen Pharmaceutica NV for an exclusive license to develop and commercialize tipifarnib in the field of oncology. Tipifarnib, a protein farnesyl transferase inhibitor, is a Phase 2-ready program that has demonstrated encouraging clinical activity in certain cancer patient populations and that may be further optimized using an appropriate patient selection strategy.  ...  also  announced that it completed a private placement of its common stock to new institutional investors and existing investors that resulted in gross proceeds of approximately $60 million   [Jun 2015]

Kura Oncology (San Diego, CA; no SBIR) declined slightly [in] its first day on the Nasdaq exchange. The company, which is developing new drugs for solid tumors and blood cancers, priced its IPO ...  to raise a total of $50 million, well below its original plan. [Alex Lash,, Nov 6, 15]

Kura Oncology (La Jolla, CA;  SBIR, 15 employees) raised $60 million and is preparing to start a Phase 2 trial of a cancer drug it has licensed. The company is also in the process of becoming publicly traded, through a reverse merger. ... The drug, tipifarnib, has been licensed from a subsidiary of Johnson & Johnson. It will be tested in certain blood and solid cancers as a precision medicine therapy, [CEO] Wilson said. [Bradley Fikes,, Mar 12, 15]

KVH Industries (Middletown, RI)

KVH Industries (Middleton, RI; $7M SBIR) up 17% [Aug 19, 20]

KVH Industries up 10% [Jul 27, 17]

KVH Industries (Middletown,RI: $5.7M SBIR) up 12% [May 9,17]  despite greater loss, [CEO] Martin Kits van Heyningen said, "We are particularly pleased with the growth in our Airtime service revenues and margins, and with our strong cash flow which allowed us to reduce our net debt by over $3.0 million at the end of the quarter.  [company press release, May 9,17]

KVH Industries (Middleton, RI; $6M SBIR) down 12% [Mar 2, 17] reported financial results for the fourth quarter

KVH Industries   (Middletown, RI; $6.3M SBIR) up 11% [Jul 20, 16]

KVH up 10% [Jan 14, 14]

KVH down 14% [Feb 12, 13].

KVH up 12% [Dec 18, 12]

KVH up 14% [Jan 12, 12]

KVH up 11% [Aug 29, 11]

KVH down 11% [Aug 8, 11]

KVHdown 12% [Aug 4, 11]

KVH down 13% [Jul 29,11]

KVH down 17% [Apr 29, 11]

KVH  up 15% [Sep 30, 10]

KVH up 12% [Jun 25, 10]

KVH  up 11% [Nov 17, 09]

KVH Industries  reports it has landed new orders from two unnamed major defense contractors worth $10.2 million for its precision fiber optic gyros (FOGs) for use in remote stabilized weapon stations. [Mass High Tech, Oct 30, 09]

KVH Industries reports it has received $2 million from multiple undisclosed customers for its navigational systems. [Mass High Tech, Oct 2, 09]

KVH up 11% [Sep 17, 09]

KVH Industries landed $2.5 million for precision fiber-optic gyros used in remote weapon systems. Under the subcontract deal, .... will supply the unnamed defense contractor with its DSP-3100 fiber optic gyros. ...  reported $82 million in revenue in 2008, with $3 million in net income. [Mass High Tech, Jul 15, 09]

KVH   up 12% [May 5, 09]

KVH Industries $3.8 million in new orders for its precision fiber-optic gyro system. The bulk of the orders -- $2.9 million -- comes from an unnamed remote weapons station manufacturer  [Mass High Tech, Apr 7, 09]

KVH down 10% [Mar 2, 09]

KVH up 10% [Jan 21, 09]

KVH up 12% [Jan 2, 09]

KVH Industries up 10% [Dec 19, 08]

KVH up 13% [Nov 25, 08]

KVH down 16% [Nov 24, 08]

KVH up 61% [Nov 21, 08]

KVH up 12% [Nov 3, 08]

KVH down 13% [Oct 10, 08]

KVH down 11% [Oct 3, 08]

KVH Industries reports it has landed $1.3 million to deliver military navigation systems from an unnamed southeast Asian customer.  [Mass High Tech, Sep 17, 08]

KVH Industries down 15% [Jul 22, 08]

KVH Industries up 11% [Jul 21, 08]

KVH Industries, a maker of in-motion satellite TV and communications systems, has landed a new contract with an undisclosed in-flight entertainment provider valued at $20M [Mass High Tech, Feb 22, 08]

KVH Industries received two orders from a US defense contractor for the purchase of components and upgrades for KVH's TACNAV vehicle navigation systems for use on U.S. military combat vehicles.

KVH up 10% [Jan 16, 08]

KVH Industries got an up-to-$6M new contract from a European defense contractor for the purchase of KVH's TACNAV® II fiber optic gyro (FOG)-based vehicle navigation systems and displays for use on new infantry fighting vehicles. [Business Wire, Apr 17, 07]

KVH down 11% on news of lower profit. (Oct 19,06) even though revenue was up 15% and that Business Week named two of KVH's live mobile media solutions among its eight "Coolest Car Gadgets for 2007." [Providence Business News, Oct 20, 06]

KVH made #20 on the NASDAQ short interest ratio list at 29 days to cover. [Oct05]

Doubters.  KVH ranked #11 on the NASDAQ short interest ratio at 43 days.  SatCon ranked # 5 on percentage increase in sextupling the short interest. {sep05]

“Sandstorm”  and “H1ghlander” by Carnegie Mellon will have fiber optic gyros (FOGs) by KVH for  the $2M winner-take-all DARPA robot vehicle race across the Mojave. Out of 118 applicants, 20 finalists will race. Last year nobody even got far from the start point. 

KVH Industries leapt into 37th place on NASDAQ short-interest ratios with 3.3M shares,  22 days worth of average daily trading volume. ViaSat  was on the list of largest (58%) percent increase, as was Emcore.  [spring 05]

Now Cellphones, ThenTV.  KVH got. a U.S. patent for a key component in the hybrid phased-array antenna used in KVH’s in-motion TracVision A5 satellite TV system for automobiles. ... A report by industry analyst Frost & Sullivan projects that by 2011 more than 36 million automobiles in the United States will be equipped with video systems and of these, more than 3 million will receive mobile satellite TV programming. [Mass High-Tech, Mar 8]

KVH Industries reports a $2.8M order from an unnamed foreign defense client through an equally unnamed US defense contractor for its TacNav vehicle navigation systems and the smarts to install and operate them. [Mass High Tech, Dec 28, 04]

KVH took home $48M from a public offering at $18.75 per share after all the hands in the pockets got their piece of the action. 

Prep Ended Too Soon. KVH Industries took a two-day hit of 17% as it reported 20% higher revenues leading to a big loss. Said the CEO, While both the fourth quarter and full-year revenues were record highs, they were lower than we had expected primarily as a result of the absence of an anticipated large order from an existing U.S. military customer.  Seems the 2002 profits, although not all that big, came from the military buying spree before the Iraq invasion. Live by the sword, ... 

KVH Industries navigation system to be standard for German army vehicles. KVH Industries Inc., of Middletown, R.I., announced today that the German Army has named the KVH M100 Ground Mobility Enhanced Navigation System (GMENS) a standard product in the German Army procurement system.  [Mass High Tech, Nov7]

After quadrupling from it" low of last autumn,KVH stock took a breather yesterday with a 14% drop (that would have been 50% of that low). 

Gene Marcial's Business Week column (Jun 16) touted KVH Industries as a big winner in the Iraq war sales derby to Defense and predicts KVH will introduce a satellite dish for cars. Unlike most SBIR firms' stock, KVH has tripled since last fall. TV in every car? So the driver can peek while talking on a cell phone? What better argument for smart highways? 

KVH Rides Defense Wave. KVH won a $3.6M Army contract as part of a multi-year $10M deal its TACNAV vehicle navigation system. The company claims our revenues grew 9% over 2000 to $32.7 million, driven by the fifth consecutive year of growth in our satellite communications business. Navigation is 20% of KVH's business. KVH was founded in 1982 and went public in 1996, has a market cap of $67.1M, and has lost about $4M over five years on steadily rising sales. Its nine 9 Phase 2 SBIR were mostly Navy for engineering of well-controlled development projects.

Kylin Therapeutics (West Lafayette, IN)

Kylin Therapeutics (West Lafayette, IN; no SBIR), a small life-sciences firm based in Purdue Research Park, has received a $1.2 million state grant to develop a technology it says could allow physicians to target drug delivery for treatment of diseases. The company, with seven employees, said it is in the preclinical stage of commercializing a technology to directly target and turn off disease-causing genes. The company said the research shows promise in treating prostate cancer, ovarian cancer and other diseases. The company received a $250,000 grant from the state in 2007.  [Indianapolis Star, Jan 9, 09]

Kylin Therapeutics (West Lafayette, IN; no SBIR) , a six-employee developer of cancer and disease-fighting biotechnology, has doubled its work force and outside investment in its operations at Purdue's Research Park in West Lafayette, the Indiana Economic Development Corp. said. The company used a $250,000 grant to help commercialize Purdue technology that allows doctors to target drug delivery for treatment of diseases that include AIDS and cancer. [Indianapolis Star, Feb 22] 

Kyma Technologies (Raleigh, NC)

Kyma Technologies (Raleigh, NC; $12M SBIR) has been awarded $3.2 million from DOE....  part of the $27 million in grants for 14 projects aimed at developing next-generation power conversion devices. The goal is to lower the cost and up the efficiency of power electronics by addressing the components that power those devices. [Lauren Ohnesorge, Triangle Business Journal, Oct 22, 13]

Thirteen NC companies will split $1 M from a new state fund intended to help businesses create environmentally friendly technologies. In the Triangle area: Ecocurrent of Raleigh received $100,000 to convert hog manure into electric power; Kyma Technologies of Raleigh received $60,000 to work with N.C. State University on a more efficient, cheaper electric switch.; 3F LLC of Raleigh received $100,000 to develop a natural fiber-reinforced concrete formula.; Piedmont Biofuels of Pittsboro received $75,000 to work on a reactor that more efficiently creates biodiesel.; Nextreme Thermal Solutions of Durham received $57,319 to manufacture a generator that converts waste heat into electricity.; Rain Water Solutions of Raleigh received $18,000 to develop a new rain barrel manufacturing process. [Raleigh News & Observer, Jul 1]

Kyma Technologies (Raleigh, NC) $2.6M VC money in a first round and says it plans a second round next year to begin production of semiconductor substrates of GaN and AlN. Kyma was co-founded by Jerry Cuomo, a research professor in NCSU, and Mark Williams, a former graduate student of Cuomo. As for Cuomo, he worked at IBM for 30 years before joining NCSU and is the holder of 115 patents. With technology licensed from NCSU, the firm started in 1998 with about $550K from angel investors and more than $2M in federal grants. Spell that SBIR [facts from Lee Weisbecker, Raleigh Business Journal, Sep 24]

Kymera Therapeutics (Cambridge, MA)

Kymera Therapeutics announced [it has entered into a multi-program strategic collaboration with Sanofi (NASDQ: SNY) to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as well as significant royalty payments. Kymera retains the option to participate in US development and commercialization for both programs. [Kymera press release, Jul 9, 20]

Cells have a built-in way of breaking down damaged or unneeded proteins. Kymera Therapeutics is trying to harness this process as a therapy—using it to get rid of disease-causing proteins. As the biotech prepares to test its technology in humans, it has now raised $65 million . [Frank Vinluan, Nov 13, 18]

Six months after getting off its [$30M] series A, Kymera Therapeutics (Cambridge, MA; no SBIR, founded 2017) nabbed a deal with GlaxoSmithKline, although exact details are under wraps. [Fierce Biotech, Apr 4, 18]  is pioneering a game-changing new therapeutic modality and platform with the potential to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases.   [company website] 

Kymera Therapeutics (Cambridge, MA; no SBIR) raised $30M Series A financing to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases.  [company press release, Oct 31, 17]

Kymeta (Redmond, WA)

Kymeta (Redmond, WA; no SBIR) startup backed by the big name and deep pockets of Bill Gates announced it has signed a major agreement with a manufacturer to get its inventive satellite antenna systems to market.  ...   will partner with Japan-based Sharp to produce small, lightweight antennas that aim to simplify satellite connections so that more people and devices can easily access broadband Internet. ...  barely 3 years old. It spun out of Bellevue patent-licensing company Intellectual Ventures. But the company’s rapid growth has enabled it to move far along for its young age. It has raised $82 million from investors including Bill Gates ...  already has existing partnerships across several industries, including with Honeywell and Airbus   [Rachel Lerman, Seattle Times, Aug 18, 15]

The next airport security scanner you have to walk through might just be using technology developed by inventors at Bellevue-based Intellectual Ventures. [which] announced it has spun out its third company, Evolv, from its "Metamaterials Commercialization Center," the same incubation team that spun out the nuclear power company TerraPower. .... Evolv will be based in Boston and is backed by $11.8 million in funding from Bill Gates [et al] .... Redmond antenna company Kymeta also recently spun out of IV [which was co-founded by Microsoft veteran Nathan Myhrvold] [Emily Parkhurst, Puget Sound Business Journal, Aug 29, 13]

Satellite antenna maker Kymeta (Redmond, WA; founded 2012) with a $50 million (Series C) financing round and the technology backing of Intellectual Ventures .... already bringing in revenue from agreements with satellite companies such as Inmarsat, with which it is developing an antenna for delivering high-speed broadband access to jets.  ... the second stand-alone company to emerge from Intellectual Ventures, the controversial—and lucrative—effort of former Microsoft chief technology officer Nathan Myhrvold to acquire intellectual property and license it to technology companies, or sue those who violate its patents.   [Benjamin Romano,, Jul 9, 13]

Kyn Therapeutics (Cambridge, MA)

Kyn Therapeutics (Cambridge, MA; no SBIR)  advancing new immunometabolism therapies for treating cancer, announced $49 million in Series A capital available to advance a pipeline of clinical- and pre-clinical stage therapies, including a program scheduled to enter clinical studies in 2018. Atlas Venture and OrbiMed provided the investment  [company press release, Dec 14, 17]

Kyocera Solar

Kyocera Solar (no SBIR) is citing weak demand for made-in-the-U.S.A. panels as it prepares for workforce reductions at the company's San Diego manufacturing facilities, the company confirmed  [Morgan Lee,, Apr 24] 

Kypha (St. Louis, MO)

Medical startup Kypha (St Louis, MO; $500K SBIR, founded 2009) raised another $950K [Brian Robbins, St Louis Business Journal, Jul 27, 18] total funding $15M []

Kypha (St Louis, MO; $500K SBIR, founded 2009), a biotechnology startup, acquired Biosensia, a medical device firm in Ireland. Terms not disclosed. .... has developed a diagnostic tool that analyzes inflammation. Biosensia has developed a point-of-care diagnosis system that produces laboratory quality quantitative and qualitative results with a disposable cartridge for up to 24 analytes in a multiplex format. [Brian Feldt, St Louis Post Dispatch, Jul 16, 18] total funding $14M []

Kypha  (St. Louis, MO; no SBIR, founded 2009) an early-stage medical device startup developing a test to monitor inflammation quickly and accurately, has raised $3.5 million from a group of investors ... has raised $6 million to support development and garnered an additional $1.5 million in grants. ... Kypha's inflammation test would work much like a pregnancy test but with the patient using a drop of blood. The patient would have his or her finger pricked — similar to a diabetes test — and place the blood on an indicator stick that would within a few minutes give a numeric value assigned to a condition.   [Brian Feldt, St. Louis Business Journal, Nov  21, 14]

Kyras Therapeutics

Kallyope wasn’t the only Columbia spinout to launch this past week. Through its Highline Therapeutics incubator, Versant Ventures put $5 million into a new company called Kyras Therapeutics  (no SBIR). The company is based on the work of Columbia’s Brent Stockwell, who is using computational methods to develop drugs that directly bind to one of cancer’s hard targets, a family of genes called RAS. Versant also formed a second company, Inception IBD, which Celgene  has nabbed an option to acquire. [Ben Fidler,, Dec 10, 15]

Kyron Clinical Imaging (Wauwatosa, WI)

Kyron Clinical Imaging (Wauwatosa WI; one SBIR) got a $200K NIH SBIR. Kyron has a software application that allows doctors to look at different kinds of magnetic resonance images to better diagnose, treat and manage brain tumors and other neurological disorders. ... founded in 2004 by three Medical College of Wisconsin radiology professors. [Milwaukee Journal-Sentinel, Oct 17]  It got FDA clearance in December for its BrainViewRx Viewer and a 2006 $1.5M investment from a local hospital. [company website]


Kytopen (Cambridge, MA; $1M SBIR) a biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, today announced it has raised $30 million in an oversubscribed Series A funding. The new capital will be used to commercialize Kytopen’s Flowfect® Tx for cGMP-compliant cell therapy manufacturing and move towards treating the first human patient with Flowfect® engineered cells. [company press release, Sep 28, 21]

Kytopen, a startup working on gene-modified cell therapies, announced it has raised $3.6M in seed financing [Boston Business Journal,May 28, 19]

The Engine, a new VC fund in Cambridge, MA aims to bridge that [long lead time] gap by investing in breakthrough technologies that require extensive time and funding. Its [announced] first round of investments consists of seven startups (Analytical Space (Boston, MA, laser satellite data links w former Gen Pete Worden as advisor), Baseload Renewables (co-founded by Professor Yet-Ming Chiang who co-founded A123 Systems), C2Sense (Cambridge, MA; patented chemiresistive sensing C2Sense is able to selectively target gases unable to be sensed through other methods ), iSee (next generation of humanistic artificial intelligence technology for human and robotic collaborations), Kytopen (better genetically engineer cellsby developing technology that modifies microorganisms 10,000 times faster than current state-of-the-art methods ), Suono Bio (Cambridge, MA, ultrasonic therapeutics), and Via Separations (industrial separation processes, sonme SBIR) in sectors including aerospace, advanced materials, genetic engineering, and renewable energy. .... a for-profit, public-benefit corporation and a fund that’s separate from MIT ... MIT also contributed $25 million to your first investment fund of $200 million.    [Elizabeth Woyke,,  Sep 19, 17]

------ KKKKKK -----

------ LLLLLL -----

LAAMScience (RTP, NC)

LaamScience (Morrisville, NC; $800K SBIR that developed antiviral and antimicrobial fabrics, is shutting down in bankruptcy amid $1.16 million in debts to the N.C. Biotechnology Center and others. ......  licensed rights for a key material, a nonwoven fabric used to make surgical masks and reusable sanitary napkins, from N.C. State University and Emory University  [Chris Bagley, Triangle Business Journal, Aug 9, 13]

LaamScience (Raleigh, NC; no SBIR, founded in 2006) raised about $5 million from wealthy individuals to continue developing its first products, including surgical masks that can kill viruses on contact. [David Ranii, Raleigh News & Observer, Jun 10, 09]

About a decade ago, Steve Michielsen was like a lot of inventors. He had a great idea, no money and only a vague plan for how to unleash his genius on the world.  This week, a specially treated fabric is rolling off machines that will be used to make face masks that Michielsen thinks will kill virtually any human or animal virus on contact. ... lofty goals for LAAMScience (RTP, NC; no SBIR) ... He is eager to send the research and test runs to the FDA this spring and hopes to have approval as soon as this fall -- just in time for the flu season. [Tim Simmons, Raleigh News & Observer, Apr 19]

LaBelle Associates (Bellingham, WA)

Aiming to maximize the potential of bovine colostrum to benefit global health, PanTheryx (Boulder, CO; no SBIR, founded 2007) is announcing two major acquisitions that make it the world’s premiere manufacturer of nutrient rich colostrum. In separate purchases, PanTheryx has acquired the two leading producers of colostrum and related nutritional products, APS BioGroup (Phoenix,AZ; no SBIR) and La Belle Associates (Bellingham, WA; no SBIR). In March of 2016, PanTheryx announced that it entered into a $53 million financing with Pegasus Capital Advisors. ... The terms of the acquisitions were not released. [company press release, Feb 14, 17]


LabNow (Austin, TX; no SBIR, founded 2004, six employees) has received $605,000 of a planned $850,000 round of financing. ...  develops devices that test the white blood cell count of HIV patients ...  had raised to $34 million [by 2007] [Austin Business Journal, May 13, 10]

LabNow (Austin TX)   (Austin TX; no SBIR) biotech company that has developed a portable device that will help treat AIDS patients in Africa and Asia, has secured an investment of $20M. ... on a shoestring budget only seven months ago after spending its initial $14M investment, now has a "chance to do everything we had hoped with this money," CEO Rick Hawkins said. [Lily Rockwell, Austin American-Statesman, Nov 12]

Laborie Medical Technologies (Williston, VT)

Laborie Medical Technologies (Williston, VT, no SBIR, founded 1967) reports it has garnered [FDA] market clearance for its diagnostic system for urological disorders ... The -based firm's "Tetra" near infrared spectroscopy system uses non-invasive lasers to analyze bladder obstruction and other urinary functions, company officials say. Studies are under way to find further uses of the technology.  Laborie develops and markets diagnostics for urology, computerized and physical modeling tools for the bladder, as well as educational products. The privately held company employs more than 150 workers, [Mass High Tech, Mar 10, 08]

Labrys Biologics

With Exelixis (no SBIR)and Renovis (South San Francisco, CA; $500K SBIR) already under his belt, the longtime Bay Area biotech entrepreneur's newest venture, Labrys Biologics(no SBIR), has acquired a Phase II-ready experimental migraine treatment from Pfizer and snagged $31 million in a Series A financing round.   ... Labrys' new drug, called RN-307, was discovered and developed by South San Francisco's Rinat Pharmaceuticals  (South San Francisco, CA; no SBIR) which Pfizer bought in 2006   [Ron Leuty, San Francisco Business Times, Jan 3,13]

Lacerta Therapeutics (Alachua, FL)

Sarepta Therapeutics announced that it has made a strategic investment and entered into a license and option agreement with Lacerta Therapeutics (Alachua, FL; no SBIR), a gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop CNS-targeted treatments and lysosomal storage diseases. Sarepta expects to benefit from Lacerta’s expertise in AAV-based CNS-targeted gene therapies, will gain access to Lacerta’s capsid screening and proprietary OneBac manufacturing platform and process for the licensed products, and bolsters its pipeline to 11 gene therapy programs, with three CNS-focused programs from Lacerta. [Sarepta press release, Aug 6, 18]

Lactic Solutions (Madison, WI)

UW-Madison’s news service reported that Lactic Solutions (Madison, WI; no SBIR, founded 2015)  spun out of research conducted at the school, was acquired last month by Lallemand Biofuels & Distilled Spirits (Canada)  for an undisclosed sum.  Lactic Solutions had been seeking to commercialize a patented method for getting lactic acid bacteria to produce ethanol, rather than lactic acid, which can be harmful. Just as lactic acid bacteria can contaminate beer and wine by producing lactic acid instead of alcohol, it can also create snags in the ethanol production process, the university said. James Steele, a food science professor at UW-Madison, founded Lactic Solution.  [Jeff Buchanan,, Nov 20, 17]

Laguna Pharmaceuticals (formerly ChanRx,Cleveland, OH)

Laguna Pharmaceuticals (previously ChanRx, LaJolla, CA; no SBIR) which relocated to San Diego from Cleveland, OH, in February with $30 million in [Series B] new venture funding, shut down after s afety concerns emerged in a Phase 3 clinical trial for its drug, intended to treat atrial fibrillation. The drug—a 1,4-dialkylpiperazine derivative (Vanoxerine)—was the only drug Laguna had under development.  [Bruce Bigelow,, Dec 12, 15]

Laguna Pharmaceuticals (formerly ChanRx, Cleveland, OH) (formerly ChanRx, Cleveland, OH; no SBIR), has moved to San Diego ...  also raised $30 million from venture capital investors and hired as chief executive a San Diego biotech veteran  [Bob] Baltera [who] was last CEO of Amira Pharmaceuticals, sold for up to $475 million to Bristol-Myers Squibb in 2011. ... is conducting clinical trials of a drug to treat atrial fibrillation and flutter.  [Bradley Fikes,, Feb 17, 15]

La Jolla Pharmaceutical (LaJolla, CA)

La Jolla Pharma down 17% [Jun 10, 19]

La Jolla Pharma up 26% [Jun 7, 19]

La Jolla Pharma up 92% [Jun 6, 19]

La Jolla Pharmaceutical (LaJolla, CA; no SBIR) announced a merger deal with another small biotechnology company. The deal between La Jolla Pharmaceutical and  Adamis Pharmaceuticals (DelMar, CA; no SBIR) will give La Jolla shareholders as much as 30 percent ownership of the combined company, while Adamis gets $2.5 million to $3 million in cash expected to be left over from La Jolla’s operations. [Thomas Kupper, San Diego Union Tribune, Dec 8, 09]

Lake Shore Cryotronics (Westerville, OH)

When university researchers conduct experiments at extreme temperatures, their work often is aided by products from Lake Shore Cryotronics (Westerville, OH; $8M SBIR, founded 1968)  [Melissa Kossler Dutton, Columbus Business Journal, Mar 27, 15]     Last month, we announced a new partnership with Cascade Microtech (Beaverton, OR; $700K SBIR before 1996, public company), a collaboration that combines the knowledge of two industry leaders who operate in two distinct areas of the probe station market  [Lakeshore company website, Mar 25, 15]


Picked in Forbes's top 100 small companies: Synaptics $340K SBIR ; Myriad Genetics one SBIR; iRobot  $7.5M SBIR; Landec  $1.6M SBIR.

Landec down 11% [Sep 25, 13]

Landec (Mountain View, CA; $1.6M SBIR) up 16% [Jan 3, 13]

Landec up 10% [Oct 4, 11]

Landec up 15% [Mar 6, 09]

Landec up 10% [Jan 21, 09]

Landec down 20% [Jan 7, 09]

Landec  down 13% [Dec 1, 08]  On a stock bloodbath day

Landec up 10% [Nov 13, 08]

Landecup 11% [Oct 10, 08]

Landec down 11% [Oct 9, 08]

Landec down 16% [Jan 4, 08]

Landec jumped 11% after announcing two deals with Monsanto that could be worth $70 million. [Dec 4, 06] Landec  makes polymers used in food and agricultural products. It had about $1.5M SBIR 1987-2003.

Landos Biopharma (Blacksburg, VA)

Landos Biopharma (Blacksburg, VA; no SBIR), focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, announced the successful completion of its $60 million Series B financing round [company press release, Aug 13, 19] the first biotech to come out of Xontogeny, the accelerator started by former Sarepta Therapeutics chief Chris Garabedian [Fierce Biotech, Aug 14, 19]

Chris Garabedian’s accelerator has spawned its first biotech. The startup, Landos Biopharma (Blacksburg, VA; no SBIR, seven employees), has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million from Perceptive Advisors to take a LANCL2-targeted treatment for inflammatory bowel disease (IBD) into the clinic.  Garabedian sketched out when he secured $15 million from Perceptive earlier this year to set up Xontogeny. Garabedian created the accelerator to help scientists with an idea but without the means to realize it to get the clinical proof-of-concept data they need to unlock further financing and dealmaking opportunities. Xontogeny’s role is to guide founders through these early stages, not give them the money to do so. [Nick Paul Taylor, Fierce Biotech, Sep 21, 17]

Xontogeny, the Boston-based biotech startup accelerator formed by one-time Sarepta Therapeutics CEO Chris Garabedian, has taken on its first company. [to] secure a $10 million investment for startup, Landos Biopharma (Blacksburg, VA; no SBIR), that is developing drugs for inflammatory bowel disease.   New York life sciences investment firm Perceptive Advisors is the sole investor in Landos’ Series A round. Perceptive was also Xontogeny’s only investor when it raised a $25 million round earlier this year.    Xontogeny was formed to help fledgling biotechs progress experimental programs from preclinical research through proof-of-concept studies.  [Frank Vinluan,, Sep 18, 17]

Lantern Pharma (Dallas, TX)

Lantern Pharma (Dallas, TX; no SBIR, founded 2012) closed its Series A equity financing of $3.7 million ...  late-stage clinical drugs are “rescued and repurposed” by Lantern through molecular profiling to identify patients who will respond favorably.  [Olivia Nguyen,,  May 4, 17]

Lantern Pharma (Dallas, TX; no SBIR, founded 2014) landed a nearly $1 million investment. ... focuses on novel cancer treatments, is a graduate of the 2014 Health Wildcatters class. ... combines a drug platform with diagnostics and data analytics in cancer medicine to identify and treat patients. The company is initially focused on prostate and ovarian cancers. It is led by Asaithambi, a biotechnology scientist and entrepreneur who formerly was the cofounding CEO of Signal Therapeutics (no SBIR).   [Danielle Abril, Dallas Business Journal, Feb 26, 15]

Lantheus (North Billerica, MA)

The first round of grants awarded under the Massachusetts-Israel Innovation Partnership, MIIP, were announced ... A total of at least $1.3 million ... SBH Sciences (Natick, MA;  no SBIR) and Improdia (Israel) will work together toward the development and manufacture of a chronic inflammation-dependent immunosuppression prognostic kit. $400K .... Automated Medical Instruments (Needham, MA;  no SBIR) will work with STI Lasers (Israel). They will develop new technology involving radio frequency energy to perform circumferential ablation of the pulmonary veins. $230K ...  Lantheus (North Billerica); no SBIR and Check-Cap (Israel) will work on a novel 3-D imaging capsule that can be used to screen for polyps and lesions associated with colorectal cancer.$600K ... FloDesign Sonics (Wilbraham, MA;  no SBIR) and Transbiodiesel (Israel) have been selected as the clean energy award winners. Their joint project will use FloDesign’s acoustic molecule separation technology to separate oil that can be used to create fuel from Transbiodiesel’s oil-generating algae. $75K. [DC Denison, Mass High Tech, Jun 19, 12]

Lantos Technologies

Lantos Technologies (Cambridge, MA; no SBIR) a health-focused 3-D scanning technology startup, has raised the expected $1.6 million in it Series A round of funding ...  developing 3-D imaging technology that provides minimally invasive digital mapping of the human ear canal, so manufacturers can make more comfortable, custom fit audio devices such as hearing aids, earphones and noise-canceling devices ... co-founded by MIT mechanical engineering professor Douglas Hart.  In 2006, Hart sold his previous startup, Brontes Technologies (no SBIR) for $95 million to 3M Company. Brontes had focused on 3-D scanning for oral applications.   [Rodney Brown, Mass High Tech, Sep 16, 10]

Dems at commercialization, again. DOUGLAS P. HART, a [MIT] professor of mechanical engineering who sold his last start-up for a tidy $95 million, is already on to his next big thing. On Tuesday, he expects to lock up $1.5 million in funding for his new start-up, Lantos Technologies. ... developed a 3-D scanner that it hopes will streamline the current generation of earphones and hearing aids by precisely fitting them to the dimensions of the ear canal, right up to the eardrum....  able to bring his hearing aid concept closer to reality with $50,000 in backing last year from the Deshpande Center for Technological Innovation, an M.I.T. entity originally funded by two private investors, Jaishree Deshpande and her husband, Gururaj. ...  A proposal from the Obama administration would experiment with all of this by allocating $12 million among several institutions next year in what proponents hope will be a continuing effort to support and study proof-of-concept centers. If successful, supporters say, universities could spread the model faster. But the idea represents a shift in thinking about the federal government’s role in stewarding the more than $50 billion it gives to university researchers annually. Until now, that money has been for the discovery, not commercialization, of scientific breakthroughs.    [Bob Tedeschi, New York Times, Jun 27, 10]  Can the federal government do commercialization decently?  Probably not!  Where is any evidence that it ever succeeded with its host of programs? After nearly three decades of SBIR, for example, where's the economic evidence of success? Government understands science and technology, but not business, and has no incentive for agencies to succeed at business. The political cycle also works against any long-term plan as whenever the Republicans own the White House, the commercialization programs get canned. Then when the Democrats regain and re-start them, the cycle repeats.

Lariat Biosciences

North Shore InnoVentures, a technology incubator based in Beverly [MA], said that six startup companies in the clean technology and life sciences sectors have joined its program over the last few months.  .... Lariat Biosciences  (no SBIR), is developing a non-invasive diagnostic to detect early signs of cancer based on circulating free DNA within the bloodstream.      ...   Other startups recently joined include Akita Innovations, RAN Biotechnologies, Quad Technologies, and ZS Genetics, none has SBIR.  ....  A total of 21 companies are now in [residence].  [Chris Reidy, Boston Globe, Jun 5] 

Laser Design (Bloomington, MN)

CyberOptics (Minneapolis, MN; $300K SBIR) has a [$3 million all-cash]deal to acquire Laser Design (Bloomington, MN; no SBIR), a 3D measuring company [which] makes about $6 million in yearly revenue and provides scanning systems and services to major customers like Samsung and Toyota. [Branden Largent , Minneapolis / St Paul Business Journal, Jan 15, 14] 

Lasergen (Houston, TX)

Agilent Technologies is investing $80 million into Houston-based Lasergen (Houston, TX; $1.2M SBIR, founded 2002) [to get]  a 48 percent stake in Lasergen. Until March 2018, Agilent also has the option to acquire the remaining Lasergen shares for $105 million. ...  will collaborate to create an NGS [DNA sequencing technology] solutions workflow for clinical applications based on Lasergens’s Lightning Terminators sequencing chemistry.  [Olivia Pulsinelli, Houston Business Journal, Mar 9, 16]

LaserMax (Rochester, NY)

Pay to play. LaserMax, (Rochester, NY; no SBIR) that designs and manufactures laser sights for handguns and rifles, has hired former New York Senator Alfonse D'Amato to lobby Congress on its behalf in the upcoming debates over the 2016 and 2017 defense budgets, according to new lobbying registration documents.  [Foreign Policy SITREP, Sep 10]

LaserMotive (Kent, WA)

LaserMotive (Kent, WA; no SBIR) is going after a $2 million prize in the power-beaming challenge of the NASA-sponsored Space Elevator Games. .... Six partners and 10 employees  .... "We don't have a lot of competition," he said, then perhaps obviously adding, "there are not a lot of companies that have this type of background and experience."   [Charles Berman, Seattle Times, Jul 28]

Laser Tissue Welding (Houston, TX)

Laser Tissue Welding (Houston, TX; one SBIR) Using a laser to fuse tissue and stop bleeding without stitches.... founder Yasmin Wadia has invested $500,000 in cash and received $160,000 from the state’s Emerging Technology Fund. ... also received $1.3 million in federal grants. [Purva Patel, Houston Chronicle, Aug 28, 10]

Lassen Therapeutics (San Diego, CA)

Lassen Therapeutics (San Diego, CA; SBIR) announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology. [company press release, Jun 17, 20]

Lattice Biologics (Scottsdale,AZ)

In a reverse merger, Lattice Biologics (Scottsdale, AZ; no SBIR) will benefit from foreign direct investment by merging Toronto-based Blackstone Ventures. ...  creates tissue-based products used in a number of surgeries and procedures.  [Eric Jay, Phoenix Business Journal, Aug 17, 15]

Lattice Biologics (Scottsdale, AZ; no SBIR) just got $1 million from Grenville Strategic Royalty (Canada). ... brings Grenville's total Lattice investment to $3 million  ... focuses on cellular therapies and tissue engineering.   ... In September 2013, Cook acquired the assets of International Biologics and renamed the company Lattice Biologics.  ... Lattice now has a total of $8 million invested in the company, including $2 million of Cook's own money.    [Angela Gonzales, Phoenix Business Journal, May 21, 15]

Lattice Biotech (Athens, OH)

Applied Biomolecular Technologies (Athens, OH; no SBIR, founded 2006) is owned by three former Battelle biotech researchers and an entrepreneur pursuing a private path to getting research out of academic laboratories and into the marketplace. ...  One of their newest subsidiaries, Lattice Biotech LLC (no SBIR), is trying to raise $5 million to advance technology it licensed from Nationwide Children’s Hospital to make antibodies that weaken protective films around infectious bacterial colonies. But that’s just one of a half-dozen biotech ventures it’s developing ...  [also own] Burr Oak Therapeutics LLC (no SBIR), whose product is under wraps for now. In February 2014 it acquired and expanded an Athens company it renamed Binding Protein Technologies LLC (formerly Athens Research ($1M SBIR).  ... Last month Applied Bio Ventures invested in but did not acquire a fellow commercialization engine, Brainstage (Carnegie, PA; no SBIR), which itself has six biotech companies in its portfolio.   [Carrie Ghose, Columbus Business First, Apr 1, 15]

LaunchPad Medical (Lowell, MA)

LaunchPad Medical (Lowell, MA;  $500K prior SBIR) has been awarded a $2.5M Direct-to-Phase II [NIH SBIR] grant to advance the development of Tetranite, its bone adhesive biomaterial technology. [Rowan Walrath, BostInno, May 1, 20]

Lawrie Technology (Girard, PA)

Lawrie Technology (Girard, PA), has embedded fibers within an elastomeric matrix, creating a new material whose properties differ wildly from "normal" isotropic materials. Founder/boss Duncan Lawrie says his process runs from $40 to $80 per pound while competing processes cost as much as $400 per pound. The curse of all new materials is their cost. Two Phase 2 SBIRs in the mid-1990s. story from MDA Update     Lawrie has no apparent website, not a healthy sign of commercial success.

Lazarus Effect (Campbell, CA)

Medtronic said it paid $100 million cash to buy Lazarus Effect (Campbell, CA; no SBIR), which makes products for capturing and removing stroke-causing blood clots.  ....   working to get U.S. approval to sell a device called the ReCover. The ReCover works with another Medtronic device called the Solitaire, a kind of stent that can be deployed in the brain to scoop out vessel-blocking clots that cause acute ischemic stroke.  [Joe Carlson, Minneapolis Star Tribune, Sep 28, 15]

LDR Holding (Austin, TX)

Medical device manufacturer LDR Holding (Austin, TX; no SBIR) had a successful [IPO] as shares ended their first day of trading up 29 percent. ....  focuses its products on the spine ....   was founded in Y2K in Troyes, France and has offices in Germany, Spain, China, South Korea and Brazil. [Chad Swiatecki, Austin Business Journal, Oct 9, 13]

Leading Edge Crystal Technologies (Gloucester, MA)

The Department of Energy will award $128M to support 75 research projects that seek to advance the development of solar technologies. Most money went to academic and large businessses. Several awards went to former SBIR winners: Energy Materials (Norcross GA one SBIR) won a $4M Solar project award to create new methods to deposit layers of material to make the cell, develop a high-speed process ; Leading Edge Crystal Technologies (Gloucester, MA; one SBIR) won $2.5M to develop a floating-silicon method for producing high-quality single crystalline wafers ; Sunvapor (Livermore, CA ; one SBIR) won $2.5M to show how using enormous tanks that normally store liquefied petroleum gas can be used to accumulate and store solar-generated steam ; Brayton Energy (Hampton,NH; $3M SBIR) won $700K to partner w Oak Ridge Lab to examine examine creep behavior—the tendency to deform under mechanical stress—in thin-sheet nickel alloys; Ceramic Tubular Products (Lynchburg, VA; $3.2M SBIR) won $1.9M to develop silicon carbide composite receiver tubes for molten chloride salt and liquid sodium receivers; Echogen Power Systems, (Akron, OH; $300K SBIR) won $4.4M to develop a large-scale, low-cost, single-shaft compressor for supercritical carbon dioxide (sCO2) power cycles; Osazda Energy (Albuquerque, NM; one SBIR) won $1M to develop a cost-effective metal paste that strengthens the metal connections in solar cells; Scion Plasma (East Lansing, MI; $200K SBIR) won $1M to develop a tool that rapidly deposits transparent conductive oxide onto heterojunction silicon with intrinsic thin layer (HIT) solar cells; Swift Coat (Peoria, AZ; one SBIR) won $1M to make and scale multilayer, anti-reflective and anti-soiling coatings for solar glass [Jane Edwards, govconwire, Nov 7, 19]

Lead Therapeutics (San Bruno, CA)

A cancer-fighting drug that BioMarin Pharmaceutical (Novato, CA; $300K SBIR) picked up in a $97 million acquisition five years ago is at the center of a potential $570 million deal with fellow Bay Area drug developer Medivation (San Francisco CA; no SBIR).  The late-stage drug — dubbed talazoparib, or BMN-673 — is a so-called PARP inhibitor, a class of drugs that block enzymes, which cancer cells use to repair themselves after chemotherapy or other stresses.  ... BioMarin landed talazoparib with its 2010 acquisition of LEAD Therapeutics  (San Bruno, CA; no SBIR). The San Rafael company has since taken the drug into a Phase III trial against advanced breast cancer, but it also has investigated the drug across multiple tumor types, including ovarian cancer. [Ron Leuty,San Francisco Business Times, Aug 25, 15]

BioMarin Pharmaceutical (Novato, CA; $200K SBIR)  agreed to buy Lead Therapeutics (San Bruno, CA; no SBIR) which has a cancer drug in early development, for $18 million.  [SEF Brown, San Francisco Business Times, Feb 4, 10]

LeafBio (San Diego, CA)

LeafBio, the commercial arm of Mapp Biopharmaceutical (San Diego, CA; $9M SBIR), said it has begun a clinical safety trial of MB66, a rapidly dissolving film that releases anti-viral monoclonal antibodies to the vaginal mucosa. MB66 is intended to block the sexual transmission of genital herpes and HIV. MB66 is LeafBio’s second product to enter clinical trials; ZMapp is currently being evaluated for the treatment of Ebola in the United States and West Africa. [Bruce Bigelow,, Jan 18, 16]

Since Saturday, Mr. Duncan [Dallas Ebola patient]has been receiving brincidofovir — an experimental drug developed to fight smallpox and other highly infectious viruses. The C.D.C. said there are no more doses of ZMapp [developed by Leaf Biopharmaceutical (no SBIR) which got one ingredient from Mapp Biopharmaceutical  ($9M SBIR)], another experimental drug used on two American aid workers who later recovered from Ebola.  [DAVE PHILIPPS and KEVIN SACK, New York Times, Oct 7] What SBIR cannot do (in principle) is fund production of the drug as it transitions from chemistrry experiment to in-use pharmaceutical. In practice. in an emergency, the USG has the power to do almost anything.

When we need something now. An experimental drug given in Liberia to two Americans healthcare workers infected with the deadly Ebola virus was produced by Mapp Biopharmaceuticals (San Diego, CA; no SBIR, founded 2003), a small biotech. With funding provided by U.S. and Canadian bio-defense grants, MappBio worked with LeafBio  (San Diego, CA; no SBIR), a commercialization partner, and Defyrus, a private bio-defense company in Toronto, Canada, to make ZMapp, a drug cocktail composed of three “humanized” monoclonal antibodies. According to David Kroll in Forbes, ZMapp helps to stimulate an immune response to the Ebola virus. MappBio says the drug was only identified eight months ago and has not been evaluated for safety in humans.  [Bruce Bigelow,, Aug 7, 14] 

Learning Ovations (Paradise Valley, AZ)

Scholastic announced that it has acquired Learning Ovations (Paradise Valley, AZ; $2.1M SBIR) the creator of A2i (“Assessment to Instruction”), a literacy screening, progress monitoring assessment and instructional planning system for classrooms and community organizations. ... financial terms not disclosed [Scholastic press release, Sep 8, 2022]

LeCroy   (Chestnut Ridge, NY)

LeCroy up 55%  [May 29, 12] after the maker of electronic signal-testing equipment agreed to be acquired by Teledyne Technologies in a cash deal valued at $291 million. [Chris Dieterich, Wall Street Journal, May 30]

Lecroy  down 12% [Jan 25, 12]

LeCroy up 10% [Jan 9, 12]

LeCroy up 10% [Nov 28, 11]

LeCroy up 15% [Oct 26, 11]

LeCroy up 11% [Oct 4, 11]

LeCroy up 11% [Aug 23, 11]

LeCroy  down 10% [Aug 18, 11]

Lecroy down 10% [Aug 8, 11]

LeCroy up 11% [Jun 21, 11]

LeCroy up 16% [Jan 3, 11]

LeCroy  up 11% [Sep 30, 10]

LeCroy down 10% [Sep 23, 10]

LeCroy up 14% [Jun 21, 10]

LeCroy  up 12% [Aug 11, 09]

LeCroy down 10% [Aug 10, 09]

LeCroy up 11% [May 29, 09]

LeCroy  up 24% [May 6, 09]

LeCroy  up 16% [Apr 16, 09]

LeCroy  up 16% [Apr 9, 09]

LeCroy  up 23% [Mar 23, 09]

LeCroy  down 18% [Jan 26, 09]

LeCroy  up 12% [Dec 29, 08]

LeCroy up 10% [Dec 26, 08]

LeCroy down 12% [Dec 22, 08]

LeCroy up 11% [Dec 12, 08]

LeCroy down 11% [Dec 11, 08]

LeCroy up 10% [Dec 10, 08]

LeCroy down 13% [Dec 3, 08]

LeCroy up 13% [Nov 28, 08]

LeCroy up 12% [Nov 17, 08]

Lecroy up 12% [Nov 13, 08]

Lecroy up 11% [Oct 30, 08]

Lecroy down 13% [Oct 15, 08]

Lecroy up 11% [Mar 18, 08]

LeCroy (Chestnut Ridge, NY; one Phase 2 SBIR a decade ago) up 19% on good profit news. [Oct 17, 07]

LED Lighting Fixtures [Morrisville, NC]

Cree is increasing its bet on the burgeoning market for energy-efficient lights [saying] it will buy LED Lighting Fixtures (Morrisville NC) for up to $100M+. LED Lighting is run by F. Neal Hunter, who 20 years ago co-founded Cree. ... Buying LED Lighting will add $1 M to Cree's revenue for the current quarter and $30M in revenue during the fiscal year that starts in June. Cree reported $394M in revenue in its last fiscal year.   [Alan Wolf and David Ranii, Raleigh News&Observer, Feb 9, 08]

LED Lighting Fixtures (Morrisville NC) claims a technology breakthrough that will dramatically lower the cost of lighting homes and offices with LEDs ... uses 5.8 watts of power, compared with 60 watts for an equally bright incandescent bulb  [Frank Norton, Raleigh News& Observer, Nov 28]

LED Lighting Fixtures  (Morrisville NC; no SBIR) raised $16.5M in private equity to expand its line of power-efficient lighting products and accelerate research and development. LLF is among the first companies in the world to design and manufacture general-purpose fixtures that hold light-emitting diodes, or LEDs. ...The cash infusion is the company's second since being co-founded in 2005 by current chairman Neil Hunter, one of the founders of Cree.  LLF, which raised $6.5 million last year, uses Cree LEDs in some of its products. [Frank Norton, Raleigh News&Observer, Nov 3, 07]

LED Lighting Fixtures [Morrisville, NC] signed the first customer for its energy-efficient light fixtures. The startup, led by Cree co-founder Neal Hunter, will supply recessed light fixtures to Loyd Builders, a custom home builder. [Raleigh News and Observer, Mar 21]

Lehigh Technologies (Tucker, GA)

Lehigh Technologies (Tucker, GA; one SBIR in FL) raised $5 million in an investment round ... working to solve the problem of end-of-life tires and other post-industrial rubber by turning them into a material that can be recycled into high-performance tires, asphalt sealants, plastics and paints. Lehigh transforms scrap rubber material into a powder-like substance called micronized rubber powder through a high-efficiency milling process ... has raised $13 million of the planned $19 million   [Urvaksh Karkaria, Atlanta Business Journal, Jul 20, 12]

Leica Microsystems

Edico Genome (La Jolla, CA; no SBIR, founded 2013) took first place [in The Scientist top ten innovation list] for its Dragen Bio-IT Processor. The add-on card accelerates the analysis of genomic data by a factor of 30, says Pieter van Rooyen, Edico's president and chief executive.  ....  Genome sequencers from Illumina took second and third place   [Bradley Fikes,, Dec 1, 14]  Other winners: BioNano Genomics, RainDance Technologies  (Lexington, MA; $1.1M SBIR) , Leica Microsystems, Organovo  (San Diego, CA; $300K SBIR), Haplogen Genomics, Immucor, Sciencescape.    [The Scientist, Dec 1, 14]

Leto Solutions (San Antonio TX)

Leto Solutions  (San Antonio TX; no SBIR)  [seeking to raise $2 million initially to complete beta testing] seed funding for its initial product, the Aquilonix Prosthesis Cooling System. The thermoelectric temperature management system fits into the sockets of prosthetics to prevent problems associated with heat generation in lower-limb amputees.  ...  spawned from a project at the University of Texas at San Antonio involving a handful of engineering students, including a veteran who lost his leg as a result of injuries suffered in Iraq.  [W. Scott Bailey, San Antonio Business Journal , Feb 25, 14]

Leuko (Boston, MA)

Leuko (Boston, MA; no SBIR), an MIT-born technology startup developing the first non-invasive white blood cell monitoring device, today announced it has raised $1.8 million in seed financing [company press release, Jul 17, 19]

LexaGene (Beverly, MA)

biotech LexaGene (Beverly, MA; no SBIR) placed its first beta prototype into Massachusetts Veterinary Referral Hospital in Woburn. [Sri Kalyanaraman, BostonInno, Jun 7, 19]

Lexeo Therapeutics

Lexeo Therapeutics (New York, NY; $3M SBIR) has raised $100 million to advance a pipeline of treatments for genetic cardiovascular and central nervous system conditions. The series B fundraising comes barely two months after Lexeo snapped up three heart disease programs through the acquisition of Stelios Therapeutics. [ Annalee Armstrong, Fierce Biotech; Sep 9, 21]

Lexeo Therapeutics (New York, NY; $1.8M SBIR) is coming out of stealth with $85 million and 18 gene therapy programs primarily developed at Weill Cornell Medicine. [Amirah Al Idrus, Fierce Biotech, Jan 7, 21] Stealth questionable since SBIR awards are publicly published.

Lexicon Genetics

Lexicon Genetics up 10%. [Apr 13, 07] 

Lexicon Genetics up 11% [Feb 22, 07] after a broker's upgrade.

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals (formerly Lexicon Genetics, The Woodlands, TX; one SBIR),  announced positive topline results from its Phase 1a study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1, or AAK1, in development for the treatment of neuropathic pain. [company press release, Dec 18, 18]

Lexicon Pharmaceuticals (Houston, TX; one SBIR in 1996, founded 1995) announced that the FDA has approved its treatment for diarrhea caused by carcinoid syndrome, telotristat ethyl (Xermelo)  Lexicon says it is the first orally administered therapy to treat carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapies, which target the root cause of the problem: overproduction of hormones.   [Angela Shah,, Feb 28, 17]

Lexicon Pharmaceuticals (Woodlands, TX; one SBIR in 1996 as Lexicon Genetics) up 61% [Aug 3,15] on volume of one third the total stock shares, announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care [press release]

Lexicon Pharmaceuticals (founded as Lexicon Genetics in 1995, Woodlands, TX; one SBIR) has a new CEO after jobs cuts to nearly half the company's workforce signaling a failed transition to development and commercialization ....  was trying to court giants like Philadelphia-based GlaxoSmithKline PLC (NYSE: GSK) to partner with on its later stage trials of its diabetes drug.  [Josh Cain, Houston Business Journal, Jul 8, 14]

Two financing infusions [$200-500M] announced this week will help Lexicon Pharmaceuticals complete its shift from a genetic research company to a biopharmaceutical firm on its own terms, analysts said. [Purva Patel, Houston Chronicle, Jun 19]

Lexington Medical (Billerica, MA)

Lexington Medical (Billerica, MA; no SBIR) a medical device company delivering minimally-invasive surgical stapling solutions, and BOWA Medical (Germany), a leading innovator of energy based surgery products for medical applications, have entered into a commercial agreement the companies announced. [company press release, Jul 22, 20]

Leyden Energy (Fremont, CA)

Leyden Energy (Fremont, CA; one SBIR) which is developing longer-lasting lithium ion batteries for consumer mobile devices, electric vehicles, and energy storage, said that it has raised $20 million in Series B financing [, Aug 3, 11]

Libra BioSciences

venture capital firm PureTech Ventures is launching a new company Vedanta Biosciences ... a spin-off from PureTech’s Libra BioSciences (no SBIR), a stealthy entity set up to explore commercialization opportunities in the biogenome field.  Incubated in PureTech’s Boston offices, ... aims to commercialize research newly published today in the academic journal Science that indicates beneficial, gut-dwelling bacteria may also be useful for combating allergies and inflammatory bowel disease (IBD). [Galen Moore, Mass High Tech, Dec 23, 10]

LifeCell (Branchburg,NJ)

Acelity LP (San Antonio, TX; no SBIR) is again expanding its product portfolio. The advanced wound care and regenerative medicine company is rolling out its BIOSORB Gelling Fiber Dressing in the U.S. [W. Scott Bailey, San Antonio Business Journal, Jul 28, 16]  a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, LifeCell. and Systagenix Wound Management, Limited. [company website]

Little more than a year after Acelity’s LifeCell Corp (San Antonio, TX; $4M SBIR) subsidiary obtained a preliminary injunction against TELA Bio (no SBIR) and two of its officers over its TELAMax hernia mesh product, the two sides are back in court [with] a new patent infringement lawsuit.  [W. Scott Bailey, San Antonio Business Journal, Jul 12, 16]

Kinetic Concepts (San Antonio, TX)say [subsidiary] LifeCell ($4M SBIR) has acquired an advanced adipose Tissue Injector, or aTI, from TauTona Group, a medical device incubator based in Menlo Park, Calif. [W. Scott Bailey,  San Antonio Business Journal, Jan 31, 14]

China's Commerce Ministry said it had approved U.S.-listed laboratory equipment maker Thermo Fisher Scientific Inc's $13.6 billion takeover of Life Technologies Corp , subject to certain conditions. The conditions are that Thermo Fisher cut the prices of two types of its products sold in China, sell its cell culture and gene adjustment businesses, and its stake of 51 percent in China's Lanzhou National Hyclone Bio-engineering Co Ltd.  [Reuters, Jan 16, 14]

KCI  (San Antonio, TX; no SBIR), LifeCell (Somerville, NJ;  $3.8M SBIR), and Systagenix  (UK) now form one company, a global leader in medical technology with more than $2 billion in revenue, poised for future success as a geographically diversified company with world-class wound care and biologics franchises. [KCI press release, Oct 28, 13]

LifeCell (Branchburg, NJ; $4M SBIR) up 17% after agreeing to be bought by Kinetic Concepts for $1.7 B cash. [company press release]

LifeGen Technologies (Madison, WI)

LifeGen Technologies (Madison, WI; one SBIR) has agreed to be acquired for $11.7 million by a Utah company that sells anti-aging products. Nu Skin Enterprises (no SBIR) said Thursday it will acquire all of LifeGen's assets .... started in 2000 by two professors at the University of Wisconsin-Madison, Richard Weindruch and Thomas A. Prolla. It has had a collaboration with Nu Skin since 2009 and uses the company's genetic science to support an anti-aging nutritional supplement and other products.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Oct 27, 11]

Life Image (Newton, MA)

LifeImage (Newton, MA; no SBIR) maker of medical imaging storage and sharing technology, has closed out its Series B funding round at $12 million ... co-founded by CEO Hamid Tabatabaie, a serial entrepreneur who has spent 12 years in health care information technology operating startup companies in the diagnostic imaging market  [Rodney Brown, Mass High Tech, Jan 5, 11]

Life Image (Newton, MA; no SBIR) pulled in $2 million in financing, according to a filing with the SEC. ... develops web-based applications and services to ease access to patients’ medical-imaging history. [Mass High Tech, Jan 15, 10]

LifeMine Therapeutics (Cambridge, MA)

LifeMine Therapeutics (Cambridge, MA, no SBIR) a startup co-founded by Harvard University chemical biologist and serial biotech entrepreneur Greg Verdine and business colleague Weiqing Zhou, has landed a $55 million Series A round from a large group of investors  [Ben Fidler,, Sep 15, 17]


LifeSprout (Johns Hopkins U spinout, Baltimore, MD; no SBIR, founded 2015] closes $6M round [Baltimore Business Journal, Jun 29, 18] has developed a soft tissue replacement alternative that will benefit cancer and trauma patients and others cosmetically. [, Jun 29, 18] total funding $7M [}

LifeSprout, a biotechnology firm out of Johns Hopkins, has completed a $6.5M round, the Baltimore Business Journal reports. [DCInno, Jun 19, 18]

Life Technologies  (Carlsbad, CA)

The Supreme Court sided with Life Technologies in a patent infringement case that limits the international reach of U.S. patent laws.  The justices ruled unanimously on Wednesday that the company’s shipment of a single part of a patented invention for assembly in another country did not violate patent laws. Life Technologies supplied an enzyme used in DNA analysis kits to a plant in London and combined it with several other components to make kits sold worldwide.   Promega (Madison, WI; $5M SBIR) sued, arguing that the kits infringed a U.S. patent.  [AP, Feb 22, 17]

precision medicine startup Strata Oncology (Ann Arbor, MI; no SBIR) announced last week that it has raised a $12 million Series A round, to make tumor sequencing for cancer patients more accessible. ... has entered into a collaborative partnership with Thermo Fisher Scientific. ... CEO Dan Rhodes, who led Compendia Bioscience (Ann Arbor, MI; $3.9M SBIR), a cancer genomics company that was acquired by Life Technologies in 2012, co-founded the 15-person Strata Oncology team in 2015 with Keith Flaherty, an oncologist from Harvard medical school and Massachusetts General Hospital, and pathologist Scott Tomlins from the University of Michigan medical school. [Sarah Schmid,, Jun 6, 16]

A rapid test for Ebola using technology [on instruments from Life Technologies, [now] a unit of Thermo Fisher Scientific] has been cleared for emergency use. ... The test was made by the Department of Defense, and its use was authorized this week by the U.S. Food and Drug Administration.  Results of the test, which analyzes blood samples, are available in two hours, said Dan Didier, director of public health with Life Sciences Solutions — Thermo Fisher. In comparison, the waiting period for other methods of detecting the Ebola virus is one to two days.  [Bradley Fikes, utsandiego, Aug 7, 14]

OK for Europe. Thermo Fisher Scientific that provides labs with medical instruments and technology [and committed to divest its cell culture, gene modulation, and magnetic beads businesses], said that it has received approval from the European Commission for its pending $13.6 billion acquisition of Life Technologies.  .... still needs additional regulatory approvals, including one from the US Federal Trade Commission   [Chris Reidy, Boston Globe, Nov 26, 13]

[post-merger internal reshuffling is] bad news for Life Technologies’ autonomous Ion Torrent Systems unit, the No. 2 player in the high-speed DNA sequencing industry. And bad news for Ion Torrent is good news for Illumina the unrivaled No. 1 in this fast-emerging and important market. [Luke Timmerman,, Apr 29, 13]

Life Technologies up 8% as Thermo Fisher agreed to buy diagnostics equipment maker Life Technologies in a $13.6 billion deal that will significantly expand Thermo Fisher and establish it as a major force in the emerging personalized medicine market. [Robert Weisman, Boston Globe, Apr 15, 13]    formed in 2008 by the merger of Invitrogen ($4M SBIR) and Applied Biosystems (no SBIR); acquired AcroMetrix (one SBIR) in 2010; acquired Ion Torrent (no SBIR) in 2010; won a $45 million Army contract in 2012.

Life Technologies up 10% [Jan 18, 13] to an all-time high ...   is exploring a potential sale and has retained banks to advise on the process, according to the news agency Reuters. [Bradely Fikes,, Jan 18, 13]

Life Technologies has been awarded a $45 million Army contract to provide reagents and consumable supplies for the DNA Identification Laboratory at the Armed Forces Medical Examiners System, the Defense Department announced. [Nathan Max,, Aug 24, 12]

Life Technologies has become the first company to enter the Archon Genomics X-Prize, a competition meant to produce the first machines and software that can sequence 100 entire human genomes for $1,000 or less. The winner gets $10 million in prize money. .... will try to win the competition with its Ion Proton TM Sequencer, a machine that has helped the firm maintain its standing as one of the world's elite genomics companies.    [Gary Robbins,, Jul 23, 12]

Roche Holding AG is offering $5.7 billion in cash to buy U.S. gene sequencing company Illumina  in a hostile takeover bid that marks a major play by the Swiss drugmaker into the gene technology field.  ....  Companies such as Illumina, Affymetrixand Life Technologies< get 20-40 percent of their revenue from U.S. government-backed research and may take a hit from any government funding cut.  [Reuters, Jan 25, 12]  Illumina enjoyed about  $10M SBIR 1999-2010, and a $4.6B market cap before the Roche gambit. Founder David Walt now owns less that 1% of the shares. Employees: 1200.

Life Technologies said it’s taking orders for a benchtop genome sequencer that can to decode an individual’s DNA within 24 hours and at a cost of roughly $1,000. The company priced its new Ion Proton Sequencer at $100,000 to $150,000, which also represents a dramatic reduction compared with the cost of existing DNA sequencers, and might even entice some practicing physicians to buy into the idea of personalized medicine. A cross-town rival, Illumina, also introduced an improved version of its gene-sequencing machine capable of same-day service, although Forbes’ Matthew Herper says Illumina’s HiSeq 2500 is priced at $740,000.  [Bruce Bigelow,, Jan 12, 12]

Layoffs began at Life Technologies on Thursday, three weeks after executives revealed plans to cut expenses by as much as $20 million to offset sluggish demand for the Carlsbad company's research laboratory products and the fumbled launch of a new sales strategy in China.[Keith Darce,, Aug 18, 11]

Scientists at two laboratories in Germany and one in China used the [Ion Torrent, Guilford, CT; no SBIR] company's new Ion Personal Genome Machine to sequence the genome of the [e-coli] bacterium in a matter of hours. Prior to the development of the sequencing technology, it would have taken days to decode the DNA. ...  [Founder Jonathan] Rothberg has long been a major figure in DNA research. He founded the biotech company CuraGen in 1991 while a graduate student at Yale University. He later founded 454 Life Sciences, (Branford , CT; no SBIR) that was sold to Roche Diagnostics in 2007 for $155 million. Shortly after that, he started Ion Torrent, which is now a division of Life Technologies. [William Weir, Hartford Courant, Jun 2, 11]

Life Technologies is using [crowd sourcing] to improve it’s (sic) desktop genetic sequencing device, the Ion Torrent Personal Genome Machine, making it the first crowd sourcing campaign focused on a biological research and medical laboratory. [Keith Darce,, May 3, 11] Life is competing with Illumina for sales of new cheaper sequencers that are cutting the machine cost by 80-90%.

a French scientist tells me he is moving his startup, Portable Genomics, to San Diego. ...  based on the assumption that it will be possible in another year to completely sequence an individual human genome for less than $1,000—and within three years, for less than $300. This is the promise of the recent announcements coming out of Life Technologies, Illumina, and Complete Genomics, as the speed of genetic sequencing increases and costs plummet. [Bruce Bigelow,, Jan 14, 11]

Six months after salmonella forced the recall of 550 million eggs in the United States and sickened more than 2,000 people, [Life Technologies (Carlsbad, CA)] has introduced a genetic test that could make it easier to detect contaminated eggs.  [Keith Darce,, Jan 13, 11]

Illumina and Life Technologies [make the machines that separate DNA from samples of saliva, blood, skin and other tissue for genetic analysis. ] both cut their genomics teeth on DNA testing products and sequencing machines designed mainly for human medical research. However, agriculture-related business has become increasingly important to the companies in recent years, executives said.  Crop and livestock customers generated $100 million in sales for Illumina in 2009, or 12 percent of total revenue, said Tristan Orpin, a senior vice president and chief commercial officer ....  Illumina now offers separate commercial chips for testing cows, dogs, pigs, sheep, horses and corn. Each chip sells for between $195 and $295, and the largest one (for cows) tests for 500,000 markers.  In November, Life Technologies began selling a genetic testing kit for quicker detection of viral diarrhea in cows, a costly disease that can spread rapidly in a herd and reduce the body weight, and value, of sick animals. [Keith Darce,, Dec 21, 10]

Life Technologiestook a step toward lowering the cost of genetic sequencing and expanding the availability of the revolutionary technology by launching its new Ion Torrent Personal Genome Machine. ... acquired the machine in August when it purchased the device’s creator, Ion Torrent (Guilford, CT, no SBIR), in a $725 million deal. .....  among several, including Illumina of San Diego, that are racing to introduce new ways of sequencing genes that expand the use of the technology  [, Dec 17, 10]

Life Technologies was 402d on the new Deloitte Fast 500 list of fastest-growing technology companies  [Mike Freeman, signonsandiego, Oct 21, 10]

Life Technologies (San Diego, CA) said it will acquire Ion Torrent, (Guilford, CT; no SBIR, founded 2007) that has developed a new way of sequencing genes, in a deal worth as much as $725 million.  [Keith Darcé, San Diego Union Tribune, Aug 17, 10]

Life Technologies said it has acquired a 74% ownership stake in Germany-based Geneart through a tender offer to the smaller company’s shareholders. Geneart is one of five small companies around the world  that specialize in synthesizing custom-ordered genes for use in biomedical research. [Luke Timmerman, signonsandiego, Jun 11, 10]

Life Technologies has invested $10 million out of an equity financing that could be worth as much as $50 million for Synthetic Genomics (San Diego, CA; no SBIR), the startup co-founded by genomics pioneer J. Craig Venter, according to a regulatory filing. Synthetic Genomics,  uses synthetic biology techniques to create or modify cells or genomes of different organisms. The startup is seeking to apply its technology to clean energy, clean water, food production, and vaccines  [Luke Timmerman,, Jun 8]

Around 100 employees at the Carlsbad headquarters of Life Technologies gathered in their main conference room to hear a mother from New Mexico thank them for creating the DNA kits police used to find the killer of her 22-year-old daughter.... rising demand for DNA evidence has helped bolster the company’s genetic-systems division, which produces DNA kits as well as tests for food safety and pharmaceutical quality.  In the past year, the division generated $906.5 million in sales [Dean Calbreath,, May 28, 10]

Life Technologies (Carlsbad, CA) announced a partnership with the Integrated Biobank of Luxembourg under which the Carlsbad company will sequence the biobank’s collection of biospecimen samples. The bank collects and stores a wide range of samples, with an initial focus on cancer, and can combine genetic and molecular information with medical records and environmental factors related to the donor.  [Thomas Kupper, San Diego Union Tribune, Mar 24, 10]

Life Technologies reported higher-than-expected profit for the fourth quarter yesterday, as sales of the Carlsbad company’s products for scientific research continued to grow.... born of the 2008 merger of Carlsbad’s Invitrogen and instrument maker Applied Biosystems  [Thomas Kupper, San Diego Union Tribune, Jan 29, 10]

Life Technologies said it acquired the Bay Area company AcroMetrix (Benicia, CA; one SBIR) for an undisclosed amount. AcroMetrix makes diagnostic quality control products for laboratories, blood screening centers and diagnostic manufacturers.  [Thomas Kupper, San Diego Union Tribune, Jan 13, 10]

Life Technologies (Carlsbad, CA; formed last year by the merger of Invitrogen and Applied Biosystems)  reported second-quarter results yesterday that easily beat Wall Street forecasts, as sales of the company's instruments and other tools for biotechnology research continued to grow.  ....  got a boost from $15 million in sales related to work on the H1N1 (swine) flu. [Thomas Kupper, San Diego Union Tribune, Jul 29, 09] /p>

Two San Diego-area biotechnology companies yesterday were among six commercial operations to receive grants from the state's taxpayer-funded stem cell institute.  The funding included 23 grants ranging from $700,000 to $1.1 million. ...  Life Technologies, formerly known as Invitrogen, which makes tools for drug discovery, and Novocell(San Diego, CA; no SBIR) $827,000, which is using human embryonic stem cells to develop a therapy for diabetes. [Terri Somers, San Diego Union Tribune, Dec 11]

VisiGen Biotechnologies (Houston, TX; $200K SBIR), a company created by University of Houston researchers, was acquired for $20 million by Invitrogen Corp., which recently merged with Applied Biosystems to form Life Technologies. The company is working on a new process to sequence individual human genomes.  [Houston Chronicle, Dec 11, 08]

Ligand Pharmaceuticals (San Diego, CA)

Ligand Pharma down 16% [Jan 16, 19]

An experimental drug for type 2 diabetes significantly and safely lowered blood glucose, drug developer Ligand Pharmaceuticals (San Diego. CA; one SBIR in 1990s) said. The results open a path for further testing, and if all goes well, to approval of the drug. Ligand is looking for a [commercializing] partner [Bradley Fikes, San Diego Union Tribune, Sep 6, 17]

Ligand Pharma down 12% [Sep 27, 16]

Sermonix Pharmaceuticals (Columbus, OH; no SBIR, founded 2014)       startup seeking to revive the stalled FDA approval process for an osteoporosis drug has raised $1.6 million toward a potential $2.5 million round, according to [SEC] filing. [Carrie Ghose, Columbus Business First, Jul 12, 16] ...  with targeted focus towards bringing new and emerging late-stage women’s health products through clinical development, regulatory approval, and commercialization. ...  has as its lead product lasofoxifene, with exclusive global licensing rights obtained from Ligand Pharmaceuticals  (La Jolla, CA; one SBIR in 1994, market cap $2.7B).  [Sermonix website]

Ligand Pharmaceuticals said its partner Spectrum Pharmaceuticals (no SBIR) received FDA approval of melphalan (Evomela) in multiple myeloma. With the approval, Ligand earned a $6 million milestone payment from Spectrum and stands to also receive sales royalties.  [Alex Lash,, Mar 18, 16]

Biotech company Ligand Pharmaceuticals (San Diego, CA; one SBIR) acquired genetic engineering company Open Monoclonal Technology (Palo Alto, CA; no SBIR) for $178 million.  ...  OMT brings with it license agreements with biotechnology partners such as Amgen, Celgene, Genmab, Janssen, Merck KGaA, Pfizer, Seattle Genetics, Five Prime and Symphogen....   to genetically engineer animals to develop antibody therapeutics. OMT’s antibody drug discovery technology is believed to make it the only company in the world offering three transgenic animal platforms for license.  [Gina Hall, Silicon Valley Business Journal, Dec 18, 15]

Ligand Pharma down 10% [Aug 7, 15]

Viking Therapeutics (La Jolla, CA; no SBIR) marked its debut as a newly public company; priced its {IPO for $24M]. ... The biotech is developing metabolic and endocrine disorder therapies.  ...  Viking is a partner of Ligand Pharmaceuticals  (San Diego, CA; one SBIR) which has invested $9 million in the IPO. ... Ligand has licensed small-molecule compounds to Viking, which is developing five drugs based on these compounds. Its lead drug candidate, VK5211, is entering Phase 2 trials for patients who have had non-elective hip fracture surgery.   [Bradley Fikes,, Apr 29, 15]

Viking Therapeutics (San Diego, CA; no SBIR) spun out through a licensing deal with Ligand Pharmaceuticals (one SBIR), was poised to go public [for $50-60M] ... licensed five drugs from Ligand, targeting diabetes and other metabolic and endocrine disorders    [Alex Lash,, Sep 18, 14]

Ligand Pharmaceuticals (San Diego, CA; one SBIR) up 14% [Feb 11, 14]

Ligand Pharmaceuticals (LaJolla, CA; one SBIR 20 years ago) that its drug Promacta has received "breakthrough" designation by U.S. regulators for a new use in patients with a rare form of anemia. Ligand and its partner GlaxoSmithKline already market the pill to treat chronic hepatitis C and a rare condition called chronic immune thrombocytopenic purpura, in which the body attacks its own platelets.  [AP, Feb 3, 14]

Ligand Pharma up 10%  [Apr 19, 13]

Ligand Pharma  up 14% [Nov 19, 12]

Ligand Pharma up 13% [Jun 21, 12]

Ligand Pharma up 13% [Jun 20, 12]

Ligand Pharma   up 10% [Mar 19, 12]

Ligand Pharmaceuticals (La Jolla, CA; one SBIR) has licensed DARA to Retrophin, which will use the compounds to explore treatments for kidney disease. The agreement will net Ligand an upfront payment of $1 million and could lead to more than $75 million in milestone payments, and 9-percent in royalties, the company says.  [Gary Robbins,, Mar 1, 12]

Ligand Pharma up 13% [Nov 11, 11]

Ligand Pharma  down 23% [Nov 8, 11]

Ligand Pharmaup 14% [Sep 7, 11]

Ligand Pharma up 13% [Feb 16, 11]

Ligand Pharmaceuticals (San Diego, CA; one SBIR in 1994) said that its partner, GlaxoSmithKline, has won clearance to start marketing a new drug for a platelet deficiency in Europe. The treatment, eltrombopag (Revolade), is for patients for idiopathic thrombocytopenia purpura (ITP), a rare bleeding disorder in which the immune system attacks platelet cells that help people form clots. The drug, discovered by Ligand and developed by GSK, was approved in the U.S. in November 2008, and is marketed under the brand name Promact   [, Mar 12, 10]

Ligand Pharmaceuticals said it received a $1 million milestone payment from Merck subsidiary N.V. Organon under a collaboration that ended Dec. 31. [Thomas Kupper, San Diego Union Tribune, Jan 8, 10]

Neurogen (Branford, CT; two SBIRs) will be sold to Ligand Pharmaceuticals for $11M plus a possible $7M to shareholders later. [Mass High Tech, Aug 24, 09]

Ligand Pharmaceuticals (one small SBIR 1994) is another early-stage drug company with a new drug application pending before the FDA. Ligand technology was used in the development of Fablyn, which can treat osteoporosis, and was developed in collaboration with Pfizer. An FDA panel gave the chances for approval a boost in early September 2008, when it said the drug might prove more beneficial to patients given the risks. Ligand had only $9.7 million in revenues the first six months of 2008. The company is not solely dependent on Fablyn, as it has collaborations with other large drug companies including Wyeth and GlaxoSmithKline. A decision is expected sometime before the end of 2008 and if approved Ligand will receive royalty payments and cash. [Eric Fox, Investopedia, Oct 16]

Ligand Pharmaceuticals (San Diego, CA; one SBIR) fell 36% after the FDA said Promacta, a treatment Ligand is developing for patients affected by chronic thrombocytopenic purpura, or ITP, in partnership with < GlaxoSmithKline, was unable to significantly reduce bleeding when compared with a placebo. [Wall St Journal, May 29]


LightPointe,which started life on an MDA SBIR in 1999, got another $17M VC money. That was after one Phase 2 SBIR and $45M earlier rounds. The optical telecom bubble did not collapse for everyone; the company claims 2,000-plus installations in more than 60 countries. That's the kind of ROI that SBIR should seek in all the agencies. Thanks to MDA's tech commercialization page for the info. Those WO guys do a great job of tracking the good things that happen outside MDA from MDA's tech spending. They don't spend their energy in "success stories" with minor league, economically empty success. 

Light Sciences Oncology

Light Sciences Oncology   (Bellevue, WA; no SBIR), developing a novel drug/device combination treatment for cancer, stumbled in its pivotal clinical trial and is now preparing to make major cuts including layoffs. The company, founded in 1995, received more than $50 million alone from former Microsoft treasurer Craig Watjen, and well over $130 million its history from investors  [Luke Timmerman,, Oct 6, 11] things are looking better: the research-oriented startups seem poised to survive the downturn, and long-awaited clinical results could propel larger companies like Dendreon to stardom. ...  despite the financial crisis, the Accelerator, a local incubator based in Seattle's Eastlake neighborhood, created three firms last year - Recodagen, GPC-Rx and Mirina (none had SBIR) ... "Seattle is really a town of development-stage biotechs," Miller said. ... Light Sciences Oncology (no SBIR), a firm that canceled its initial public offering last February, managed to raise $10 million from venture capitalists in July. Private investors provided Redmond-based Healionics (no SBIR) — which manufactures material for implants — with a $2.6 million boost in December.  In a deal that could yield big results, Bothell-based Acucela  (no SBIR), which is developing therapies to treat blindness, signed a partnership deal in September with Japanese firm Otsuka Pharmaceutical that could potentially bring it $258 million.   [Angel Gonzalez, Seattle Times, Jan 25, 09]

LightWorks Optics (Tustin, CA)

II-VI has bought a California precision-optical system manufacturer for $31 million.  The acquisition of the outstanding shares of privately held LightWorks Optics (Tustin, CA;  $1.5M SBIR), includes the possibility of $4 million more depending on LightWorks' future financial performance. LightWorks makes visible, infrared and laser-based systems for defense, aerospace and industrial markets. [Paul Gough, Pittsburgh Business Journal, Dec 21, 12]

Ligon Discovery (Cambridge, MA)

startup Ligon Discovery (Cambridge, MA; no SBIR) reports it has landed $1 million in funding ...  using proprietary small molecule microarray technology to identify drug candidates.  [Mass High Tech, Nov 19, 09]

Lillac Solutions (Middletown, RI)

Department of Energy has selected 20 companies to receive Bipartisan Infrastructure Law funds totaling $2.8 billion to grow the battery supply chain for the power grid, as well as electric vehicles and associated components. Three companies had SBIR: 6K (North Andover, MA; $3.5M SBIR); Lillac Solutions (Middletown, RI; one SBIR); Sila Nanotechnologies (Atlanta, GA; $3.6M SBIR) [govconwire, Oct 20, 2022]

Lilliputian Systems (Wilmington, MA)

Portable power supplier Lilliputian Systems (Wilmington, MA; no SBIR)  has landed a round of funding, according to [SEC documents] ... Founded in 2001 by former MIT’s Microsystems Technology Laboratory researchers, Lilliputian says it has developed a portable charging system that will revolutionize the way consumers use electronics, by providing on-the-go power.  [Patricia Resende, Mass High Tech, Jul 3, 12]

Lilliputian Systems (Wilmington, MA; no SBIR), a secretive company that has been developing tiny fuel cells aimed at powering small consumer devices, has secured $28 million in new funding from new and existing investors. ... has raised approximately $90 million since its inception in 2001. ... plan eventually to offer a suite of products revolving around the butane-powered fuel cell technology  [Mass High Tech, Apr 2, 09]

Lily Robotics (San Francisco, CA)

Lily Robotics (San Francisco, CA; no SBIR) said they raised $14 million in new funding to help them get their startup off the ground.  "To accommodate flight software optimization, hardware improvements, and additional rounds of testing, we will be delaying pre-order shipments until Summer 2016," the leaders of one of the hottest young companies in the Bay Area wrote. ... started taking pre-orders when it came out of stealth in May with its drone-powered camera that can fly for up to 20 minutes between charges.   [Cromwell Schubarth, Silicon Valley Business Journal, Dec 18, 15]

Linares Management Associates (Medfield, MA)

The face staring through a porthole on page 100 is Bob Linares, one of many CVD diamond dreamers in the late 80s and early 90s. Josh Davis Wired (Sep 2003)  tells the story of two competing companies developing mass-produced diamonds. The DOD database shows eight Phase 1 and two Phase 2 SBIRs in the 90s - all from SDIO/BMDO (the original names of MDA) for Linares Management. The Wired story tells how Linares made a bundle selling a gallium arsenide company and building a "secret diamond research lab" to probe for the "sweet spot" of making single crystal diamond. In that quest he was one of many that SDIO/BMDO funded in what turned out, at least so far, to be a too elegant and expensive process. Crystallume and SI Diamond were two companies that went public and then broke with diamond. Linares present company, Apollo Diamond, run by his son, is competing with Gemesis. Diamond would be in great demand as a heat conductor as electronic chips shrink into pure heaters. Cheap diamond would, however, ruin the diamond jewelry industry that for centuries relied on scarcity. If the commerce works out, BMDO can claim another nurturing of a really innovative idea that did what SBIR is supposed to do - get real innovators going. 

Single Crystal Diamond. Photonics Spectra (Mar 98) reports a proprietary CVD process for single crystal diamond by Linares Management Associates (Medfield, MA). Nice. Who will make money from it? Two companies had a lot of SBIR, went public and then bust trying - Crystallume and SI Diamond. Linares has had SBIR from BMDO for both diamond and GaN. If you want to try, government is a sucker for nice science with the dreamy promise of a huge future market. Emphasize your science with lots of references to the literature, impressive credentials of investigators, lots of chemistry-speak, and an estimate of at least $2B market (no, you don't have to prove it).

Lionano (Ithaca,NY}

startup Lionano (Woburn, MA; $600K SBIR, founded 2013) raised $22M to improve the performance of batteries [with new cathode] commonly found in mobile phones and electric cars, [Srividya Kalyanaraman, BostonInno, Oct 2, 18] no prior funding []

New York State Energy Research and Development Authority awarded $250K to Lionano (Ithaca, NY;  no SBIR)  a startup company seeking to commercialize a high-performance nano-engineered anode material for the Lithium-ion battery sector. The development of this nano- anode material at Cornell University, revealed characteristics of improved capacity, extended battery life and reduced recharge time, when compared to existing available anodes. [NYSERDA, Oct 27, 14]

Lingotek (Draper, UT)

In-Q-Tel, CIA's venture-capital investment arm, has put more money into Lingotek (Draper, UT; no SBIR)  which develops Web-based collaborative translation software for corporations and government intelligence services. Still secret: how much In-Q-Tel invested in 20-employee Lingotek.  [Paul Beebe, Salt Lake Tribune, Jul 29]

Linnaeus Therapeutics (Haddonfield, NJ)

Linnaeus Therapeutics (Haddonfield, NJ; no SBIR) raised $2.3M [Philadelphia Business Journal, Feb 11, 19] a development stage biotech company engaged in the identification and development of small molecule agents that modulate cellular differentiation for the treatment of cancer and disorders of pigmentation. [company website]

LinQuest (los Angeles, CA)

LinQuest (Los Angeles, CA; $1M SBIR around 2006) announced that it had received a five-year contract from the Space Force worth $500 million. Under the indefinite delivery, indefinite quantity contract, LinQuest will provide analytical support to the federal agency and the other defense firms it works with [Elijah Chiland, LA Business Journal, Feb 5, 21]

Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]

Lion Biotechnologies (New York, NY)

Lion Biotechnologies (New York, NY; no SBIR, IPO 2015, market cap $290M) up 43% [Jun 3, 16] after the biotechnology company said it raised $100 million in a private placement of stock  [Wall Street Journal, Jun 3, 16]    is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute and is currently in use at leading cancer centers in the US. ....  Our lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of Stage 4 metastatic melanoma.     [company website]     announced that it has entered into a collaboration to conduct clinical and preclinical research in immuno-oncology with MedImmune, the global biologics research and development arm of AstraZeneca.   [company press release, Dec 2015]

Lipocine (Salt Lake City,UT)

Lipocine Inc. (Salt Lake City,UT; no SBIR, 114 employees) down 46% [Jan 11, 18] , a specialty pharmaceutical company,  announced that [an FDA committee] voted against the benefit/risk profile of TLANDO, the Company's oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism  [company press release, Jan 10, 18]

LipoScience (Raleigh, NC)

LipoScience (Raleigh, NC; no SBIR) announced it is laying off 22 people as a result of having its contract with Health Diagnostics Laboratory terminated.  .... has struggled since going public in January 2013 ....  makes a tool that measures the risk of heart disease by measuring lipoprotein particles in the bloodstream, as opposed to taking cholesterol readings. Lipoproteins cause plaque buildup in arteries.  [David Bracken, Raleigh News & Observer, May 5, 14]

LipoScience (Raleigh,NC; no SBIR) up 16% on their first day of trading, but the [IPO] of the cholesterol diagnostic test maker priced well below expectations [of $9 each]. Earlier this month LipoScience said it expected its IPO to price at $13 to $15 per share. [AP, Jan 25, 13]

Medical diagnostics company LipoScience (Raleigh, NC; no SBIR,204 employees) is reviving its plans for an initial public offering of common stock but scaling back the amount of money it hopes to raise  [David Ranii, Raleigh News & Observer, Jan 18, 13] This time, $65-75M

LipoScience (Raleigh, NC; no SBIR) company that sells a blood test to measure patients' risk for heart disease is reviving plans for an initial public offering of stock...  wants to raise $86.25 million, the company disclosed in a Securities and Exchange Commission filing.The company first filed IPO plans in 2002, but scrapped them after failing to attract enough interest on Wall Street. This time, LipoScience officials are hoping that having a few more years of steady revenue growth will help sell their story to investors. They're also counting on renewed interest in IPOs. [Alan Wolf, Raleigh News & Observer, Jun 24, 11]

Liquid Biotech (Philadelphia, PA)

Liquid Biotech (Philadelphia, PA; no SBIR) spun out of the University of Pennsylvania’s Penn Center for Innovation, raised $2 million in a private stock sale [to] Oncolys Biopharma (Japan) to further develop and refine its proprietary technology designed to identify, then isolate, individual circulating tumor cells [CTCs] from liquid biopsies.  [John George, Philadelphia Business Journal, Dec 3, 15]

Liquidia Technologies (Durham, NC)

Liquidia up 20% [Sep 2, 2022]

Liquidia up 28% [Aug 12, 22] reported financial results

Liquidia up 45% [Jul 19, 20] announced that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 10,716,793 (‘793 patent) owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso® (treprostinil inhalation solution). In its ruling, the PTAB found that, based on the preponderance of the evidence, all the claims of the ’793 patent have been shown to be unpatentable. [company press release, Jul 19, 22]

Liquidia (Morrisville, NC; one SBIR) down 19% [May 23, 22]

Liquidia Tech up 19% [Nov 6, 20]

Liquidia Tech down 28% [Nov 2, 20]

Liquidia Tech down 30% [Oct 13, 20]

Liqudia Tech down 16% [Jun 5, 20]

Liquidia Tech up 18% [May 20, 20]

Liquidia Tech up 25% [May 5,20]

Liquidia Tech down 15% [Apr 20, 20]

Liquidia Tech up 17% [Apr 8, 20]

Liquidia Tech up 15% [Mar 4, 20]

Liquidia Tech up 23% [Jan 13,20]

Liquidia Tech up 43% [Dec 26, 19]

Liquidia Tech down 19% [Sep 3, 19]

Liquidia Tech down 19% [Mar 21, 19]

Turning Point Therapeutics (San Diego CA; no SBIR, founded 2013), a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, announced it has filed [for IPO] [company press release, Mar 21, 19] total funding $144M [] plans to raise $100M  [Bradley Fikes, San Diego Union Tribune, Mar 21, 19]

Liquida Tech up 22% [Feb 22, 19]

Liquidia Tech up 16% [Feb 14, 19]

Liquidia Tech up 21% [Dec 26, 18]

Liquidia Tech up 15% [Nov 14, 18]

Innovate Biodown 14% [Nov 14, 18]

Liquidia Tech up 15% [Nov 2, 18]

Liquidia Tech up 20% [Oct 9, 18]

Liquidia Tech up 13% [Oct 3, 18]

Liquidia Tech up 13% [Oct 2, 18]

Liquidia Tech up 15% [Sep 27, 18]

Liquidia Tech up 11% [Sep 26, 18]

Liquidia Tech up 10% [Sep 24, 18]

Liquidia Tech up 11% [Sep 10, 18]

Liquidia Tech up 13% [Sep 4, 18]

Liquidia Tech up 10% [Aug 20, 18]

Liquida Tech up 11% [Aug 14, 18]

Liquida Tech up 10% [Aug 9, 18]

Gevo down 18% [Aug 9, 18]

drug maker Liquidia Technologies (Morrisville, NC; one SBIR) raised $50 million in an [IPO] [Raleigh News & Observer, Jul 26, 18]

Liquidia Technologies (Morrisville, NC; one SBIR, founded 2004 ), a drug manufacturer developing dry powder therapies for pulmonary arterial hypertension, filed for $58M IPO [, Jun 28, 18] total funding $99M []

Less than two years after spinning out a company to focus on oral health treatments, Liquidia Technologies (Durham, NC;  SBIR) has folded Lq3 back into the parent company and will re-asses the viability of developing those assets.  [Jason deBruyn, Triangle Business Journal, Mar 3, 16]

drug developer Envisia Therapeutics (Research Triangle Park, NC; no SBIR, 23 employees) reported positive results for a possible next-generation glaucoma treatment. ...  ENV515 showed comparable results to Travatan Z, a once-daily eye drop made by Alcon (no SBIR). Envisia reports these as positive because if its product can show the same results, but must be applied only once every six months, it could become a more desirable treatment.  Alcon was founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Alcon is now the second-largest division of Novartis with sales topping $10 billion.  ...  Envisia Therapeutics spun out of Liquidia Technologies (one SBIR) in late 2013. ... raised $25 million from Liquidia investors   [Jason deBruyn, Triangle Business Journal, Oct 6, 15]

GlaxoSmithKline exercised an option that gives the company the exclusive rights to nearly all inhaled uses of a particle manipulating technology developed by Liquidia Technologies  (Research Triangle Park, NC; one SBIR, founded 2004 as spun out of UNC-Chapel Hill, 50 employees).  ... More recently, [Liquida] spun out two separate companies: Envisia Therapeutics, to develop new drugs targeted at glaucoma and cataracts, and Lq3 Pharmaceuticals, to focus on advancing therapies for oral health conditions. Envisia has 23 employees and Lq3 has seven   [Jason deBruyn, Triangle Business Journal, Sep 30, 15]

Liquidia Technologies (Research Triangle Park, NC; no SBIR, founded 2004) drug-development company, has spun out its second new company in the past year. The latest spinoff, Lq3 Pharmaceuticals, will focus on developing therapies for oral health conditions using Liquidia’s technology. The company has raised $10 in venture capital ...  Liquidia's proprietary Particle Replication In Non-Wetting Templates, or PRINT, technology to develop therapies. PRINT enables precise engineering of the size and shape of microscopic particles, which can then be combined with drugs for delivery to targeted tissues within the body. ... Liquidia’s other recent spin off, Envisia Therapeutics, is also using the PRINT technology to focus on developing ophthalmology products. Envisia was launched in November and has raised $25 million from venture capital firms that have also invested in Liquidia.   [David Bracken, Raleigh News & Observer, Sep 10, 14]

The management team behind Liquidia Technologies (Research Triangle Park, NC; one SBIR) drug-development company, has created a new company to focus exclusively on using Liquidia’s technology to develop ophthalmology products. The new company, Envisia Therapeutics, announced it has raised $25 million from a group of venture capital firms [David Bracken, Raleigh News & Observer, Nov 12, 13]

Liquidia Technologies, (Research Triangle Park, NC; one SBIR) drug-development company, has signed a transformational licensing deal with pharmaceutical giant GlaxoSmithKline that could be worth up to several hundred million dollars. .... licensed the rights to use Liquidia’s proprietary nanotechnology in conjunction with its own compounds to develop vaccines and inhaled drugs for respiratory diseases [Raleigh News & Observer, Jun 20, 12]

the Bill & Melinda Gates Foundation invested $10 million to acquire a stake in Liquidia Technologies  (RTP, NC; one SBIR), a biotechnology company working on new ways to deliver vaccines. ...  an investment that can be counted toward federal requirements that it pay out 5 percent of its assets each year. ...  to connect with profit-making ventures that advance their missions. [Stephanie Strom, New York Times, Nov 24,11]

Liquidia Technologies (Durham, NC; one SBIR) developing vaccines using nanotechnology developed by renowned chemist Joseph DeSimone will announce today that it has attracted a $10 million investment from the Bill & Melinda Gates Foundation. ....  is testing a flu vaccine that uses tiny, engineered particles to deliver the medicine in patients. The company hopes to develop vaccines for other diseases, including malaria. ...  The Gates foundation, started by the Microsoft co-founder and his wife, a Duke University alumna, has given nearly $24 billion in grants since 1994. [Alan Wolf, Raleigh News & Observer, Mar 4, 11]

Nannotechnology company Liquidia Technologies (Morrisville, NC; one SBIR) has tapped the purse strings and the expertise of a North Carolina clinical research organization to close its $25 million third round of financing, the company announced [Frank Vinluan, Triangle Business Journal, Apr 20, 10]

Liquidia Technologies (Durham, NC; one SBIR) raised $20 million in venture capital financing... to continue clinical testing of its experimental flu vaccine based on nanotechnology. ... employs 46, previously raised more than $30 million in venture financing ... In addition, Liquidia and its founder, N.C. State and UNC-Chapel Hill chemist Joseph DeSimone, won a $3 million federal grant [NIST-TIP] in December. [Alan Wolf, Raleigh News & Observer, Jan 19, 10]

Liquidia Technologies  (RTP, NC; one SBIR) will receive about $3million from the U.S. Commerce Department to further develop a process of making vaccines and other products from tiny [nano] particles. The grant follows more than $30 million in venture capital financing that Liquidia has attracted. ... co-founded in 2004 by Joseph DeSimone, a chemist at UNC-Chapel Hill and N.C. State University.  [Alan Wolf, Raleigh News & Observer, Dec 18, 09]

Liquidia Technologies (Durham, NC; one SBIR) scored $7 million in venture capital to continue developing chemotherapy and other treatments that won't attack healthy tissue. [John Murowski, Raleigh News & Observer, Aug 1, 09]

Liquidia  (Durham, NC; no SBIR), co-founded in 2004 by Triangle scientist Joseph DeSimone, will work with Abbott on a new type of cancer treatment known as short interfering RNA, or siRNA.  [Sabine Vollmer, Raleigh News & Observer, Jan 8]

Optimism. Neal Fowler quit his job as head of a multibillion-dollar Johnson & Johnson subsidiary based on the big promise of a young Durham nanotechnology company. For the past 20 years, Fowler worked for large pharmaceutical companies ... he took a pay cut to join Liquidia Technologies (no SBIR), which employs 35 ... The object of everybody's desire is a clear, nonstick material, called Fluorocur. Developed by UNC-CH chemistry professors Joe DeSimone and Ed Samulski and three of their students, Fluorocur is liquid at room temperature and hardens when exposed to ultraviolet light. What makes Liquidia's technology attractive is its scale. Fluorocur creeps into crevices so small they can only be seen with the most powerful microscopes.  [Sabine Vollmer, Raleigh News&Observer, Mar 14] Since it won't be going back and back to SBIR for endless externally funded R&D, it must find a profitable app, one is enough when capital and patience are limited, on which to base a growing enterprise.

Liquid Light (Monmouth, NJ)

Make lemonade. A startup called Liquid Light (Monmouth, NJ; no SBIR) has developed an electrochemical process to use waste carbon dioxide as a starting ingredient for chemicals. The company says its method is significantly cheaper than conventional methods for converting CO2 into chemicals.   [Martin LaMonica,, Mar 11, 14]  If you're thinking of turning CO2 into fuel, study chemical thermodynamics to see how much energy it takes to break the bonds after the forming of the bonds released huge energy of combustion.

Liquid Metal Battery (Cambridge, MA)

Liquid Metal Battery (no SBIR), that is working on what it calls “game-changing” technology to allow electricity generators to store power for when its needed, has changed its name to reflect its Cambridge roots  --  Ambri, [Mass High Tech, Aug 27, 12]

Liquid Metal Battery (Cambridge, MA; no SBIR) spun out of MIT in 2010 and funded by Bill Gates, has secured a $15 million Series B round of funding, the company announced....  Gates became interested in the company after he was pointed to Sadoway’s online course, according to Giudice. “He was engaged and reached out to Don (Sadoway) to have conversation and visited with him at MIT. In the course of the conversation Bill Gates told Don he would be happy to invest.”  Total also joined Bill Gates for the A round in 2010, according to Giudice.  ....  currently has 20 employees   [Patricia Resende, Mass High Tech, May 25, 12]

Liquid Metal Battery (Cambridge, MA; no SBIR) said today that it has secured the rights to key patent technology from MIT and that it has received financing from a French energy company and from Bill Gates of Microsoft fame.... specializes in developing new forms of electric storage batteries that work in large, grid-scale applications ... Patents for the technology to develop such batteries were licensed from the Massachusetts Institute of Technology. The core technology was invented by Donald Sadoway and David Bradwell, two of Liquid Metal Battery’s cofounders. [Chris Reidy, Boston Globe, Jul 7, 11]

LiquidPiston  (Bloomfield, CT)

The developer of a line of advanced rotary diesel and multi-fuel internal combustion engines is expanding into the renewable energy game. LiquidPiston's X-Engine, which we've covered previously and is helping the Air Force develop vertical takeoff and landing concepts, can now run on hydrogen gas. [Greg Nichols for Robotics, ZDNet, June 25, 2021]

the Air Force wants a shortcut to an unmanned electric vertical takeoff and landing (eVTOL) concept for urban transport. The secret sauce? Pairing emerging electric vehicle technology with an innovative rotary internal combustion engine to keep batteries charged and extend flight times. ... AF awarded an STTR contract to LiquidPiston (Bloomdfield, CT; $400K prior SBIR), a developer of an advanced rotary internal combustion engine called the X-Engine. Paired with a generator, the X-Engine can be configured to charge the eVTOL vehicle's battery and keep it charged during flight, significantly extending the range of an electric propulsion system. Alternatively, it can be configured in parallel with an electric drive, using the engine directly to produce thrust or lift. [Greg Nichols for Robotics,, Mar 15, 21]

LiquidPiston (Bloomfield, CT; one SBIR, founded 2003) has an iPhone-sized engine it says could lead to quieter power generators, lighter weed-whackers, and more efficient unmanned flying drones.  At 4 pounds, the three-horsepower X Mini gasoline engine, which the Bloomfield company planned to unveil Wednesday morning at an industry conference in Italy, boasts just two moving parts — a shaft and a rotor — and weighs 30 percent less than engines of comparable strength. ...has measured as much as a 30 percent improvement in fuel use, and though the company knows the engine is quieter than comparable models, [CEO] Shkolnik has no numbers on noise reductions.  [Brian Dowling, Hartford Courant, Nov 19, 14]

LiquidPiston (Bloomfield, CT; one SBIR) working on a fuel-efficient rotary internal combustion engine, has boosted its most recent fundraise from $5 million to $6.5 million.  .... on thermo-dynamics principles that officials say can improve fuel efficiency as much as 250 percent.   [Mass High Tech, Dec 17, 11]

LiquidPiston (Bloomfield, CT; one SBIR) has landed $5 million in a Series B round of financing, bringing the total equity financing in the Bloomfield company to $6.25 million.  [Rodney Brown, Mass High Tech, Jan 26, 11]

LiquidPiston (Bloomfield, CT; a little SBIR) which develops specialized internal combustion engines, received $700,000 in second-round financing.  [Hartford Courant, Oct 18,08] 

LiquidPiston (West Hartford, CT; one SBIR), a recent runner-up in MIT's $100K business plan competition, has secured its first round of venture funding, adding $1.25M.

Liquid Robotics (Palo Alto, CA)

Boeing and Liquid Robotics (Palo Alto, CA; one SBIR) announced a partnership to make water-borne robots that can handle a variety of surveillance jobs, ranging from hunts for submarines to the detection of drug traffickers. Liquid Robotics is the manufacturer of the Wave Glider SV3, a $300,000 self-powered, seafaring data center that offers customers -- until now, mostly researchers and marine industry companies -- tools for investigating the open seas for months at a time. ....   The new deal is aimed at augmenting Boeing's existing maritime surveillance systems -- airplanes like the P-8 submarine hunter and the Maritime Surveillance Aircraft -- with autonomous devices that can monitor the seas around the clock.  .....  The Boeing partnership is the company's second major deal. In 2012, Liquid Robotics teamed up with Schlumberger Oil and Gas, the world's-largest oil services company, to form Liquid Robotics Oil and Gas. Customers include Conoco Phillips, Chevron, BP and others.  [Daniel Terdiman, CNet News, Sep 24, 14]

An army of robots gliding across the world's oceans is ready for business after its leader [Liquid Robotics  (Palo Alto, CA; one SBIR)] raised $45 million in funding to secure deals with governments, oil and gas companies and scientists.  ..  ..makes unmanned robotic water gliders that collect all sorts of data underwater. The company has so far produced about 200 robots, many of which are now deployed around the world in pilot programs.  [Venture Wire staff, Wall Street Journal, Mar 26, 13]

Liquid X Printed Metals (Pittsburgh, PA)

Liquid X Printed Metals (Pittsburgh, PA;  no SBIR, founded 2010) a Carnegie Mellon University startup company announced the closing of a Series A financing round ...  to continue development of Liquid X's metallic conductive ink technology, which allows the printing of metal traces and films on to a number of applications, including medical devices and consumer electronics components.  [Louis Corsaro, Pittsburgh Business Times, Jul 3, 13]


Connecticut announced that it planned to invest $700,000 to help keep specialized lubricant maker LiQuifix (Stamford, CT; no SBIR) in the state, with the possibility of adding more than 50 jobs over the next three years. ... makes what it calls a non-toxic, environmentally friendly spray lubricant that is used on industrial equipment. Its customers include Ford Motor Co. and U.S. military agencies.  [Mass High Tech, Mar 23, 10] Note: SBIR is a national competition that should not fund any project nor company for the purpose of keeping it anywhere except within the USA.

Lithium Technology (Plymouth Meeting, PA)

Lithium-ion battery maker Lithium Technology (Plymouth Meeting, PA; three SBIRs) is discontinuing flat cell production at the company's headquarters in . "This step is necessary to allow the company to focus all its efforts on cylindrical cells that are its core competency," Lithium said. "The company will expand its present manufacturing capability in Germany."  [Philadelphia Business Journal, Jun 27, 08]

LiveData (Cambridge, MA)

LiveData (Cambridge, MA; $800K SBIR)  made a research and development partnership with Idaho National Laboratory . to test the security of LiveData's ICCP Protocol Server for the electric power industry. [Mass High Tech, Apr 4]

LiveLeaf Bioscience (San Carlos, CA)

LiveLeaf Bioscience (San Carlos, CA; no SBIR) working to use the restorative properties within plants to improve the intestinal health of pigs ...  a microcosm of what goes on in Silicon Valley every day.  .... [Alex] Huang and his co-founder, Gin Wu, stumbled into the work while trying to solve a different problem.---looking to the plant world for ways to reduce the spread of food- and water-borne illness in developing countries.  ....   The potential for the Silicon Valley model to solve problems is becoming clearer by the day.....    The idea -- open to almost any company -- is to build a cauldron of creativity and remain open to new ideas that might seem to come out of the blue. The ability to think big and beyond is huge.  [Mike Cassidy, San Jose Mercury News, Mar 8, 13]  Finding connections and spin-offs works better when a smart guy has daily contact with a lively community of smart guys, especially smart guys with capital to invest in new ideas. 

Living Carbon (San Francisco, CA)

Living Carbon (San Francisco, CA; $500K SBIR) published research showing it has developed a way to make the photosynthesis process better so leaves and their woody stalks can catch up with the pace of human-created emissions. [Sara Bloomberg, Bay Area Inno, February 24, 2022]

LKC Technologies (Gaithersburg, MD)

LKC Technologies (Gaithersburg, MD; no SBIR, founded 2014), biotech raising $635K of a maximum $1.2M round of equity according to SEC filings. ... makes devices for visual electrophysiology testing – measuring retina function to diagnose eye diseases and disorders. ... brings total funding to $3.8M. [Kieran McQuilkin, DCInno, Mar 11, 19]

Locana (San Diego, CA)

(San Diego, CA; no SBIR), a biotech working on gene therapies that target RNA rather than DNA, raised $55 million to expand its platform and pipeline as well as to build out its leadership team. The company is taking aim at diseases such as Huntington’s and amyotrophic lateral sclerosis (ALS) that are caused by problems in RNA that stop cells from producing essential proteins. [Amirah Al Idrus, Fierce Biotech, May 23, 19]

Locus Biosciences (Research Triangle Park, NC)

Locus Biosciences (Research Triangle Park, NC; no SBIR)  developing precision antibacterial therapies, announced it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage™") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. .. Locus will receive $20 million in initial payments, and is eligible to receive up to a total of $798 million in potential future development and commercial milestone payments, and royalties on any product sales. [company press release, Jan 3, 19]

Locus Biosciences (Morrisville, NC; no SBIR) a developer of precision antibacterial therapies, has signed an exclusive collaboration and license agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The deal could be worth up to $818 million. The companies will team up to develop, manufacture and commercialize a product targeting a key bacterial pathogen for the potential treatment of infections of the respiratory tract and other organ systems. [ncbiotech, Jan 4, 19]

Just over a year after its first-round financing, CRISPR company Locus Biosciences (Research Triangle Park, NC; no SBIR) has signed up Johnson & Johnson as its first big pharma partner and pocketed a $20 million upfront fee. [Phil Taylor, Fierce Biotech, Jan 3, 19] prior funding $26M []

Locus Biosciences (Research Triangle Park, NC; no SBIR, founded 2015), an emerging biotechnology company focused on the discovery and development of a next generation CRISPR-Cas platform for precision antimicrobials, announced today it has closed $19 million in Series A funding. [company press release, Nov 14, 17]

Lodo Therapeutics (NYC, NY)

Rockefeller University spinout Lodo Therapeutics (New York, NY; no SBIR) inked its first deal, a partnership with Genentech to identify and develop novel molecules for a variety of diseases. Xconomy profiled Lodo’s work sequencing the genetic information of microbes in 2016.   [Frank Vinluan,, May 11, 18]

Seattle’s Accelerator Corp. made its long-awaited splash in New York last week with its first Manhattan biotech startup, Petra Pharma (NYC, NY; no SBIR). Now here comes Lodo Therapeutics  (NYC, NY; no SBIR), Accelerator’s second startup, right in Petra’s wake [with $17M].    Lodo didn’t get the big $48 million round that Petra did last week. But the startup, built around the work of Rockefeller University researcher Sean Brady, got a respectable $17 million Series A round and, what’s more, some of that money comes from The Bill & Melinda Gates Foundation—which has over the past few years increasingly sought to back biotech startups that align with its mission of improving global health.  [Ben Fidler,, Jan 10, 16]

Logical Therapeutics (Waltham , MA)

Logical Therapeutics (Waltham, MA; no SBIR) has closed a $16.9 million Series C equity funding .... development of its Bio-activated Technology, a platform designed to alter the chemical composition of non-steroidal anti-inflammatory drugs, taken for osteoarthritis and rheumatoid arthritis, for the sake of lowering the drugs’ gastrointestinal side effects. Its lead compound, LT-NS001, an anti-inflammatory drug candidate, is currently in a Phase 2b/3 clinical study, which is expected to close later this year.  [Mass High Tech, May 28, 10]

Logical Therapeutics (Waltham , MA; no SBIR) expanded its Series B round by $2.7 million from inside investors to increase its manufacturing operations and add a new product.  In 2007, the developer of anti-inflammatory therapies raised about $30 million for its Series B round.  [Mass High Tech, Dec 8, 08]

LogicBio Therapeutics (Cambridge, MA)

Logic Bio down 32% [Oct 1, 20] announced the pricing of its previously announced underwritten public offering

Logic BioThera down 21% [Dec 13, 18]

LogicBio Thera down 17% [Nov 27, 18]

LogicBio Thera up 20% [Nov 23, 18]

LogicBioThera up 18% [Nov 9, 18]

LogicBio Thera up 25% [Oct 29, 18]

LogicBio Thera down 22% [Oct 24, 18]

LogicBio Therapeutics (Cambridge, MA; no SBIR, founded 2014), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, announced the pricing of its [IPO to raise] $70M [company press release, Oct 18, 18] prior funding $49M []

LogicBio Therapeutics (Cambridge, MA; no SBIR), a preclinical gene editing biotech developing therapies for rare diseases, announced terms for its IPO to raise $75 million [, Oct 10, 18]

LogicBio Therapeutics (Cambridge, MA; no SBIR, founded 2016), a gene therapy developer, filed for an [$58M] IPO to fund clinical tests of its experimental treatment for a rare inherited liver disease. [Ben Fidler,, Sep 28, 18] total funding $49M []

LogicBio Therapeutics (Cambridge, MA; no SBIR), a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases, emerged from stealth mode to announce that it has successfully raised approximately $50 million in financing to date. ....  The GeneRide technology harnesses the natural power of homologous recombination to enable precise, site-specific transfer of therapeutic genetic material without the use of promoters or nucleases. This strategy minimizes the risk of carcinogenicity spurred on by strong promoters used in traditional gene-therapy approaches. 2) A library of novel synthetic,non-pathogenic recombinant adeno-associated viral (rAAV) vectors, designed specifically to enable significant clinical performance advantage over established clinical capsids.  [company press release, Jun 27, 17]

Logisys Technical Services (Huntsville, AL)

[small biz] Total Technology (Baltimore, MD; no SBIR), Pioneering Decisive Solutions (California, MD; $4.5M SBIR in management software) and Logisys Technical Services (Huntsville, AL; no SBIR) have landed spots to compete for task orders under a potential five-year, $125 million U.S. Army contract for test and support services. [Nichols Martin, GovConWire, May 22, 18]

Logos Tech (Arlington, VA)

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners:  Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary;  OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems  secondary, twice;  Planar Energy Devices (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.

Lohocla Research (Aurora, CO)

Lohocla Research  (Aurora, CO; $3M SBIR, five employees) research biotech landed a $6.5 million [five year] federal grant to develop a potential medication to combat alcoholism by reducing cravings and alcoholics’ relapse rate. ... The company’s drug, Nezavist, is aimed at brain receptors involved in the process of chronic alcoholics developing a tolerance to alcohol   [Greg Avery, Denver Business Journal, Oct 12, 15]

Lombard Medical (Irvine, CA)

Altura Medical (Menlo Park, CA; no SBIR), a venture-backed stent graft developer, has been acquired by Lombard Medical (Irvine, CA; no SBIR) in a deal valued at up to $50.5 million. ... Altura's low-profile endovascular stent graft technology is aimed at the treatment of abdominal aneurysms.  Lombard plans to launch the device in Europe early next year and to recruit for a U.S. clinical study later in 2016.  [Cromwell Schubarth, Silicon Valley Business Journal, Jul 30, 15]

Longeveron (Miami,FL)

Longeveron (Miami, FL; $5.2M SBIR) down 18% [Apr 4, 22]

Longeveron (Miami, FL; $5.2M SBIR, 12 employees) down 22% [Dec 1, 21]

Longeveron (Miami, FL; $5.2M SBIR, 12 employees) down 21% [Nov 26, 21]

Longeveron (Miami, FL; $5.2M SBIR, 12 employees) up 146% [Nov 24, 21]

Longeveron (Miami, FL; $5.2M SBIR, 12 employees) down 39% [Nov 23, 21]

“There’s a joke among epidemiologists,” Brandon Dean, an emergency-response planner in the Los Angeles County Public Health Department, told me. “If you’ve seen one pandemic, you’ve seen one pandemic.” [Jeneen Interlandi, [CDC] ambitious $200 million center to predict future outbreaks, NYTimes, Nov 23, 21]

Longeveron (Miami, FL; $5.2M SBIR, 12 employees) up 181% [Nov 22, 21]

Longeveron (Miami, FL; $5.2M SBIR, 12 employees) up 46% [Nov 19, 21]

Longeveron (Miami, FL; $5.2M SBIR, 12 employees) up 135% [Nov 18, 21] announced that [FDA] granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. [company press release, Nov 18, 21]

Longeveron LLC (Miami, FL; one prior SBIR, founded 2014) received a $3.8M [NIH SBIR] million grant toward developing stem cell therapies for aging frailty, a physiological decline from aging that the company says heightens vulnerability to advers e and serious health conditions in older people. [, Oct 24, 18]

Maryland Technology Development Corp approved awards of $8.5 million to 29 new stem cell research projects. The for-profit firms each receiving over $1M are:  TissueGene (Rockville, MD; $100K SBIR), Longeveron LLC (Miami, FL; no SBIR), MaxCyte (Gaithersburg, MD; $1M SBIR), Propagenix (Rockville, MD; no SBIR),  Seraxis (Germantown, MD; no SBIR), and 3Dnamics (Germantown, MD; no SBIR).   [Morgan Eichensehr, Baltimore Business Journal, May 16, 17]

Longeviti Neuro Soluti0ns (Cockeysville, MD)

Medical device startup Longeviti Neuro Solutions (Cockeyville, MD; no SBIR, founded 2016) secures $6M in new funding [Morgan Eichensehr, Baltimore Business Journal, Sep 23, 2020] collaborates closely with industry and academia to develop and commercialize implantable neurosurgical devices [company website]

Longeviti (Cockeysville, MD; no SBIR) raising up to $12.6M , is developing and commercializing implants for use in complex brain surgeries. [Morgan Eichenseh, Baltimore Business Journal, Jul 18, 2019]

LonoCloud (La Jolla, CA)

ViaSat said it acquired LonoCloud (La Jolla, CA; no SBIR, 10 employees) for an undisclosed price.The satellite outfit said LonoCloud is an early-stage company with expertise in cloud networking software. ViaSat plans to use the technology with its Exede/WildBlue broadband network [Mike Freeman,, Apr 12, 13]

Lookingglass (Arlington, VA)

Lookingglass (Arlington, VA; no SBIR) cybersecurity firm, has closed a $20 million Series B round  ...  takes a preemptive approach to protecting technology systems from hackers, according to CEO Chris Coleman, who described the strategy as "playing whack-a-mole" with any signs of intrusive activity.   [Kasra Kangarloo, Washington Business Journal, Mar 24, 15]

Loon Medical (Tolland, CT)

Two Yale professors will receive $500,000 grants from the [Connecticut Bioscience Innovation Fund] in the hopes that the money will help the researchers hasten the day their discoveries become salable products ... The state borrowed the money for both  ... how much of that money will be a loan vs. a venture capital style investment is yet to be negotiated. Businesses are not eligible for grants under the terms of CBIF. ... Loon Medical (Tolland, CT; no SBIR) is developing a remote monitor for ill people who do not have caretakers on site at all times, such as people with dementia. Tangen Biosciences (Branford, CT; no SBIR) is developing an affordable, mobile diagnostic test for tuberculosis for use in the developing world.    [Mara Lee, Hartford Courant, Nov 17, 14]

Lotus Tissue Repair (Cambridge,MA)

Lotus Tissue Repair (Cambridge, MA; no SBIR) said it has closed on a $26 million Series A financing ... is developing a proprietary recombinant collagen technology as a treatment for skin conditions. ...  to advance this technology as a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a disease that causes devastating skin blisters and early mortality, the company said.  [Chris Reidy, Boston Globe, Jun 30, 11]

Loxo Oncology (New York City)

Loxo Oncology (Stamford, CT; no SBIR, market cap $2.2B)  announced that it has entered into a global collaboration with Bayer to develop and commercialize larotrectinib and LOXO-195, Loxo Oncology’s franchise of highly selective TRK inhibitors for patients with TRK fusion cancers. ...Loxo Oncology will receive a $400M upfront payment, [and] is eligible for $450M in milestone payments upon larotrectinib regulatory approvals and first commercial sale events in certain major markets and an additional $200M in milestone payments upon LOXO-195 regulatory approvals and first commercial sale events in certain major markets. [company press release, Nov 14, 17]  $65M IPO 2014 ...  established and funded by Aisling Capital, and Array BioPharma [company website]

Array BioPharma (Boulder, CO; no SBIR), a biotech drug research company, has inked a partnership deal with startup Loxo Oncology (New York City,; no SBIR) under which Array will work on potential new cancer drugs and receive up to $434 million in payments if the research hits certain milestones. [Denver Business Journal, Jul 13]

LPath Thera (San Diego, CA)

LPath down 18% [Dec 22, 16]

LPath (San Diego, CA; $4.7M SBIR) up 68% [Dec 21, 16]  after the company said it was awarded a two-year, $1.45 million grant by the U.S. Department of Defense to support the study of Lpathomab for the treatment of pain associated with traumatic brain injury. .... a week after the company was forced to enact a one-for-14 reverse stock split   [Tomi Kilgore, MarketWatch, Dec 21, 16]

LPath down 16% [Aug 23, 16]

Lpath (San Diego, CA; $6.8M SBIR) up 39% [Aug 19, 16]

LPath down 22% [Mar 25,15]

Lpath (San Diego, CA; $6.6M SBIR) said its experimental drug to treat renal cell carcinoma, the most common form of kidney cancer, failed to meet its main goal in a mid-stage trial. [Reuters, Mar 24, 15]

Drug developer LPath Thera (San Diego, CA; $6.8M SBIR) said it agreed to sell $12.5 million of stock in a direct offering to investors.  ...  recently announced what it called encouraging interim results in a Phase 2a clinical trial of Asonep, a drug for metastatic kidney cancer. It's also in Phase 2 trials of a drug called Isonep for "wet" age-related macular degeneration that has been licensed by Pfizer.   [ Bradley Fikes, utsandiego,com, Sep 19, 14]

Lq3 Pharmaceuticals (Research Triangle Park, NC)

Less than two years after spinning out a company to focus on oral health treatments, Liquidia Technologies (Durham, NC;  SBIR) has folded Lq3 back into the parent company and will re-asses the viability of developing those assets.  [Jason deBruyn, Triangle Business Journal, Mar 3, 16]

GlaxoSmithKline exercised an option that gives the company the exclusive rights to nearly all inhaled uses of a particle manipulating technology developed by Liquidia Technologies  (Research Triangle Park, NC; one SBIR, founded 2004 as spun out of UNC-Chapel Hill, 50 employees).  ... More recently, [Liquida] spun out two separate companies: Envisia Therapeutics, to develop new drugs targeted at glaucoma and cataracts, and Lq3 Pharmaceuticals, to focus on advancing therapies for oral health conditions. Envisia has 23 employees and Lq3 has seven   [Jason deBruyn, Triangle Business Journal, Sep 30, 15]

Liquidia Technologies (Research Triangle Park, NC; no SBIR, founded 2004) drug-development company, has spun out its second new company in the past year. The latest spinoff, Lq3 Pharmaceuticals, will focus on developing therapies for oral health conditions using Liquidia’s technology. The company has raised $10 in venture capital ...  Liquidia's proprietary Particle Replication In Non-Wetting Templates, or PRINT, technology to develop therapies. PRINT enables precise engineering of the size and shape of microscopic particles, which can then be combined with drugs for delivery to targeted tissues within the body. ... Liquidia’s other recent spin off, Envisia Therapeutics, is also using the PRINT technology to focus on developing ophthalmology products. Envisia was launched in November and has raised $25 million from venture capital firms that have also invested in Liquidia.   [David Bracken, Raleigh News & Observer, Sep 10, 14]

LS9 (San Carlos, CA)

after nine years and $81 million, the owners of LS9 (San Francisco, CA; no SBIR) sold the company last month to biodiesel maker Renewable Energy Group for $40 million in cash and stock, with an additional $21.5 million promised if technology and production milestones are met.  LS9 had hoped to be selling diesel to refineries at least two years ago  [Martin LaMonica,, Feb 5, 14] Sweet technology, too expensive.

Midori Renewables (no SBIR) launched last week as the latest sustainable-minded businesses Flagship supports, joining LS9 (no SBIR), Oasys Water (no SBIR) and Joule Unlimited (no SBIR). Brian Baynes, founder and chairman of Midori, [said] that the company is just now starting to market their technology: a solid material that can be heated up to break down the tough cellulose in plant matter, turning it into a simple sugar.  [Don Seiffert, Boston Business Journal, Sep 9, 12]

Sunlight companies.  Joule Unlimited (Cambridge, MA; no SBIR) said it was the first company to patent an organism that secretes hydrocarbon fuel made continuously, directly from sunlight. Other companies, including Amyris Biotechnologies (Emeryville, CA; $700K SBIR), and LS9 (San Carlos, CA; no SBIR), are working on organisms that will make fuel if fed sugar from corn or cellulosic sources, but Joule’s bacterium does not require any sugar. Another company, Aurora Algae (Alameda, CA; no SBIR), said that it had developed an algae-based platform for production of fuel, pharmaceuticals and other valuable chemicals.  [Matthew Wald, New York Times, Sep 14, 10]

Biofuel Valley. More than fifteen hundred miles away from the Midwest's corn belt, several California-based, venture-backed startups founded by pioneers in the fledging field of synthetic biology are creating new microörganisms designed to make biofuels other than ethanol.  .... planning to produce novel hydrocarbons ... At LS9 in San Carlos, CA, researchers are turning E. coli into a hydrocarbon producer by reëngineering its fatty-acid metabolism (see Better biofuels, forward, july august 2007) [David Rotman, MIT Tech Review, Dec 20]  Ethanol is an expensive fuel that requires special handling; only government subsidy keeps it alive.

While much of the focus is on ethanol, LS9 (San Carlos, CA; no SBIR) is using relatively new "synthetic biology" techniques to engineer bacteria that can make - secrete - hydrocarbons for gasoline, diesel, and jet fuel. ... Overall, LS9 says, its process would consume 65% less energy than ethanol production. The company hopes to bring hydrocarbon biofuels to market in four or five years. [Neil Savage, MIT Tech Review, J/A07]

Luca Technologies (Golden, CO)

Luca Technologies (Golden, CO; no SBIR) has raised $76 million to scale up a process that uses coal-digesting microorganisms to convert coal into methane. The process is designed to operate underground, inside coal mines.  ...  Scott, working at the University of Texas in the mid-1990s, helped show that a significant fraction of natural gas is constantly being produced by microorganisms that feed on coal. First, one type of microbe breaks the long hydrocarbon molecules found in coal into shorter molecules. Other microbes convert these molecules into organic acids and alcohols. Finally, microbes called methanogens feed on these and produce methane. [Kevin Bullis, MIT Tech Review, Jan 8]

Lucerno Dynamics ((Morrisville, NC)

Lucerno Dynamics (Morrisville, NC; no SBIR) announced  the completion of its series A equity funding round with a total $6.34 million raised.  [company press release, Oct 6, 16]  to gear up for commercialization of its product .... has developed patented sensors that detect radiation that would be used in conjunction with PET scans to ensure the prescribed quantity of the radioactive isotope injected for those tests are reaching the tumor.  [David Ranii, Raleigh News & Oberver, Oct 6, 16].

Lucidux (Providence, RI)

Lucidux LLC  (Providence, RI; no SBIR), a startup that makes 3-D imaging technology for surgery and other medical applications, has received $250,000 in funding from the Slater Technology Fund, a non-profit corporation that works like a venture capital firm ... founded in 2011, is developing its technology with corporate partner, Photon-X (Huntsville, AL; $6M SBIR)  The real-time, three-dimensional imaging of internal organs and tissues uses software-enhanced presentation and can be used by surgeons during procedures such as laparoscopy and arthroscopy. The company says it can highlight diseased tissue, allowing surgeons to remove it without damaging healthy tissue nearby.  [Don Seiffert, Mass High Tech, Jul 30, 12]

Lucigen (Middleton,WI)

Lucigen (Middleton, WI; $9.4M SBIR)  said it has been awarded a $1.5 million federal Phase II grant.  Gene cloning technology could allow it to expand from tools for working with bacterial proteins to other disease-related areas.   ... has raised $2.2 million from investors this year [Kathleen Gallagher, Milwaukee Journmal Sentinel, Jul 2, 15]

Lucigen (Middleton, WI; $9.3M SBIR)  developing molecular diagnostic tests for Ebola and other infectious diseases, said  it has made further progress on a proposed $2.5 million equity funding.  ... sells a catalog of several hundred products for research use, and recently added the effort to develop molecular diagnostic tests  [Kathleen Gallagher, Milwaukee Journal Sentinel, Mar 18, 15]

Lucigen (Middleton, WI;  $9.4M SBIR) biotech company, has raised nearly $2 million of funding from outside investors, according to [SEC] filing ...  developing molecular diagnostic tests for Ebola and other infectious diseases.  sells a catalog of several hundred products for research use, [CEO Ralph] Kauten said. The company's effort to develop molecular diagnostic tests is newer. ...  "we're developing a game-changing platform for diagnosis," Kauten said.  [Milwaukee Journal Sentinel, Jan 19, 15]

Lucigen (Middleton, WI; no prior SBIR) said it received a $2.8 million [NIH Phase II SBIR]  ... to develop a point-of-care diagnostic testing device for influenza A, B and respiratory syncytial virus ..with high confidence in less than 30 minutes directly at point of need.   [Milwaukee Journal Sentinel, May 24, 12]

Lucigen (Middleton, WI; $9M SBIR)  said it has been awarded $350,000 in grants from the National Institutes of Health to fund additional research and development.   The two grants will be used to develop genetic sequencing tools, and to create an affordable tool to help researchers study data from genes and proteins within individual cells.  [Kathleen Gallagher, Oct 12, 11]

Lucigen (Middleton, WI; $6.2M SBIR) in partnership with Auburn University, has been awarded a $500,000 [NSF SBIR] grant to develop tools for improving the health of farm-raised fish. ....   is trying to come up with inexpensive ways to detect and control Edwardsiella ictaluri, the most common pathogen in farmed catfish. Farmers suffer substantial economic losses when fish are infected with this pathogen, the company said. .... Founded in 1998, Lucigen develops life science research products and technologies for gene cloning, genomics and protein expression.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Feb 16,11]

Lucigen (Middleton, WI; $6.2M SBIR) said it has been awarded a $1.46 million [NIH SBIR] ... to develop research tools with the potential to improve human health. Lucigen develops life science research products and technologies for gene cloning, genomics and protein expression. [Milwaukee Journal Sentinel, Jan 17, 11]

Lucigen (Middleton, WI; $6M SBIR) will receive a $200,000 low-interest loan from the state Commerce Department to develop a DNA sequencing technology  [Kathleen Gallagher, Milwaukee Journal Sentinel, May 13]

Lucigen (Madison, WI; $5M SBIR) said it has been awarded more than $1.7 million in federal innovation grants (SBIR) . $400,000 for development of a virus detection system; $165,000 to advance its existing cloning methods; and $1.2 million to enhance a system for gene expression. ... offers a range of products and technologies that help scientists find new enzymes, clone genes and perform other research.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Apr 21, 10]

Lucigen (Madison, WI; $4.5M SBIR) said it has received a $750,000 grant to develop enzymes that help sequence DNA faster. The  company said it will use the money over the next two years to help figure out how to determine patients' genetic makeup more quickly and inexpensively.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 16, 09]

Lucigen (Madison, WI; $5M SBIR) has been awarded a $100,000 grant from the National Science Foundation to develop ways to control disease in farmed catfish.  The Madison biotech company will work with collaborators at Auburn University to develop molecular diagnostic tests and treatments to help eliminate the spread of disease in farm-raised channel catfish, an important food crop, Lucigen said Tuesday. ...  With the grant, Lucigen said it has received more than $700,000 of funding during the past 12 months and more than $4.2 million in total.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 8, 09]  ... founded in 1998 to develop novel, useful products and technologies for advancing life science research [company website]

Lucigen  (Middleton,WI; $5M SBIR), that has discovered new heat-stable enzymes in boiling hot springs, said Tuesday it has won two new federal grants....  $100,000 to further develop the enzyme, which it says has properties that might be useful in cancer diagnosis and infectious disease detection. ... also will share in an award of $300,000 from the National Institute of Allergy and Infectious Diseases to work with Abhay Vats at the University of Pittsburgh on tests they are developing for respiratory viruses.  [Milwaukee Journal Sentinel, May 5, 09]  founded in 1998, is a privately held company manufacturing and selling products worldwide for gene cloning and genomics. [company website]

LumaSense Technologies Santa Clara, CA)

LumaSense Technologies (Santa Clara, CA; no SBIR, founded in 2005, 300 employees) has quietly built a profitable $100 million business out of selling thermal sensing equipment  ....  has about 5,000 customers around the world who use its infrared cameras and temperature-sensing pyrometers ...  dubbed its new product "Sixth Sense" because it takes the river of data being generated from its devices to predict what customers will want to know and do..  ...  Joshi has built the company through the acquisition of eight companies, each focused on highly specialized sensor technologies.  [Cromwell Shubarth, Silicon Valley Business Journal, Jan 28, 13]

Lumen Bioscience (Seattle,WA)

Lumen Bioscience (Seattle, WA; $900K SBIR) a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B financing [to] support continued advancement of Lumen’s three clinical programs for C. difficile, norovirus and traveler’s diarrhea. [company press release, Sep 1, 20]

Lumen Bioscience (Seattle,WA; no SBIR, founded 2017, 23 employees) synthetic biology company announced that it has raised $13 million ... poised to have a big impact on the $1.5 billion market for natural colorants  [Clare McGrane, GeekWire,  Dec 5, 17] focused on the development of the blue-green algae Spirulina as an industrial scale production platform.  [company website]

Lumencor (Beaverton, OR)

Lumencor (Beaverton, OR) Formed December 2006 . The product: Specialized high-performance lights for biotechnology, called light engines. They are used for basic and applied research in life sciences, including drug research, blood analysis and DNA sequencing. Prototypes are being tested; the plan is to have units for sale in six months. The founders: Steven Jaffe, 46, president and chief executive, is a physicist who has developed optical displays. He founded Quantum Vision (one Phase 2 SBIR), a California startup that folded in 2006. ... Arlie Conner, 53, vice president for engineering, is an inventor, optical engineer and mathematician who has designed projectors and LED lighting systems and worked at InFocus, a Wilsonville maker of digital projectors. He started Lightware (Beaverton, OR; no SBIR) which was purchased by 3M.  [The Oregonian, Mar 8,08]

Lumena Pharmaceuticals (San Diego, CA)

Lumena Pharmaceuticals (San Diego, CA; no SBIR, 17 employees) has been sold for $260 million in cash to Irish drug company Shire, the companies announced  ... Shire will also make near-term milestone payments for ongoing clinical trials, and a payment for Lumena's net cash at closing.  ... is clinically testing a drug called LUM001 for rare liver diseases. The company filed in April for a $75 million initial public offering. In March, the company raised $45 million  [Bradley Fikes,, May 12, 14]  

Lumena Pharmaceuticals (San Diego, CA; no SBIR, founded 2011) filed for [IPO], just weeks after the biotech raised $45 million for clinical trials of its liver-disease drugs.   ....  in Phase 2 development of a drug called LUM001 for four liver diseases that have the common underlying cause of high bile acid levels in that organ. It has received orphan drug designation for each of the diseases  [Bradley Fikes,, Apr 5, 14]

Lumena Pharmaceuticals  (San Diego, CA; no SBIR, founded 2011),  a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders,  announced that it has secured $45 million in Series B financing. ...  will use the funding to advance the clinical development of LUM001, its lead product candidate, for the treatment of rare cholestatic liver disease in pediatric and adult patients, as well as LUM002 for the treatment of nonalcoholic steatohepatitis (NASH).  ...  has raised a total of $78 million in private financings [company press release, Mar 11, 14]

Lumena Pharmaceuticals (San Diego, CA; no SBIR) recently received an [FDA] orphan drug designation  for its lead candidate drug, LUM001.    ...   being tested to treat four rare liver diseases  ....  [CEO Grey says] We dusted it off the shelf of a large pharma company (which had originally developed it as a cholesterol drug). The attraction of that asset is it had been developed very extensively. It has been in 12 clinical studies, 1,430 patients. So we have a tremendous amount of knowledge  [Bradley Fikes,, Oct 14, 13]

Lumena Pharmaceuticals  (San Diego, CA;  no SBIR), a startup developer of drugs for rare liver diseases, said it has raised $23 million in venture funding.  ....  for testing the company’s lead drug for cholestatic liver diseases in adults and children, said [CEO] Mike Gray [Bradley Fikes,, May 8, 13]

Lumense (Atlanta, GA)

startup Lumense (Atlanta, GA; no SBIR, founded 2011) raised a reported $2.65 million from the GRA Venture Fund and The Coca-Cola Company.   .... offers chemical and biological sensors targeted for use in the poultry, food and beverage, and water quality industry.  In poultry, Lumense is working to help poultry growers measure levels of ammonia in their poultry houses  ... in tech business incubator Advanced Technology Development Center, has developed technology based on $20 million in funded research conducted at Georgia Tech    [Urvaksh Karkaria, Atlanta Business Chronicle, Nov 14, 13] 

Lumicell Diagnostics (Waltham,MA)

Lumicell Diagnostics (Waltham, MA; no SBIR) has raised $2.7 of a planned $3.9 million financing round, according to federal documents.  ...  developing a handheld device that, when used in conjunction with a dye that radiates fluorescent light when in contact with a cancer enzyme, can detect minute amounts of cancer cells left behind after a cancer surgery. [Rodney Brown, Mass High Tech, Jun 2, 11]


GigPeak (formerly iTerra Communicationsand GigOptixmarket cap $134M,San Jose, CA; $750K SBIR), which provides semiconductor and optical components, acquired chip and software provider Magnum Semiconductor [for $55M].  [Gina Hall, Silicon Valley Business Journal, Apr 5, 16]  launched from Microvision in Y2K as Lumera (Bothell WA; $600K SBIR)   ..  acquired Helix (Switzerland)  in 2008

Lumera which is merging with GigOptix  of California, reported that it trimmed its third-quarter loss to $1.5 million, [Puget Sound Business Journal, Oct 21, 08]

Light Over Life.  Lumera, (Bothell, WA; one SBIR) optic-communications company, scrapped its life-science-tools subsidiary and announced a merger agreement with GigOptix.  Lumera's board determined that it does not have enough cash to continue running Plexera Bioscience and is focusing instead on its optics business.  [Ben Romano, Seattle Times, Mar 28]

Lumera  down 14% [Feb 21, 08]

Lumera  up 10% [Feb 20, 08]

Lumera up 38% [Jan 29, 08]

Lumera up 12% [Oct 15, 07] after announcing the release of its 40 Gbps electro-optic polymer modulator for optical transmission systems. [press release]

Lumera  up 29%.  [Aug 8, 07]

Lumera up 13% [May 18, 07]

Lumera up 24% [Mar 12, 07] on a Lockheed purchase order for polymer materials with the possibility of a licensing deal.

Lumera lost 20% after reporting a bigger loss. [Mar 9, 07]

Lumera still rolling, up another 18% [Nov 6, 06]

Lumera up 10% on no more news; that's up about 25% for the week. [Nov 3, 06]

Lumera, which once had a Phase 1 SBIR, rocketed 38% after it said that Harvard Medical School researchers are building discovery and diagnostics methods with Lumera's ProteomicProcessor biosensor. [Wall Street Journal, Nov 1] 

Luminar Technologies

Luminar Technologies said that its new Iris sensors will be ready to launch commercially on production vehicles beginning in 2022, ready to be sold for as little as $500 each. [Cromwell Schubarth, Silicon Valley Business Journal, Jul 11, 2019] acquired subsidiary Black Forest (Colorado Springs, CO; $8M SBIR)

Luminary Micro (Austin TX)

Startup Luminary Micro (Austin, TX; no SBIR) is beginning to hit its stride, expecting this year to sell millions of microcontrollers, which are tiny low-cost brains that run everything from industrial equipment to household appliances. The company has raised $44 million in venture backing, expects to become profitable next year and, if all goes well, will shoot for a public stock offering in 2010. Not bad for a company that was conceived less than four years ago over fish, chips and beers at Mother Egan's Irish Pub. .... 62 employees, many of them highly skilled veteran chip designers, and has launched 132 new chips. Some indeed sell for a buck apiece, while others go for several dollars more. [Austin American-Statesman, Jul 28, 08]/p>

Luminary Micro  a three-year-old Austin chip startup (no SBIR) , raised another $25 M in venture capital, the company's third venture round since it was started. [Austin American-Statesman, Aug 23]

Luminex (Austin TX)

Luminex down 28% [Aug 7, 18] announced financial results for the second quarter

Luminex (Austin TX; $1M SBIR) conducted a reorganization in December of 2016 to both facilitate the integration of Nanosphere and to better focus on our core business. The restructuring included a headcount reduction of over 50 employees, a reallocation of responsibilities within the R&D organization and a significant reduction of biodefense efforts.  [Luminex press release, Jan 10, 17]

Luminex  down 12% [Nov 1, 16]

Luminex (Austin, TX; $1.1M SBIR) received federal authorization for a technology that can test for a broad range of indicators of the Zika virus in patients, giving physicians a new tool to combat the mosquito-borne disease that is causing anxiety as its gains a foothold in the continental U.S.   [Will Anderson, Austin Business Journal, Aug 8, 16]

Luminex (Austin, TX; $1.1M SBIR) and Nanosphere (Northbrook, IL; $3.8M SBIR) announced that the companies have entered into a definitive agreement under which Luminex will acquire Nanosphere, a leader in the molecular microbiology and molecular diagnostic market in an all cash transaction valued at approximately $58 million.  With its focus on the molecular microbiology segment, Nanosphere delivers proprietary diagnostic tools that enable rapid and accurate detection of respiratory, gastroenteric and bloodstream infections  [Luminex press release, May 16, 16]

Luminex (Austin, TX; $1.1M SBIR) up 17% [Aug 4,15]

Luminex down 13% [Feb 3, 15]

BioPhysical (Austin, TX;  $1.1M SBIR, founded 1982, 53 employees)  raised $4.1 million of a $5 million round of funding that it will use to pay for an office expansion in Houston and Austin in 2015. ... has yet to turn a profit  [Chad Swiatecki, Austin Business Journal, Nov 14, 14]  manages and markets biomarker-based health assessments direct to consumers and corporations ...  provides the most comprehensive blood-based assessments of an individual's health. ... history: 1982 Inland Labs (no SBIR) is founded; 1995 Luminex ($1.1M SBIR) is formed from Inland Labs; 2002 Rules Based Medicine (no SBIR) is formed from Inland Labs; 2005 Biophysical forms from Rules Based Medicine.  [company website]

Luminex (Austin, TX; $1.2M SBIR) that develops diagnostic technology to identify diseases, is seeing its MAGPIX technology used by scientists in the U.S. Army Medical Research Institute of Infectious Diseases in Africa to identify strains of the deadly Ebola virus that has killed nearly 800 people in recent weeks.   [Chad Swiatecki, Austin Business Journal, Aug 5, 14]

Luminex up 17% [Apr 29, 14]

Luminex said it will cut its workforce by 5 percent and close its office in Australia to provide more funding for research and development.  ....  will save between $5 million and $6 million annually.  [Lori Hawkins, Austin American Statesman, Aug 8, 13]

Luminex down 13% [Jul 30, 13]

Luminex received FDA and European clearance of its genotyping assay kit xTAG CYP2D6 and has submitted another kit for FDA review. The recently approved kit analyzes a patient’s likely response to certain drugs and therapies, enabling doctors to tailor treatments to lower the likelihood of adverse drug reactions [Chad Swiatecki, Austin Business Journal, Jul 16, 13]

Luminex  (Austin, TX; $1M SBIR, founded 1995) has renewed its agreement with German researcher Merck KGaA to distribute its selection of xMap systems  [Chad Swiatecki, Austin Business Journal, Jun 3, 13]

Luminex (Austin, TX; $1M SBIR) down 18%  [Jul 9, 12]  after the company said it plans to buy a California biotech company for $50 million.  Luminex, which develops biological testing systems, intends to buy GenturaDx (Hayward, CA; no SBIR), a company that is developing an automated testing system designed to speed molecular diagnostics testing available to hospitals and patients. The California company is expected to have commercial products available in 2014. [Kirk Ladendorf, Austin American Statesman, Jul 9, 12]

Luminex (Austin, TX; $800K SBIR) ) has agreed to acquire a Wisconsin diagnostic testing company for $34 million in cash. .... Luminex, which makes testing systems for biotechnology companies, said EraGen Biosciences (Madison, WI; $4.7M SBIR) ) provides it with access to a highly complementary portfolio of molecular diagnostics. Founded in 1999, EraGen generated $8 million in product revenue in 2010. Luminex said it expects the acquisition to add between $5 million and $7 million to its 2011 revenue. EraGen has 70 employees. Luminex said operations are expected to remain in Wisconsin. [Austin American Statesman, Jun 22, 11]

Luminex (Austin, TX; $370K SBIR) which develops biological testing systems, was No. 291 ....  on the new Deloitte Fast 500 list of fastest-growing technology companies. ...  Its 2009 revenue of $120.6 million was up 185 percent from 2005. [Austin American Statesman, Oct 20, 10]

Luminex (Austin, TX; $300K SBIR in 2003) was listed as 42nd fastest growing company by Fortune magazine. The testing equipment manufacturer was founded in 1995 and employs about 471 workers.  [Austin Business Journal, Aug 20, 10]

Luminex (Austin, TX; one SBIR) posts 4th-quarter revenue of $38.2 million, up 35% from 2008 ....  makes biological testing systems for medical and life sciences customers  [Austin American Statesman, Feb 6, 10]

Luminex (Austin TX; no SBIR, 300 employees), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its xTAG(TM) Respiratory Viral Panel (RVP). xTAG RVP is the first FDA-cleared assay to simultaneously detect and identify 12 viruses and viral subtypes that together are responsible for more than 85 percent of respiratory viral infections. [company press release]

Luminus Devices (Billerica, MA)

Luminus Devices (Billerica,MA; no SBIR) designer, developer and manufacturer of LEDs, announced the closing of its round of funding totaling $19 million.  [Boston Globe, Feb 23, 10]

LED maker Luminus Devices (Billerica, MA; no SBIR) closed $72M in new funding, bringing the company's total raised to nearly $140M since its photonic lattice technology was spun out of MIT in 2002 [Mass High Tech, Mar 17]

Lumitex (Strongsville,OH)

Faster than SBIR. the Air Force Research Lab [was] approached in 2004 and asked to develop such a system. Working with Lumitex (Strongsville,OH; no SBIR) the effort was part of a rapid-reaction program where researchers were given up to $100,000 and one year to come up with a product. ... The group produced 108 prototypes in six months [James Hannah, AP, Feb 20  reprint by Albany Times-Union]  The product is a LED - fiber-optic strip that emits in the IR to mark friendly forces on the ground.

Lumisyn (Rochester, NY)

LLC (Rochester, NY; three prior SBIRs, founded 2014) received a $1 million [Phase II SBIR] from the U.S. Department of Energy  ...  will work to double the efficiency of LED lights  [Kerry Feltner, Rochester Business Journal, Jun 6, 17] develops high-performance cadmium-free phosphors to enhance lighting and optoelectronic products. [company website]

LumiThera (Poulsbo, WA)

LumiThera (Poulsbo, WA; no SBIR) a medical device company focused on treating people with the main type of age-related vision loss – is commercializing the company’s vision-loss device.

Three companies in Washington will receive Proof of Concept grants to accelerate maturation of promising health-related technologies from ideas into commercial products, the  Life Sciences Discovery Fund (LSDF) announced:   Zwitter Technology  (Seattle, WA; no SBIR), $250,000 to conduct preclinical testing of a new leukemia treatment anticipated to have greater efficacy than current drugsM3 Biotechnology  (Seattle WA; no SBIR), $250,000 to validate the effectiveness and safety of a novel treatment for Parkinson’s disease in preparation for clinical testing; LumiThera  (Poulsbo, WA; no SBIR), $250,000 to build and test a device that may delay progression of the dry form of age-related macular degeneration.  [press release, Life Sciences Discovery Fund, Apr 21, 14]

Lumos Pharma (Austin, TX)

Lumos Pharma (Austin, TX; no SBIR) completed a $34 million Series B funding to develop new therapeutics in the company’s pipeline [of orphan diseases].  [Christopher Calnan, Austin Business Journal, Apr 6, 16]

Lumos Pharma (Austin, TX; no SBIR) raised $34 million in a Series B round to help pay for clinical trials this summer for a potential therapy for creatine transporter deficiency (CTD).  ....  believes its drug candidate, LUM-001, can turn the debilitating disease into a more manageable condition. About 42,000 Americans were born with and currently have the metabolic disorder. [Angela Shah,, Apr 6, 16]

Lumos Pharma (Austin, TX; no SBIR)  received a $5.5 million award from the Wellcome Trust on top of a $14 million Series A raise earlier this year  ....  continue its development work on creating a treatment for creatine transporter deficiency, a development condition in boys that results in speech deficits and seizures and is typically misdiagnosed as autism.   [Chad Swiatecki, Austin Business Journal, May 5, 15]   London-bound tourists can visit the wonderful Wellcome Trust Museum opposite Euston Station. 

Lumos Pharma (launched 2014) reported raising $6.5 million of planned $7.5 million financing from three investors, according to [SEC]  filing ... supporting the development for a therapeutic treatment for those suffering from Creatine Transporter Deficiency, a rare, Autism-spectrum disease, the news release says.  [Christopher Calnan, Austin Business Journal, Feb 6, 14] 

Lumos Pharma (Austin, TX; no SBIR, founded 2011) biotech startup has raised $14 million to begin clinical trials of its new therapy for an autism spectrum disorder. ...  focuses on bringing novel therapies to patients with severe, rare, genetic diseases. [Austin American Statesman, Feb 4, 14]

Luna Innovations

Luna Innovations up 21% [Aug 8, 19]

Luna Innovations (Roanoke VA; $180M SBIR, 200 employees) up 17% [Mar 4, 19]

Luna Innovations up 16% [Aug 1, 18]

Luna Innovationsdown 16% [Apr 6, 18]

Luna Innovations (Roanoke, VA; something like $130M SBIR) announced the sale of its shape-sensing technology for medical applications to Intuitive Surgical.  The terms of the deal include Luna receiving $12 million upfront in two tranches and up to an additional $18 million upon certain technical milestones and commercial measures. Intuitive will acquire Luna’s fiber optic shape-sensing and localization technology, including related patents, and hire a number of engineering employees formerly utilized in Luna’s medical shape-sensing business. [Business Wire, Jan 22, 14]  After all that SBIR "investment" and an 87% jump, the market cap is $36M. Was the government really investing, and if so, should its portfolio manager find a new home?  Remember that investment to a politician is money flowing into the home constituents. 

Luna Innovations  up 12% [Feb 19, 10]gained ground after plunging almost 70%

the day before when it said that the FDA had decided not to approve Horizant, also known as gabapentin enacarbil, for the treatment of restless-legs syndrome, citing concerns that early animal studies had indicated the product might trigger pancreatic tumors. [, Feb 20, 10]

Luna Innovations  up 20% [Feb 17, 10]

Luna Innovations  up 10% [Feb 1, 10]

Luna Innovations down 11% [Jan 13, 10]

Luna Innovations up 21% [Jan 12, 10]

Luna Innovations down 19% [Jan 11, 10]

Luna Innovations zoomed 72% [Jan 8, 10] p>Luna Innovations announced today that it will be extending its development and supply agreement with Intuitive Surgical to continue integrating Luna’s shape sensing technology into Intuitive’s products. [Luna press release]

Luna Innovations up 12% [Jan 6, 10] which puts it at 10x its low point for 52 weeks but still 75% below its 100 week high.

Luna Innovations up 19% [Sep 28, 09]

Luna Innovations doubled, up 95% [Sep 25, 09]

Luna Innovations  up 13% [Nov 4, 08]>Luna Innovations down 11% [Oct 6, 08]

Luna Innovations down 17% [Oct 3, 08]

Luna Innovations down 18% [Sep 29, 08]

Luna Innovations down 11% [Sep 8, 08]

Luna Innovations up 10% [Jul 18, 08]

Luna Innovations rebounded 20% [Jun 30, 08]

Luna Innovations down 21% [Jun 27, 08]

Luna Innovations down 18% [Jun 26, 08]

Luna Innovations up 16% [Mar 27, 08]

Luna Innovations up 16% [Mar 25, 08]

Luna Innovations down 17%  [Mar 6, 08]

Luna Innovations up 11% [Feb 13, 08]

Luna Innovations  down 14% [Jan 9, 08]

Luna Innovations up 10% [Dec 28, 07]

Luna Innovations up 13% [Nov 14, 07] on near doubling of profit.

Luna Innovations down 15% after reporting another loss. [Nov 9, 07]

Luna Innovations up 11% [Oct 30, 07]

Luna Innovations up 14% [Oct 24, 07]

Luna Innovations up 24% on news of a deal with Intuitive Surgical (the global technology leader in robotic-assisted minimally invasive surgery) wherein Luna will develop and supply fiber optic-based shape sensing and position tracking system. [Jun 14, 07]

Luna Innovations gave back 14% which is about 20 of the 68 percentage point gain the day before.

Luna Innovations rocketed 68% on news that its company's blood circuit monitor used in cardiac surgery won clearance from U.S. health regulators. [Reuters, May 21] But still below its post-IPO trading price. 

Luna Innovations took a 27% tumble and an inverstment downgrade after forecasting lower revenue for next quarter. [Sep 06]

Luna Innovations went public at $6 a share, half its week-ago target of $12. There it closed its short first trading day.  Luna's technologies got a big helping hand from the government with $25M of SBIR in the last five years, plus another $10M before that as Fiber & Sensor Technologies. It claims to be a researcher and developer (and commercializer) of molecular technology and sensing solutions. Its home is Roanoke VA, the same home as Pixel Optics.  Parts of the company had already been bought by bigger companies: Luna Energy was acquired in December 2004 by Baker Hughes, a leader in oil field services, and  Luna i-Monitoring by IHS Energy in October 2003. [Jun 3,06] Even if $35M SBIR seems a lot of kerosene to start a fire, SBIR can claim at least some kind of ROI for a company attracting public capital. And something is better than the nothing that almost all other SBIR spending shows as a return.

Luna Technologies

Luna Technologies' Optical Backscatter Reflectometer (OBR(TM)) with distributed sensing has received a 2007 R&D 100 Award from the editors of R&D Magazine as one of the 100 most technologically significant new products introduced into the marketplace in the last year. [Business Wire, Jul 12]  But will it be profitable? Who knows. The market seems skeptical since the stock is a third below its starting price a year ago. But that is better than being down the half it was last month.

Lung Therapeutics (Austin,TX)

Lung Therapeutics (Austin, TX; one SBIR, founded 2013) raised a $36 million Series C round to take a treatment for a serious complication of pneumonia through phase 2 studies. [ Nick Paul Taylor, Fierce Biotech, Jun 5, 19] prior funding $14M []

Lung Therapeutics (Austin, TX; no SBIR, at least $1.7M NIH grant), a clinical stage pharmaceutical company developing novel therapeutics for niche, orphan drug indications in fibrosis, lung injury and disease, announced the successful completion of a $14.3 million Series B financing. The proceeds will support ongoing LTI-01 clinical trials in Australia and New Zealand, as well as development activities to advance the Company's transformative drug for fibrosis, LTI-03. The total outside funding Lung Therapeutics has raised is now $17 million. This is in addition to the $27M in non-dilutive funding awarded for discovery research and development for both drug candidates. [company press release, Jun 6, 17]

Lung Therapeutics (Austin, TX; no SBIR) received $1 million of a planned $6 million funding from two investors. [Christopher Calnan,Austin Business Journal, mar 14, 16]     targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis ... three-year, $1.69 million grant will be used to develop the drug candidate LTI-01 as a first-in-class therapy for  pleural effusion with loculation, the company announced [Nov 2015] [company website]

Lung Therapeutics (Austin, TX; no SBIR) pharmaceutical startup, has $1.69 million [three-year NIH grant] to pump into the development of a drug [candidate LTI-01] that could help people afflicted with pneumonia. ...  LTI-01 aims to maximize scar removal around the lungs, promoting fluid drainage while minimizing bleeding risk for pneumonia patients. [Austin Business Journal, Oct 27, 15]

Lung Therapeutics (Austin, TX (incubator); no SBIR), a health care startup that develops therapies for lung injuries and diseases, has raised $1.5 million of a $2.5 million round of funding, according to a recent SEC filing.  ....  received $12 million from [NIH] to fund development of drug candidates. The company has also received seed funding from the UT Horizon Fund, which is a strategic venture fund within the university. ...  CEO Brian Windsor stated at the time that the treatment of complicated pleural disease, which is the condition the company’s main drug candidate seeks to treat, is estimated to represent a billion dollar global market annually.  [Chad Swiatecki, Austin Business Journal, Sep 17, 14]


Innovative Pulmonary Solutions (Bellevue, WA; no SBIR), a stealthy medical device startup, has raised more than $10 million in venture capital and recruited a new CEO with experience selling a couple of other startups,  .... sold his previous companies, Lutonix (no SBIR) and Velocimed (no SBIR), to C.R. Bard and St. Jude Medical, respectively. [Luke Timmerman,,  Sep 20, 12]

Luxtera (Carlsbad,CA)

Luxtera (Carlsbad, CA; two SBIRs), which recently raised $21.7 million in venture funding, says today it has signed a partnership with European semiconductor giant STMicroelectronics to produce a new generation of chips that combine high-performance optics with silicon-based electronics.  [Bruce Bigelow,, Mar 1, 12]

Luxtera (Carlsbad, CA;  two SBIRs a decade ago) developer of optical silicon, said it has raised $21.7 million in a third round of venture capital funding.  ....  formed in 2001 to develop photonics using CMOS, a chip making technology that is less expensive than more exotic materials often used to make photonics. It aims to bring costs down so that high bandwidth photonics can be used in Local Area Networks and other shorter range applications.  [Mike Freeman,, Feb 28, 12]

Luxtera a startup based in Carlsbad, CA, that spun out of the California Institute of Technology, has announced the first optical cable based on the same silicon technology used to make microprocessors. The company says that the cable, called Blazar, can send 40 gigabits of data per second through its fiber but will cost as little as today's 20-gigabit-per-second optical cables. [Kate Green, MIT Tech Review, Aug 16]

Intel isn't alone in the silicon-laser race. Luxtera, a start-up (Carlsbad, CA; two Phase 1 SBIRs), is planning to enter the market in the fourth quarter with chips that include the equivalent of four lasers, each of them able to send 10 gigabits of data a second. Alex Dickinson, Luxtera's chief executive, said Intel's development is interesting from a scientific point of view. But he argues that Luxtera's approach can bring practical benefits sooner, for applications such as connecting together servers to create a supercomputer. From a practical point of view, Mr. Dickinson said he doesn't think Intel's announcement "moves the ball forward."  [Don Clark, Wall Street Journal, Jul 25, 07]

Lycera (Cambridge, MA)

Lycera (Cambridge, MA; no SBIR) has received a second tranche of its Series A financing worth $11 million. The total amount of the Series A round was $36 million ... developing oral medicines to treat autoimmune diseases as an alternative to injectable therapies  [Mass High Tech, Apr 28, 10]

Small molecule pharmaceutical developer Lycera (no SBIR), formerly based in Ann Arbor, Mich., has moved its headquarters to Cambridge ... develops drugs to treat autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease. Founded in 2006, the company maintains a research and development facility in Michigan. In April, Lycera raised $36 million in a Series A round  [Mass High Tech, Jan 7, 10] a spin-out of the University of Michigan ... benefiting from the State of Michigan’s commitment to strengthening the presence of emerging life science companies in the region.  [company website, 2006]

LyGenesis (Pittsbugh, PA))

LyGenesis (University of Pittsburgh spin out, Pittsburgh, PA; no SBIR, founded 2017) announced it raised $3 million in Series A financing ..... claims to have come up with a way to create working liver tissue in patients whose organs have been destroyed by disease. ... concept has worked in mice, but the money will allow the company to finish the groundwork necessary for trials in humans, Chief Scientific Officer Eric Lagasse said. [Kris B. Mamula. Pittsburgh Post-Gazette, May 9, 18]

Instead of giving people liver transplants, doctors could inject liver cells into their lymph nodes so that auxiliary livers grow there.  Strange as it might sound, it appears to work in mice, where the surrogate mini-livers made up for the missing function of a diseased liver. Tests in pigs have been encouraging, too, and now trials in humans could begin late in 2018 if Eric Lagasse and Michael Hufford can raise about $10 million for their startup, LyGenesis (at U Pittsburgh Innovation Institute, Dec 8, 17  [Brian Bergstein,, Dec 8, 17]

Lyncean (Palo Alto, CA)

Shrinking the Synchrotron.  The Compact Light Source by Lyncean (Palo Alto, CA; $9.8M SBIR incl one of $6.4M)'s generates X-rays suitable for advanced tomography. The car-sized device is a miniature version of football-field-sized X-ray generators known as synchrotrons and it emerged from basic research at SLAC in the late 1990s and early 2000s. ... The CLS employs an electron beam and laser beam to accomplish the same effect. The shift from periodic magnets used in a typical synchrotron light source, to the laser beam used in the CLS, allows a reduction of energy and scale by a factor 200 – a stadium size machine becomes a room size machine!   [company website May 7, 15]

Lyndra Therapeutic (Watertown, MA

Lyndra Therapeutics (Watertown, MA; $1.9M SBIR), making daily pills a thing of the past, has announced a partnership with Gilead Sciences to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra- long-acting formulations related to HIV. ... partnership announcement comes just months after Gilead joined Lyndra’s oversubscribed $60.9 million Series B financing round  [Lyndra press release, Jun 9, 19] Gilead pays startup $123M  [Allison DeAngelis, Boston Business Journal, Jul 9, 19]  

Lynntech (College Station,TX)

SBIR Love Fest. When asked what time it is, he explained how the clock works. In testimony before the House SB Committee, DOD's SBIR manager/coordinator said next to nothing about what DOD has achieved toward SBIR goals in more than two decades. The NIH coordinator hinted that VC participation (codeword=flexibility) is important for health related innovation to get to market. The big difference is that DOD doesn't care about post-SBIR economic success. The DOEnergy manager said he didn't have money to explore program payoff. SBA reported "success" that would get any VC fired.  Lynntech (College Station, TX; 400+ SBIR Projects) said it is the largest SBIR contractor in the State and one of the largest in the country. It is fair to say that we have found the program to be beneficial for our company. Having taken down zillions in free capital, Lynntech further says: Government is not well-organized to assist in the transition effort. That is: a new government handout program to help us pretend that the $100+M poured into our company has long term economic payoff. All of which would trigger a revitalization of the SBIR program and continue to improve an already stellar level of performance. The whole show avoided any hard questions about what SBIR is supposed to do and why it is even needed.

Multi-SBIR winner Lynntech's full page ad in Wired for its Ozone Generator says we need more ozone. True, for the upper atmosphere. On earth, though, ozone is a hazard, especially in smog and inside jet airplanes. Still, advertising never went wrong insulting the intelligence of the consumer. Many times SBIR proposers insult government SBIR reviewers in analyzing their technology's economic future. It does not follow that since you know the technical details of your science that you also know, or can ignore, the economics of its use.

Lynx Biosciences (San Diego, CA)

Lynx Biosciences (San Diego, CA; no SBIR) startup team from the University of Wisconsin to advance their technology for optimizing treatment regimens for cancer patients won the audience vote for best pitch at the EvoNexus Spring Demo Day. ... founder and CEO Chorom Pak said her startup has developed microfluidic technology that uses live cancer cells to determine how multiple myeloma patients would respond to different treatment regimens. ... has funded development of the technology through $4.3 million in non-dilutive research grants, and LynxBio is now in the process of raising $1.25 million in seed funding. [Bruce Bigelow,, Apr 2, 18]

Lyra Therapeutics (Watertown, MA)

Lyra Therapeutics (Watertown, MA; $6.3M SBIR) up 22% [Apr 8, 22] announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting offering expenses. [company press release, Apr 8, 22]

Ear, nose and throat (ENT) diseases biotech Lyra Therapeutics (Watertown, MA; no SBIR) aims to drive through the coronavirus market volatility and gun for a $58 million IPO. This comes just over a month after the asa $30 million series C. [Ben Adams, Fierce Biotech, Mar 9, 20]

Lyra Therapeutics, a maker of ear, nose, and throat medicines, has raised $29.5 million to fund Phase 2 testing of its lead drug. [Ben Fidler,, Sep 28, 18]

Lysosomal Therapeutics (Cambridge, MA)

Allergan (Irish) now has the right to acquire Lysosomal Therapeutics  (Cambridge, MA; no SBIR) drug developer for Parkinson’s disease seeking to exploit the link between neurodegeneration and a family of rare genetic disorders.....  purchased an option right to acquire Lysosomal after LTI completes a Phase 1b trial for its lead drug, LTI-291. Allergan announced that it is giving LTI an upfront payment for research and development, though the companies didn’t release specific financial terms of the deal. Both companies are going to oversee the development of the drug.  [David Holley,, Jan 9, 17]

drug developer, Amylyx Pharmaceuticals (Cambridge, MA; no SBIR)  received a $5 million Series A financing to take its nerve cell-targeting treatment, AMX0035, into a Phase 2 trial for ALS patients. The treatment is a combination of sodium phenylbutyrate, a drug commonly used to remove ammonia from the body, and tauroursodeoxycholic acid, a derivative of stomach bile acid. ... funding was ]partly] provided by  former Genzyme CEO Henri Termeer. Since selling Genzyme to Sanofi for $20 billion in 2011, Termeer has been an active investor and advisor to startup biotechs, including Moderna Therapeutics, Lysosomal Therapeutics  (Cambridge, MA; no SBIR), Aura Biosciences  (Cambridge, MA; no SBIR) , and X4 Pharmaceuticals  (Cambridge, MA; no SBIR).   [David Holley,, Aug 22, 16]

Lysosomal Therapeutics (Cambridge, MA; no SBIR) aiming to be at the forefront of discovering new drugs for neurodegenerative diseases, announced today that is has raised $4.8 million in a seed found of funding. ....  to further leverage its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, including Gaucher disease and Parkinson’s disease.  .... founded by ex-Genzyme executives   [Dennis Keohane,, Apr 12, 14]

Lytro (Mountain View, CA)

Lytro  (Mountain View, CA; no SBIR) the startup that developed technology that lets photographers shoot first and focus later, said on Wednesday it raised $40 million in new funding. ....  will use the funding on growth and expansion of its technology, called light field photography, with new products and audiences.  Lytro's long rectangular cameras made a splash when they were unveiled. They sell for between $299 and $399.   [Cromwell Schubarth, Silicon Valley Business Journal, Nov 20, 13]

Semprius (Durham, NC; $500K SBIR) startup that claims to have developed the world’s most efficient solar panel made a prestigious roster of the most important emerging technologies in the world.- the annual list compiled by [MIT] Technology Review, [on] criterion for emerging technologies: their potential to change the world   ....  has raised $44 million from venture capitalists and Siemens  [John Murawski, Raleigh News & Observer, May 2, 12]  The other nine technologies are:  egg stem cells by OvaScience  (Boston, MA; no SBIR) ;  A camera that lets images be adjusted after the shot by Lytro (Mountain View, CA; no SBIR); solar powered micro-grids by Mera Gao Power  (Reusa, India); 3-D transistors by Intel; a faster Fourier transform by MIT; nanopore DNA sequencing by Oxford Nanopore
(Oxford, England); crowd-funding by Kickstarter (New York City); high speed materials discovery by  Wildcat Discovery Technologies (San Diego, CA; no SBIR); and Timeline interface by Facebook.

helping small high-tech companies get from idea to market